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Pathogenesis of Malignant Catarrhal Fever in Cattle 
Mohammed Hamzah Abdulkadhim Al-Saadi 
Abstract 
Malignant Catarrhal Fever (MCF) is a fatal disease of cattle. The 
principal aetiological agent is ovine herpesvirus 2 (OvHV-2). It is carried by 
sheep that act as an asymptomatic reservoir host. The disease is 
characterised by complicated pathogenesis with no preventive vaccine.  
Previous studies in our laboratory have shown that cattle without MCF 
can carry OvHV-2, indicating other factors, possibly herpesviruses are 
involved in MCF. Therefore, the aim of this study was to investigate OvHV-2 
and other related ungulate herpesviruses. To do this, we investigate γ-
herpesviruses in both asymptomatic and MCF hosts by recruitment of two 
PCR formats (PAN-herpesvirus consensus and Real time PCR) as qualitative 
and quantitative approaches. The results showed for the first time that, 
although the related bovine herpesvirus 6 and ovine herpesvirus 1 are 
endemic commensals of cattle, they could afford cross-protection from 
infection with OvHV-2 and development MCF. 
OvHV-2 latency could also act a key factor in MCF-triggering. 
Therefore, a toolkit including antisera against OvHV-2 latency-associated 
nuclear antigen (oLANA) was produced in this study to demonstrate the 
latency in situ in cells of OvHV2-infected sheep, cattle without MCF, and 
cattle with MCF, using immunohistochemistry (IHC). The results 
demonstrated abundant OvHV-2- latency in epithelial and endothelial cells as 
well as leukocytes, regardless of species and disease. This finding could 
open new areas for the diagnosis and pathogenesis of MCF- latency. 
Modified vaccinia Ankara (MVA) is an attenuated virus derived from 
vaccinia that was developed during the smallpox eradication programme. 
The technology for producing recombinant MVA expressing foreign proteins 
is available. It has a known safety profile and recombinant MVAs expressing 
proteins from other pathogens are already being used as 
vaccines/vaccination candidates in man and other animals. We have 
generated MVA recombinants expressing OvHV-2 gB and gH/L as vaccine 
candidates for protection against the development of MCF in ungulates. 
These vectored-subunits generated antibodies to the native proteins after 
infection of mice. Therefore, they could represent logical vaccines in the 
future. Our results give critical insight into the pathogenesis and prevention of 
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1. Chapter one: Introduction 




1.1 Herpesviruses  
Herpesviruses are enveloped double stranded DNA viruses that are 
responsible for numerous human and veterinary diseases. All herpesvirus 
members share similar biological structure. However, their pathological effect 
and tropism are variable due to viral- host interactions by which 
herpesviruses have evolved a sophisticated mechanism to control host cells 
and switch between lytic and latent cycles for life-long viral survival (Griffin et 
al., 2010).  
1.1.1 Herpesvirus classification 
Herpesviruses have characteristic epidemiological, biological and 
genetic features (Kimura, 2018). The order herpesvirales is split into three 
main families according to their pathogenicity and host-replication behaviour: 
Alloherpesviridae, Herpesviridae and Malacoherpesviridae. The 
Herpesviridae family is divided into three subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae.  Nowadays, developments of 
2 
 
the molecular and biochemical techniques have helped in determining 
herpesvirus taxonomy. However, numerous species within the family, 
subfamily, and genus are still unassigned (Davison, 2010). 
1.1.2 Biological properties of Herpesviridae 
1.1.2.1 Alpha-herpesviruses 
Alpha-herpesviruses can infect many of hosts including mammals 
(human and animal), birds, and reptiles. This subfamily has wide cell type 
tropism (neuronal and epithelial cells). Establishment of latency occurs inside 
sensory nerve ganglia. Alpha-herpesviruses are subdivided into Simplexvirus 
and Varicellovirus genera of which Herpes simplex virus-1 (HSV-1) and 
Varicella zoster virus are well presented prototypes respectively (Modrow et 
al., 2013). 
1.1.2.2 Beta-herpesviruses  
Beta-herpesviruses have narrow cell type spectrum (lymphoid cells, 
kidney, and secretory glands). These viruses replicate in vitro slowly. Beta-
herpesviruses can induce cytomegaly inside infected cells (appear enlarged). 
Importantly, these viruses can establish the latency inside immune cells 
associated with monocyte series (Modrow et al., 2013).  
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1.1.2.3 Gamma-herpesviruses  
Gamma-herpesviruses have a very restricted host tropism, related 
within a family or order of a natural host. The period of replication cycle is 
variable according to the virus type. These viruses have a specific cell type 
tropism (either B or T lymphocytes). For instance, Epstein-Barr virus (EBV) 
can establish latency inside B lymphocytes whereas saimiriine herpesvirus 
infects T lymphocytes latently. Lytic replication occurs in other cell types such 
as fibroblast, epithelial, and endothelial cells (Modrow et al., 2013).   
1.1.3 Herpesvirus structure 
Herpesvirus particles have a diameter of 150-200 nm, composed of 
three structural parts: nucleocapsid that has icosahedral geometry that 
encloses the viral genome, which is large (120-230 kb in size); an envelope 
that consists lipid bilayer carrying glycosylated proteins. The space between 
them that is filled with a proteinaceous matrix known as tegument (Figure 1-
1) (Modrow et al., 2013). The genome of herpesviruses is complex with 
unique and repeated regions. The DNA is double-stranded and linear, but 
during latency, it circularized as an episome. This episome remains inside 
the nucleus and maintains itself by tethering into host chromosome during 


















Figure 1-1. Schematic diagram depicts the structural components of herpes 


















1.1.4 Herpesvirus genomes  
Herpesvirus DNA genomes are constituted of linear and double 
stranded DNA that organised in number of ORFs which encode proteins 
ranging from about 70 to more than 200. All herpesvirus members contain 
unique and repeated sequences. These repeats are variably organised 
according to the genera of the herpesviruses. In herpesvirus simplex 1 and 2 
(a prototypes of α-herpesviruses), the genome contains long and short 
segment. Each one constitutes of a long and a short unique sequence 
region. These are flanked by inverted repeats. In gamma-herpesviruses, the 
identical terminal sequence is repeated at both ends of the genome such in 
KSHV. In some members such as EBV, additional internal unrelated repeat 
sequences (internal repeats) are present within the genome (Modrow et al., 
2013).      
1.1.5 Herpesvirus infection   
The most characteristic feature in herpesvirus biology is their ability to 
form lytic and latent infection through complex interactions within host cells. 
These two biological forms are controlled by numerous enzymes that effect 
viral nucleic acid metabolism and replication (Minarovits et al., 2007). 
Herpesviruses have also numerous evasive strategies to avoid the host 
immune system. This mainly occurs by suppression of the MHC class I and II 
which is responsible for processing and presentation of virus-derived 
antigens on the surface of infected cells (Griffin et al., 2010; Zuo & Rowe, 
2012). Recently, it has been shown that herpesviruses can also utilise the 
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host exosomes as a pathway to infect host cells (Sadeghipour & Mathias, 
2017).    
The infection is initiated by viral attachment and binding to specific 
host receptors then the viral entry is initiated (Spear et al., 2000). The capsid 
structure translocated via the microtubules into the host nuclear pores where 
viral genome can be injected into the nucleus (Cohen et al., 2011). After that 
viral DNA enters the nucleus, a highly controlled cascade of gene expression 
occurs in three kinetic stages: immediate early, early, and late. These stages 
are linked to viral DNA replication and viral encapsidation. The latter induced 
via covering the capsid by shell originated from the inner nuclear membrane 
then replaced by the vesicular membrane of the trans-Golgi apparatus. This 
leads to modify the envelop proteins by enzymes produced within these 
organelles. All these complicated steps resulted finally to enveloped the viral 
particle to egress from host cell membrane by cell to cell and exocytosis. 
Consequently infect other cells (Stenglein et al., 2009). Viral transmission 
occurs in numerous ways, including direct contact of infected mucosal 
secretions, tissue transplantation, and blood transfusion (Münz, 2016). 
1.1.5.1 Human herpesviruses  
Human herpesviruses can cause symptoms ranging from neuropathy 
to cancer (Britton & Jones, 2014). Humans are susceptible to infection by 
eight species of herpesviruses (Table 1-1) and have been extensively 
studied. The severity of pathogenesis and duration are variable according to 
the viral species. For instance, HSV-1 can cause cold sores and keratitis, 
while Human cytomegalovirus induces systematic symptoms. In contrast, 
7 
 
EBV is ubiquitous in humans. It replicates in lymphoid tissues and persists in 
a latent form inside memory B cells. Also, it can cause several types of 
human malignancy (Bouvard et al., 2009). The aim of this section is to review 
what is known about human herpesviruses with emphasis on HSV and KSHV 
as prototypes for the lytic and latent infection.    
 
Table 1-1. List of human herpesviruses with their relevant diseases, adapted 
from (Jha et al., 2016; Sadeghipour & Mathias, 2017).  
Herpesvirus Disease 
Alpha-herpesviruses  Herpes simplex-1 Cold sores 
Herpes simplex-2  Genital infection 
Varicella zoster virus Chicken pox  
Beta-herpesviruses  Human 
cytomegalovirus 
Systemic disease  
Human herpesvirus-6
  
Fever and rash in 
young and 
mononucleosis in old  
Human herpesvirus-7  Pityriasis rosea 
Gamma-
herpesviruses  
Epstein-Barr virus  Infectious 
mononucleosis 
T-cell lymphoma  
T/NK cell lymphoma  
Gastric carcinoma 
Breast cancer  
Burkitt’s lymphoma  
Hodgkin’s lymphoma   
Kaposi’s sarcoma 
herpesvirus 









1.1.5.1.1 Lytic infection  
One of the best studied alpha-herpesvirus for lytic infection is herpes 
simplex virus (HSV). Initial infection normally occurs at an early age and by 
close contact. It results in the establishment of sensory neuronal latency from 
which the virus can replicate and cause recrudescent disease whenever the 
immune system is suppressed (Tabery, 2010). The initial infection is normally 
localised within the oral or genital mucosa, then the viral particles pass along 
the neuronal axons into ganglionic nuclei where latency is established as an 
extrachromosomal episome. At this stage, it can stay dormant till viral 
reactivation (Whitley, 2014). 
There is a wide range of viral proteins that are encoded by the huge 
genomic coding capacity for herpesvirus biology. As in all other viruses, 
these proteins can be categorised as structural and non-structural that are 
necessary for successful replication (Adler et al., 2017).  
In the structural proteins, unlike some other viruses, herpesviruses 
have more than one glycoprotein embedded in its envelope. These 
glycoproteins play an important role in host cell entry (endocytosis or fusion 
of plasma membrane). The common glycoproteins found in all herpesviruses 
members are gB, gH, gL, and gM. However, some herpesviruses have 
additional unique glycoproteins present in the host cell membrane and/or 
embedded within the virus envelope (Modrow et al., 2013). Importantly, some 
glycoproteins are expressed as heterodimers such as gH/gL, to induce 
remodelling in host cell fusion activity and thus viral internalisation (Spear et 
al., 2000). Additional glycoproteins such as gD are also recruited to perform 
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particular roles such as cell tropism specification, receptor binding and/or 
enhancing  gH/gL binding (Eisenberg et al., 2012).  
The tegument component is another structural protein. This protein-
rich layer is localised between the viral envelope and capsid structures. This 
layer contains many proteins which are thought to play important roles in the 
late, lytic, and immediate early gene expression after viral internalisation. The 
mechanisms of this perspective was reviewed by (Owen et al., 2015) in HSV-
1, where modulation of specific host cell factors involved in host innate 
immunity by Infected Cell Protein 0 (ICP0), which is an immediate-early 
protein. Another role of tegument includes delivering the viral capsid to the 
cell nucleus by directing microtubules through the retrograde mediation 
pathway, and also during envelopment of cytoplasmic capsids with host 
membrane at the final assembly stage (Cohen et al., 2011). 
1.1.5.1.2 Latent infection  
Establishment of latency is characteristic in all herpesviruses, but host 
cell tropism and latency encoding-genes or proteins are variable. For 
instance, alphaherpesvirinae can establish latency in neuronal cells while 
betaherpesvirinae are harboured by monocytes; gammaherpesvirinae form 
latent infection in lymphocytes (Brunson et al., 2016).  
Human herpesvirus 8 (HHV-8) or Kaposi’s sarcoma- associated 
herpesvirus (KSHV) has an efficient latency strategy (Purushothaman et al., 
2016). After early infection, the herpesvirus genome circularizes inside the 
nucleus and shuts off virus/host gene expression to avoid the host immune 
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response. However, specific virus/host proteins are still expressed to 
maintain viral activity for later steps.  
Latency associated nuclear antigen (LANA) is one of the most 
abundantly expressed proteins that has a leading role in latency during 
infection (Minarovits et al., 2007). LANA is encoded by Open Reading Frame 
73 (ORF73) of γ-herpesviruses. It consists of three domains: N terminal 
domain, central domain and C terminal domain (Figure1-2) (Kelley-Clarke et 
al., 2009). Because γ-herpesviruses are highly related, the amino acid 
sequence of the corresponding LANA protein exhibits a strong evolutionary 
relationship (Figure 1-3). The OvHV-2 LANA (oLANA) shows similar features 
to other related γ-herpesviruses. For instance, the C terminal domain is 
highly similar, while the central domain is highly acidic with variable length 
due to multiple tandem repeats. The N terminal region is highly polymorphic 
(Figures 1-4) (Hart et al., 2007).  
Latency maintenance in KSHV in host cells was reported by tethering 
the viral genome to the host mitotic chromosomes via binding the N terminal 
domain of LANA with host chromosomes while the C domain binds with the 
Terminal Region of the viral DNA (Kelley-Clarke et al., 2009). LANA has 
been shown to be localised around the chromosomal centromeres, which is 
thought to assure  equal viral genome segregation into each new daughter 
cell upon cell division (Kelley-Clarke et al., 2007; Xiao et al., 2010). However, 
super-resolution laser confocal and correlative fluorescence electron image 
analyses have also shown that the LANA of KSHV is localised randomly on 
the bodies of condensed chromosomes for efficient virus segregation during 
the mitotic phase (Rahayu et al., 2016).  
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KSHV LANA contains nuclear localisation signals (NLS) (Figure 1-2); 
these unique sequences are responsible for LANA transport into the nucleus. 
This occurs through the phosphorylation by protein kinase A and cdc2- type 
kinase. Phosphorylation within the NLS leads to the nuclear import system to 
re-localise LANA protein to the nucleus (Verma et al., 2007). 
In KSHV latency, it was shown that LANA possibly modulates many of 
cellular factors. For instance, LANA can cause accumulation of a 
transcription factor known as β-catenin. This occurs by interaction of LANA 
with Glycogen Synthase Kinase 3 beta (GSK-3β) that is necessary for the 
phosphorylation of β-catenin. Thus, the degradation of this molecule leads to 
translocation of the cytoplasmic GSK-3β to the nucleus and consequently 
depletion of phosphorylated cytoplasmic β-catenin (Figure 1-5) (He et al., 
2010; Verma et al., 2007). Moreover, KSHV also encodes a G-protein 
coupled receptor (vGPCR) homologue. This deregulates the expression of 
Wnt/β-catenin to support its nuclear accumulation then induce malignancy 
(Angelova et al., 2014).  
Latency can also be induced by repression of the transcriptional 
activity of Replication and Transcription Activator (RTA) which is encoded by 
ORF50 of KSHV. Interestingly, RTA is found to be self-regulating and thereby 
activates transcription for lytic cycle switching. Thus, inhibition of this 
pathway likely leads to induction of the persistency cycle (Deng et al., 2000; 
Lan et al., 2004).  
A further strategy was found in LANA expressed by Herpesvirus 
Saimiri via modulating cell cycle regulatory proteins such as retinoblastoma 
protein (pRb) that is modulates the host cell cycle into the synthesis phase (s 
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phase) in which host DNA replication occurs to induce cell immortalisation by 
degradation of P53 (Borah et al., 2004).  In this case, host P53 plays a role 
as a tumour suppression factor. Therefore, LANA-P53 interaction in KSHV 
leads to oncogenesis due to down-regulation of P53 transcription. This 
occurs thorough ubiquitylation (Suzuki et al., 2010) or phosphorylation and 
ubiquitylation of P53 (Cai et al., 2012).  
Recently, it has been found that LANA can also recruit host Polycomb 
Repressive Complexes (PRC1 and PRC2) to suppress lytic genes through 
after initial attachment to the viral genome (Toth et al., 2016). Furthermore, 
LANA modulates cellular factors that are involved in cell cycle control such 
as: RING3/Brd2 and Brd4, that are commonly expressed in mammalian cells 
and have transcriptional roles (You et al., 2006); other cellular factors are 
thought to have similar roles such as: Interferon-Inducible Protein, Acetyl 
Transferase pCBP and p300, and Id Proteins (Verma et al., 2007). The 
mechanisms by which γ-herpesviruses can establish latency are 







Figure 1-2. Schematic diagram shows the structure of LANA protein in 
KSHV. The nuclear localisation signals (NLS) are found in the N and C 
terminal domains which have a role in LANA-nuclear transportation. The 
acidic domain constitutes of several tandem repeats. The N terminal domain 
is highly polymorphic whereas the C terminal domain is highly conserved 




Figure 1-3. Diagram shows the evolutionary relationship of OvHV-2 AIHV-1, 
HVS, KSHV, RRV, MHV-68, and equine HV2. The sequences of LANA 
amino acid are deposited at gene bank under (AF410847.1, APB09494, 
AAC55944, AFQ99213, AAF60071, NP_044913, and AIU39518) accession 
number respectively. Maximum Likelihood method phylogram with Bootstrap 
analysis (1,000 replicates) to provide support for individual nodes was 
conducted  by MEGA7 software, version 7.0.21 (Kumar et al., 2016).   
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MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV         1 ------------------------------------------------------------ 
HVS          1 ------------------------------------------------------------ 
OvHV-2       1 ------------------------------------------------------------ 
AlHV-1       1 MVLLRSGLGTRPGEEDCDGGPSTRTRGHGPLGPNIKSAAGIGGKFPPSPQGRKRKKGPKK 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV         1 ------------------------------------------------MAPPGMRLRS-- 
HVS          1 ------------------------------------------------------------ 
OvHV-2       1 ------------------------------------------------------------ 
AlHV-1      61 SGGKKKKRKVTGEGPGGGEGPGGGEGPGGGEGPGGGEGPGGGEGPGGGEVPGGGEVPGGG 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV        11 -----------GRST-GAPLTRGSCRKRNRSPERCDLGDDLHLQPRRKHVADSIDGR-EC 
HVS          1 ------------------------------------------------------------ 
OvHV-2       1 ------------------------------------------------------------ 
AlHV-1     121 EGPGGGEGPGGGEGPGGGEGPGGNSRKRKRGDGSKKHGG-----KKKK--KTTVTGEGGS 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV        58 GPHTLPIPGSPTVFTSGLPAFVSSPTLPVAPIPSPAPATPLPPP-----ALLPPVTT-SS 
HVS          1 ------------------------------------------------------------ 
OvHV-2       1 ------------------------------------------------------------ 
AlHV-1     174 GPEG------PERDDPDGPGSQEGPKREEGPLGPDGPEGPEGPEGEGPEGLEGPKGEGPE 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV       112 SPIPPS--HPVSPGTTDT----HS-------PSPALPPTQSPESSQRPPLSSPTGRPDSS 
HVS          1 ------------------------------------------------------------ 
OvHV-2       1 ------------------------------------------------------------ 
AlHV-1     228 GPEGPEGDSPDGPGAQEGPEGLEGPEGDEGPEGPEGPEGEGPEGPEGPKGDSPDGPGAQE 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV       159 TPMRPPPSQQTTPP---HSPTTPPPEPPSKSSPDSLAPSTLRSLRKRRLSSPQGPST--- 
HVS          1 ------------------------------------------------------------ 
OvHV-2       1 ------------------------------------------------------------ 
AlHV-1     288 GPEGPGGPDEDEGPEEPEGPEGEGPEGPEG-----EGPEGLEGPEGEGPEGPEGPEGDSP 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV       213 LNPICQSPPVSPPRCDFANRSVYP-------PWATES-----------------PIYVG- 
HVS          1 ------------------------------------------------------------ 
OvHV-2       1 -------------------------------------------------------MVLLR 
AlHV-1     343 DGPDAQEGPEGPGGPDEDEGPEEPEGPEGEGPEGPEGPEGEGPEGPEGPEGEGPEGLEGP 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ------------------------------------------------------------ 
RRV          1 ------------------------------------------------------------ 
KSHV       248 --SSSDGDTPP-----------RQP--PTS-----------PISIGSSSPSEGSWGDDTA 
HVS          1 ------------------------------------------------------------ 
OvHV-2       6 SGTSTDGD-------EDGRGRRPGPKKRPVTE---------GKGEGPGGEEEGPGGEGEG 
AlHV-1     403 EGEGPEGPEGPEGDSPDGPGAQEGPEGPEGPEGEGPEGLEGPEGEGPEGPE-GP--EGEG 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2    1 ----MADSEKRGPGRPPKKPR-------DGDGGDGER-------PGPSKKQPKGDGVKKP 
RRV          1 ------------------------------------------------------------ 
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KSHV       282 MLVLLAEIA----EEASKNEKECSE---NNQAGEDNGDNEISKESQVDKDDNDNKDDEEE 
HVS          1 ------------------------------------------------------------ 
OvHV-2      50 PGGEVEGPGG---------EGEGPGGEVEGPGGEGEGPGGE----------VEGPGGE-- 
AlHV-1     460 PEGP-EGPEGEGPERPEGPEGEGPEGP-EGP--EGEGPEGP---EGPERDSPDGPGA--- 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2   43 PHKRPRDDDGGDGERP--------------GPSKKPTKG---------------DGVRKP 
RRV          1 ------------------------------------------------------------ 
KSHV       335 -QETDEEDEEDDEEDDEEDDEEDDEEDDEEDDEEDDEEDDEEDDEEDDEEDDEEEDEEED 
HVS          1 ------------------------------------------------------------ 
OvHV-2      89 -VEGPGG----EGEGPGE-EVEGPG-GEGEGP-E----G---------E----GEG---- 
AlHV-1     510 -QEGPEGPEGPEGEGP-E-GLEGPE-G--EGP-E----G---------PEGPEGEG---- 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2   74 P-----RKRPRD--GDGGDREKPGPSKKPKHDDGQKSKQKRRGAWKLPHTRSRGTPPVKW 
RRV          1 ------------------------------------------------------------ 
KSHV       394 EEEDEEEEDEEDDDDEDNEDEEDDEEEDKKEDEE--DGGDGNKTLSIQSSQQQQEPQQQE 
HVS          1 ------------------------------------------------------------ 
OvHV-2     120 ------PG---------GEGEGPGGE------------GEGPG--------GE--VEGPG 
AlHV-1     546 ------PEGP-----EGPEGEGPEGPEGP---ER--DSPDGPG--------AQEGPEGPE 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  127 PP-KSPGMGYKPWTQGGKKKKKRHPKPKPKEDPKPGPGPGPDPGPDPGPGP--DP--GPG 
RRV          1 ------------------------------------------------------------ 
KSHV       452 PQQQEPQQQ-EP-LQEPQQQ---EPQQQEPQQQEPLQEPQQ---------------QEPQ 
HVS          1 ------------------------------------------------------------ 
OvHV-2     143 GE--GEGPG-GE-VEGPGG---------EGEGPEGEG-----------EGPGGE-GEGPG 
AlHV-1     582 GPEEDEGPE-GP--EGPEGE---GPEGPEGEGPEGLEGPEGDEGPEEPEGPEGDSPDGPG 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  182 P------------D------P--------GP-GPDP---GPGP----DPGPGPDPGPGPD 
RRV          1 ------------------------------------------------------------ 
KSHV       492 QQEPLQEPQQQEPQ-QQEPQQQEPQQQ--EPQQQEPQQQEPQQQEPQQ--QEP-Q--QQE 
HVS          1 ------------------------------------------------------------ 
OvHV-2     178 GEE--EGPGG---E-------------EEGPGGEEEGPGGEGE-GPGGEGEGP-VGEGEG 
AlHV-1     636 AQEVPEGPKGPEGECQSGPSSCEGQQVPKGPDGPEEGSSGPGS----SEGEGP-SGPGSS 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  208 PGPG------PDPGPGPDPGPG---PDP-------GPGPDP--GPGPD-PGPGP------ 
RRV          1 ------------------------------------------------------------ 
KSHV       544 PQQQEPQQREPQQREPQQREPQQREPQQ-REPQQREPQQREPQQREPQQREPQQQDEQQQ 
HVS          1 ------------------------------------------------------------ 
OvHV-2     218 P---------GGEGEGP----G-------GEEE--GPGGE---EEG-----PGGE----- 
AlHV-1     691 EGQQVPKGAEGSEGEGPCR-PG--GPDEDGDPE--GPDGTE--GEGP--CGPGGPDEDGD 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  243 DPG--PGPDPGPGPDPEPGPDPEPGPEPDPPINF------LDFWFEFPPYPSPTHDSTDG 
RRV          1 ------------------------------------------------------------ 
KSHV       603 DEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQQQ 
HVS          1 -----------------MAPRRRKAKRR---RHTLRSECKDKCKCHVQCYVSPRKRRRKL 
OvHV-2     243 GEG-PEG--EGEGPGGEG------------------------------------------ 
AlHV-1     742 PEG-PDGT-EGEGPCGPGGPDEDGDPEE-------SEGTEDDIKVGLTELLGS----MKL 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  295 PPPPSDP-----D------PDP----------K----------------PKP-------- 
RRV          1 ------------------------------------------------------------ 
KSHV       663 DEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQQQDEQEQQDEQEQQDEQEQQDEQQQDE 
HVS         41 KPQGDDD-----I-----NTTHQQQA-ALTEEQRREEVEEEGE-----ERERRGE----- 
OvHV-2     258 ------------------------------------------------------------ 
AlHV-1     789 DSSDSDS-----D-----NSSD--------------------------SANRRA------ 
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MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  310 ---------------------KPEPEPEPEPELEPEPEPEPEPEPELE-------PEPEP 
RRV          1 ------------------------------------------------------------ 
KSHV       723 QQQQDEQQQQDEQQQQDEQQQQDEQQQQDEQEQQEEQEQQEEQEQELEEQEQELEDQEQE 
HVS         80 ------------EEREGEGGEEGEGREEAEEEEAEEKEAEE---EEAE--EAEEEAEEEE 
OvHV-2     258 ---------------EGPGGGGPGG---EEEEEEEEGEEEEEEEEEEE--EEEEE--EEE 
AlHV-1     807 --------------LEGVCGSHSSSKDSDDEEEEEEEEEEEEEEEEDD--EEEEEDDEEE 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  342 EPEPEPELEPEPEPEPEPEPELEPEPEPEPEPEPELEPEPEPEPEP-------------- 
RRV          1 ------------------------------------------MWGS-------------- 
KSHV       783 LEEQEQELEEQEQELEEQEQELEEQEQELEEQEQELEEQEQELEEQEQELEEQEQELEEQ 
HVS        123 AEEAEAEEEEAEEE-E-------AEEEEAEEAEEE-EAEEA---EE-----EAEEE---- 
OvHV-2     296 EEE-EEEEE--EEEEE--------EEEEEEEEEEE-EEE--------------------- 
AlHV-1     851 EEDDEEEEEDDEEEEE-------DDEEEEEDDEEE-EEEEVIIITS-----SGEDGCGSS 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  388 --------EPEPEDKK----------------------------------------DPPP 
RRV          5 -----------------RQHRSGIVSGHGLRSSCRGHCGRRGGTREQAGRRGRGRGTAAP 
KSHV       843 EVEE---QEQEVEEQEQEQEEQELEEVEEQEQ-----------------E----QEEQ-- 
HVS        162 EAEEE--AEEEAEEAE-EAEEEAEEEAEEAE------------------E-------A-- 
OvHV-2     323 -------EEGEGE-------------GPGGEG-----------------E-------G-- 
AlHV-1     898 DVVCVGEEKGEGEKGK-GREEDGGEGGEGGEGG-EGGEGGEGGEGGEGGEGGEGGEGG-- 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  400 PPPPLPRPPPPPQPQPRFPPPLPRLPPDWPLPRIPFQ----------------------- 
RRV         48 AAAPAPPAPTTSGPQVRAVAEQG-HGSDTE-TATESRHG--------------------- 
KSHV       877 EEQELEEVEEQEEQELEEVEEQ--EEQELE-E-VEEQE---------------------- 
HVS        192 E--EAEEAEE--EAE--EAEEEA-E--EAE-EEAEE------------------------ 
OvHV-2     337 ---P---G-----G---E---G---------E---------------------------- 
AlHV-1     954 EGGEGGEGGE--GGEGGEGGEGG-EGGEGG-EGGEGGEGGEGGEGGEGGEGGEGGEGGEG 
 
MHV-68       1 ------------------------------------------------------------ 
EquinEHV2  437 ------------------------HQPLSHPFPSSRFPFFAPPGRFPSPWPWIDPFWCGF 
RRV         85 ------------S--SQGSPSGSG----SESVIVLGSPT-------PSPSGSAPVLASGL 
KSHV       911 -----QQELEEVEEQEQQGVEQQEQETVEEPIILHGSSS----------EDEMEVDY-PV 
HVS        218 ------AE--EAEEAEEAEEEAEEAE-EEEEEAGPSTPR---------LPHYKVVGQ--- 
OvHV-2     343 ------GPGGEG------------------------------------------------ 
AlHV-1    1010 GEGGERGKGGEGGEGGEGGEGGEGSEEDKKPFPCPRSPG---------VSGFYDLTW-SS 
 
MHV-68       1 -------------------------MP------------------------TSPPTTRNT 
EquinEHV2  473 PY-NFGGDGPPLPPLHSQFFLPPPPLPPPPPPPPPPPPPPPPPPPPEPEPKPKPPPEPEP 
RRV        120 SPQNTSGSSPASPASHSP-----PPSPP------------SHPGPHSP----APPSSHNP 
KSHV       955 VSTH-----------------------------------------EQIA--SSPPGDNTP 
HVS        257 ----------------------------------------------------------KP 
OvHV-2     349 ------------------------------------------------------------ 
AlHV-1    1060 SDRSTEGSR-G------------------------------SPGPDDLD--GRPGSQGPP 
 
MHV-68      12 -------TSGKTR----SGCKRRC--FNKPAAMPPKRRRAPKRPAPPPPPGCQGDEESSQ 
EquinEHV2  532 KPKPPPEPEPKPKPPPEPEPKPKPPPEPEPKPKPPPEPEPKPKPPPPPEPKPKPPPEPEP 
RRV        159 --------SPNQQPS--SFLQPS----HHDSPEPP-E------P-----PTSLPPPDS-- 
KSHV       972 ------DDDPQPGPS--REYR------YVL------------------------------ 
HVS        259 ------STQPGGVPK--L---------------------------------CL------- 
OvHV-2     349 ------------------------------------------------------------ 
AlHV-1    1087 ------TLSPQGFPG--SGYGSN----YDDDREPPVL------S-----PQCGGPSGN-- 
 
MHV-68      59 GTQTPNPPS-----------------PPVPPSSPTLPSSPVPPSSP-------------- 
EquinEHV2  592 KPKPPPPPEPEPKPKPPPPPEPEPKPKPPPPPEPEPKPKPPPPPEPKPRPPPPPEPKPKP 
RRV        191 ---------P------G------------PPQSPTPTSSP-PPQSP----PDSPGPP--- 
KSHV       988 ------------------------------------------RTSP----PHRPGVR--- 
HVS        271 ------------------------------------------KMQP----QHR------- 
OvHV-2     349 ------------------------------------------------------------ 
AlHV-1    1122 ---------E------G------------DESDPDSSREP-PDLSP----QNPPEGD--- 
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MHV-68      88 --------------------------VHEPPSP-----SPPPA---PPSPDVD------- 
EquinEHV2  652 PPPPEPKPRPPPPPEPKPKPPPPPEPKPKPPPPPEPKPKPPPQPQPKPKPGPDVGKWPLP 
RRV        216 -QSPTPQQ--APSPNTQ--QA--VSHTDHPTGPSRP--G-PPF-PGHTSHSYTVGGWGPP 
KSHV       999 ------------------------------------------------M----------- 
HVS        278 ------------------------------------------------------------ 
OvHV-2     349 ------------------------------------------------------------ 
AlHV-1    1147 -NGNE-------------------------------------------S----------- 
 
MHV-68     107 ---------VEGLDVGETDDPGP---------------------------------PPPK 
EquinEHV2  712 QICEKFGDPSHGVHVGSKSDPGPDPYCRPTTSTGDG---------------------GTR 
RRV        265 TRA--------------GGVPCLRLRCTSHNSHEDEAPERQQEQEGEERQQQPARPPRPP 
KSHV      1000 -----------------RRVPVTHPKKPHPRYQ------------------------Q-- 
HVS        278 ---------------------SRLPKGK-------------------------------- 
OvHV-2     349 ----------------------EGPGGEGEEGEEPE---------------DPMEGPS-- 
AlHV-1    1152 -----------------DSDPSYQPLGGSSSSSEDD---------------DPGEGT--- 
 
MHV-68     125 RYSRYQKPH---NPSDPLPKKYQGMRRHLQVTAPRLFDPEGHPPTHFKSAVMFSSTHPYT 
EquinEHV2  751 KYPRYQHSAPHPDPTPPPSKKYLAGWKFFKDYLNGLC-HW-IPGCGWRFMVMISGTDPEK 
RRV        311 RPPRYPIPIPYPSSEEEVPRKYRPQRRFYRQV-L-GPRIDPPRPGPWCHGVIFCNSDPYS 
KSHV      1017 ------PPVPY-RQIDDCPAKARPQHIFYRRF-LGKDGRRD-PKCQWKFAVIFWGNDPYG 
HVS        285 ------------QSHDKVPKKYQARNKF---FSQAAPSVLDLSPKSWCWVVDFWG-PTDA 
OvHV-2     370 ------SGPPV-RGRRKRPPKHQPETDRAKR--KKLAPIWDPTLKEATYSLHLNCTSKDP 
AlHV-1    1177 ----------S-QGPPKRPPKHHPQTKRAQGKTLGLDPLYDPRQKAATFSLHLGCPTKDP 
 
MHV-68     182 LNKLHKCIQSKHVLSTPVSCLPLVPGTTQ--QCVTYYLLSFVEDKKQAKKLKRVVLAYCE 
EquinEHV2  809 LYRISKYCCQDGYCPTGVQASPKTP----LTTHDVWNVQVWCQSRDQALGLQGCITAYTT 
RRV        369 LYRLARCLQFPGIRASSVRVLPDAPGSPVI---PAFCITVFCQSRGTAKAVKKARRRWER 
KSHV      1068 LKKLSQAFQFGGVKAGPVSCLPH---PGPDQSPITYCVYVYCQNKDTSKKVQMARLAWEA 
HVS        329 LYRLSRSLSFPGAVSSGIQTFPKGPHATGP---WVYFITVYCRTFQTAKEVIKAQKKYEK 
OvHV-2     421 VVRVSRSVRA---------LNPNAPHSNIFFTGGMYTFVIYGNDKEAVESLFQFLLQDAM 
AlHV-1    1226 LVRLSRMIRT---------LHPEGPHSSIFFTGGQYVVVFYVTSYFEAKKLKDFIIREQN 
 
MHV-68     240 KYH--SSVEGTIVKAKPYFPLPEPPTEPPTDPEQPSTSTQASGT------QHGPTASLDA 
EquinEHV2  865 IYP--PLLQASIGSFWPPVDLGERNYRPDAYPPGPGEEEGQLGATPESSPESGPGDPRNT 
RRV        426 HHPSAPHFQASIVRMDRGLPIQH------------------------------------- 
KSHV      1125 SHPLAGNLQSSIVKFKKPLPLTQPGEN-----QGPGDSPQEMT----------------- 
HVS        386 KYPRSAKLKASLGKFSKSLPIE-------------------------------------- 
OvHV-2     472 NNPQAGAVNISTGPLTPSLPFNQQ------------------------------------ 
AlHV-1    1277 RNPLQGRVNVSLARHYPPFPFPHE------------------------------------ 
 
MHV-68     292 GAEQGATGSPGSSPGQQGQGSQT-------- 
EquinEHV2  923 GEDDGRDP----TNPDEGDGDPVIVLSDDSD 
RRV            ------------------------------- 
KSHV           ------------------------------- 
HVS            ------------------------------- 
OvHV-2         ------------------------------- 
AlHV-1         ------------------------------- 
 
 
Figure 1-4. Alignment analysis of LANA amino acids homologue of different 
γ-herpesviruses including:  MHV-68, Equine HV2, RRV, KSHV, HVS, OvHV-
2, and AIHV-1, corresponded with GenBank accession numbers 
(NP_044913, AIU39518, NP_570820, ACY00477, NP_040275, AAL05844, 
and NP_065570) respectively. This was performed using “Clustal Omega” 
program and displayed by the “BOXSHADE” server. This highlights 
sequence diversity of LANA in which the highly identical residues (can be 
seen predominantly within C terminal homologue) are depicted in black. 
Similar residues are depicted in grey (appear mostly within N terminal 
homologue). The predominant tandem repeats appear within the central 
domain of LANA. The Glutamic acid is coloured in blue while the Proline are 
highlighted red.   
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Figure 1-5. Schematic diagram shows tethering of viral genome with host chromatin. The stable expression of LANA into host 
cytoplasm leads to translocate into nucleus by NLS to maintain viral latency, at the same time LANA modulates Wnt signals by 
binding to GSK-3B, moving it into the nucleus. Thus, the level of cytoplasmic GSK-3B declined, resulting in accumulation of non-
phosphorylated B- catenin, leading to translocate it to the nucleus to associate with LEF and TCF family protein of transcription 
agents. This is one example of how LANA maintains viral latency and modulates host gene transcription. Adopted from (Verma et 
al., 2007).  
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1.2 Herpesvirus infection in ruminants   
There is wide range of herpesviruses belonging to alpha- and gamma 
herpesvirinae that can cause variety of syndromes in ruminants. Some 
herpesviruses can target neuronal cells to cause neuropathy and establish 
latency. Others however, target lymphoid tissue in their lytic and latent forms 
and induce immuno-deregulation. In both strategies,  viral  cycles can persist 
for life within their hosts (Engels & Ackermann, 1996). Herein, examples of 
closely related ruminant alphaherpesviruses and gammaherpesvirus are 
reviewed with emphasis on their enzootic, pathology, and diagnosis.   
1.2.1 Infectious Bovine Rhinotracheitis/Vulvovaginitis  
BoHV-1 is classified as an α-herpesvirus within varicellovirus genus. 
Its genome consists of double-stranded DNA, 135,301 kb in length (Davison, 
2010). To date, there are five strains that can cause disease in cattle. 
Commonly, it causes two forms of clinical disease: the genital syndrome 
called “Infectious Pustular Vulvovaginitis” (IPV) in female as well as 
“Infectious Pustular Balanoposthitis” (IPB) in male; and a respiratory form 
known as “infectious bovine rhinotracheitis” (IBR) (Muylkens et al., 2007). 
The disease is wide spread in many countries (Raaperi et al., 2014).  
The severity of the disease is variable according to age. For instance, 
in adults, severity ranges from mild clinical signs with reduction in milk yield 
to abortion and infertility (Muylkens et al., 2007). However, in younger aged 
cattle, it can cooperate with other agents to cause a state known as bovine 
respiratory disease (BRD) complex or “shipping fever”. The agents related to 
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this include: bovine viral diarrhea virus (BVDV), bovine parainfluenzavirus-3 
and bovine respiratory syncytial virus. As a result of this, other opportunistic 
bacterial infections such as Mannheimia haemolytica and Haemophilus 
somnus  can lead to increased morbidity and mortality rate (van Drunen 
Littel-van den Hurk, 2006).  
The mode of BoHV-1 transmission includes invading the mucosal 
membrane of the upper respiratory tract or the conjunctival mucus through 
the direct contact of contaminated aerosol, also by means of the genital tract 
membrane during animal mating or infected semen. At this point, the virus 
causes a lytic infection in epithelia (Muylkens et al., 2007).   
The virus can be highly pathogenic during the acute infection. It can 
cause upper respiratory tract immune suppression by expression of three 
viral genes (bICP0, UL41, US4) that cause inhibition of interferon 
transcription, by the bICP0 hindering viral peptide presentation to CD8+ T-
cells and by expressing gG that acts as a chemokine- binding protein and 
interferes with the chemo-attraction of lymphocytes (Jones & Chowdhury, 
2007).  
Although, sensory neurons are the main sites for latent infection, 
BoHV-1 can also form persistency and reactivation in other tissues such as 
lymphoid tonsil, suggesting a possible role of the pharyngeal tonsil in 
transmission of the virus during reactivation (Winkler et al., 2000). In the 
central nervous system where the virus establishes latency, expression of 
bICP0 is repressed (Jones et al., 2006). However, during viral reactivation, 
expression of this protein increases. The bICP0 is a trans-activator of viral 
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promoters and its main function is to activate viral gene expression and 
suppress host cell mediated immunity (Biswas et al., 2013).    
Maintaining latency is also achieved by expression of two viral genes, 
the latency related (LR) gene and ORF-E (Jones et al., 2006, 2011). 
Expression of bICP0 is antagonised by LR gene transcripts when BoHV-1 
becomes latent (Biswas et al., 2013).    
The disease has been tackled using effective attenuated or inactivated 
vaccines, as well as live and killed gE-deleted marker vaccines in Europe 
that distinguish between infection with the vaccine and virulent virus. 
However, viral latency and the isolation of virulent virus from diseased 
animals or from aborted foetuses that were previously vaccinated make the 
control strategies more difficult (van Drunen Littel-van den Hurk, 2006; Fulton 
et al., 2016; Mahan et al., 2016).  
Recently, a polymerase spiral reaction (PSR) has been developed to 
detect BoHV-1 by (Malla et al., 2018). This technique provides accuracy, 
cost, and time effectiveness for diagnosis (Liu et al., 2015). 
1.2.2 Bovine herpesvirus 5 
BoHV-5 is belonging to the α-herpesvirinae subfamily within the 
varicellovirus genus. The virus is commonly named ‘’Bovine encephalitis 
virus”. Genetically, it is closely related to BoHV-1 (Davison, 2010). However, 
BoHV-5 and BoHV-1 have different pathogenesis. The central nervous 
system is the target for BoHV-5 latency especially in young cattle (Delhon et 
al., 2003) whereas BoHV-1 causes infectious rhinotracheitis in cattle. A 
recent study has suggested that unique microRNAs encoded by both viral 
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species possibly play an important role in this pathological discrepancy. 
Fundamentally, these microRNAs interfere with RNA translation and stability 
to control protein expression. These microRNAs detected in locus within or 
near the bICP0 and LR genes that are expressed abundantly in lytic and 
latent infection, respectively. These have been found in BoHV-1 but not in 
same locus of BoHV-5 genomes, these miRNAs are likely to be involved in 
the regulation of viral and host genes during infection and may also play a 
role in pathology (Tang et al., 2014).     
Interestingly, BoHV-5 and BoHV-1 co-infection was demonstrated in a 
high percentage of cattle in Brazil (75.9 %). All of these cases were infected 
latently (Campos et al., 2009).  
BoHV-5 is considered as a neuro-virulent species. Experimentally, it 
was reported to latently-infect calf brains. However, systemic infection was 
reported during reactivation (Vogel et al., 2003). It has also been reported 
that establishment of latency and reactivation occur not only in CNS but also 
in non- neuronal tissue such as tonsillar lymphoid tissue (Favier et al., 2014).  
Both BoHV-1 and BoHV-5 were detected in bull’s semen by PCR 
(Oliveira et al., 2011) but BoHV-5 was isolated and sequenced from healthy 
bull’s semen. Therefore, in artificial insemination, precautions should be 
taken to avoid viral transmission (Rodríguez et al., 2012). Other economic 
and epidemiologic aspects of BoHV-5 infection includes cross-infection into 
sheep which seem to be susceptible to both acute and latent forms combined 
with  high pathological impact (Silva.M et al., 1999).  
Previously, numerous efforts to produce a vaccine using BoHV-1 have 
failed to show cross protection against BoHV-5. However, a recombinant 
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BoHV-5 live vaccine has been developed by deleting thymidine kinase and 
glycoprotein E genes. This has successfully protected cattle from disease 
against both viral species with observed reduction in viral shedding (Anziliero 
et al., 2011). A similar reduction in viral shedding was also demonstrated by 
using a vaccine where glycoprotein I (gI), glycoprotein E (gE) and membrane 
protein US9 (BoHV-5 gI/gE/US9-) were deleted. Nevertheless, this model did 
not protect against establishment of latency and virus reactivation (Campos 
et al., 2011).   
The diagnosis of BoHV-5 was reported in several studies such as in 
situ PCR hybridisation assay to detect the virus DNA (Cardoso et al., 2010) 
and multiplex q-PCR assay that was developed by (Diallo et al., 2011) to 
differentiate between BoHV-5 and BoHV-1. This technique was combined 
with a restriction length polymorphism assay to provide simple, and fast viral 
subtyping identification (Maidana et al., 2013). Another q-PCR assay based 
on reference control with SYBR-Green fluorescence was used to detect this 
species reliably, specifically with less time consumption (Cardoso et al., 
2013).  
Recently, development of an indirect ELISA as a serological 
diagnostic assay based on recombinant glycoprotein D viral antigen has 
been used to detect BoHV-5 in less laborious procedures (Dummer et al., 
2016). In addition, a latex agglutination test for rapid detection of BoHV-5 and 
BoHV-1 antibodies has been developed (Fan et al., 2012).  
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1.2.3 Caprine herpesvirus 1  
CpHV-1 is classified as alphaherpesvirus, clustered within 
varicellovirus genus; commonly named “goat herpesvirus” (Davison, 2010). It 
is closely related to BoHV-1 (Engels et al., 1992). This species is widely 
distributed in several European countries and sometimes causes  occasional 
major outbreaks (Piper et al., 2008; Thiry et al., 2008) while in Poland it was 
not identified (Czopowicz et al., 2010).   
The severity of the clinical signs are age-dependent as in young kids, 
it is characterised by fatal gastro-enteric infection whereas in aged goats, 
infection appeared as a mild respiratory syndrome (Keuser et al., 2004b, a; 
McCoy et al., 2007; Tempesta et al., 1999). As in BoHV-1, there are genital 
signs within infected females characterised by vesicular-ulcerative vulvo-
vaginitis and abortion while in male signs involve ulcerative balanoposthitis 
(Camero et al., 2015; McCoy et al., 2007). CpHV-1 targets the genital system 
that acts as the main port for viral transmission. Therefore, it can affect 
pregnancy, especially during the second phase of gestation (Tempesta et al., 
2000, 2004).   
There are numerous infection risk factors that lead to CpHV-1 
spreading but the venereal method seems to be the most important one as it 
happens seasonally during the oestrus cycle and natural mating or in any 
other stressful factors (Silva et al., 2013); However, the airborne and oral-
faecal mode of transmission are still unknown. Nevertheless, respiratory and 
digestive system histological changes have been observed in naturally 
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infected kids, suggesting that CpHV-1 might be transmitted through these 
pathways (Roperto et al., 2000).  
The diagnosis of CpHV-1 includes using serological, biological, and 
molecular methods as used by (Keuser et al., 2002, 2004a). Previously, it 
was diagnosed by PCR after reactivation from the latent phase of the sacral 
ganglia (Tempesta et al., 1999). However, due to the fact that there is a need 
to discriminate diagnosis of  BoHV-1, BoHV-5, CpHV-1, cervine herpesvirus 
1 (CvHV-1) and CvHV-2 which are closely, antigenically and genetically, 
related to each other, murine monoclonal antibodies (MAbs) have been 
developed against each of these species and used in several immunological 
techniques such as ELISA, IFA, and radio-immuno-precipitation (Keuser et 
al., 2004b). An ELISA test was also developed by using CpHV-1 specific 
IgG1 and IgG2 (Marinaro et al., 2009).  
Numerous studies have been conducted to provide a successful 
vaccine against CpHV-1, such as using inactivated virus (Camero et al., 
2007; Tempesta et al., 2001) or recombinant, using BoHV-1 live attenuated 
virus without glycoprotein E vaccine (Thiry et al., 2006a, b). Inactivated 
CpHV-1 vaccine with heat-labile enterotoxin of Escherichia coli adjuvant 
(LTK63) as leads to a strong immune response and protection against fatal 
CpHV-1  (Tempesta et al., 2007).  
1.2.4 Cervid herpesvirus 2 
CvHV-2 is a member of the alphaherpesvirinae, within varicellovirus 
genus. It is commonly named Reindeer herpesvirus (Davison, 2010). Like 
other ruminant-specific members of the subfamily: such as CvHV-1 and Elk 
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herpesvirus (ElkHV), CvHV-2 is related to BoHV-1 as well (Deregt et al., 
2005; Kautto et al., 2012; Lillehaug et al., 2003; Vanderplasschen et al., 
1993). The sero-prevalence of these members has been demonstrated in 
several regions including: Alaska, Canada, Greenland, Finland, Sweden, and 
Norway in which it is widely distributed (das Neves et al., 2010). Recently, an 
outbreak of infectious keratoconjunctivitis (IKC) has been recorded in semi-
domesticated reindeer in Norway, this demonstrating the economic 
importance of this virus (Tryland et al., 2009) in which viral isolation from 
naturally infected deer has been reported for the first time. 
The clinical signs of CvHV-2 in experimentally infected cattle were 
noticed as mild rhinitis with possibility of natural transmission. However, 
isolation and reactivation of this species from its natural host “reindeer” by 
therapeutic immuno-suppressors, “dexamethasone” leads to severe systemic 
viremia combined with abortion, that suggest vertical transmission (das 
Neves et al., 2009a). Furthermore, CvHV-2 appears to be endemic latently in 
the semi-domesticated reindeer and as in most alphaherpesviruses, the 
trigeminal ganglia are likely to be the target tissue for latency. Importantly, 
this species can also cause fatal respiratory syndrome due to the respiratory 
transmission pathway (das Neves et al., 2009b, c).  
A commercial BoHV-1-blocking ELISA has been used to detect CvHV-
1 antibodies. This assay is likely useful to screen α-herpesviruses in different 
hosts (das Neves et al., 2009e, d).  
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1.2.5 Bovine herpesvirus 2 
BoHV-2 is classified within the alphaherpesvirinae subfamily, 
simplexvirus genus. It is closely related to Ateline herpesvirus 1, 
Cercopithecine herpesvirus 2, and human herpes simplex virus type 1 
(Davison, 2010). Commonly, it is known as bovine mammillitis virus or 
Allerton virus or pseudo-lumpy skin disease virus. 
It causes vesicular, erosive and necrotic lesions of the teat and udder 
of the infected cow. These lesions seem to be a way to infect suckling calves 
or even to spread the virus by any direct skin contact (Ehlers et al., 1999a). 
The udder lesions possibly also predispose cattle to mastitis. This is due to 
the fact that BoHV-2 supress immune defences, particularly the physical skin 
barrier, thus it allows opportunistic pathogens to proliferate and cause 
inflammation. To date, there is no available commercial vaccine to reduce the 
occurrence of BoHV-2 cases (Wellenberg et al., 2002).  
Interestingly, a novel herpesvirus, closely related to BoHV-2, was 
detected in naturally infected rabbits with acute clinical disease. This virus 
was classified as a new member of the simplex virus genus (Jin et al., 2008). 
The pathogenesis of BoHV-2 is still unclear. The subclinical infection 
of heifer cows can develop into acute disease during the first period of 
lactation, which is considered as a predisposing factor (Torres et al., 2009). 
Cattle are naturally susceptible to the disease with acute and latent forms of 
infection observed (Torres et al., 2009, 2010). In the natural infection of 
cattle, latency is thought to be in the trigeminal ganglia, which seems to be 
the target site not only for BoHV-2 but also for BoHV-4 co-infection (Campos 
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et al., 2014). However BoHV-2 can also persist in the inguinal nerves of 
cattle (Torres et al., 2009).  
Further evidence of BoHV-2 infection was reported in Hungary as roe, 
red, fallow, and mouflon deer species as well as domestic sheep were 
diagnosed to be positive by PCR for BoHV-2 with variable infection 
percentage ranging (3-50 %). However,  there was no report of positive 
cases in goats (Kálmán & Egyed, 2005).  
In BoHV-2 diagnosis, although PCR has been available since 2002 to 
detect this virus (De-Giuli et al., 2002; Imai et al., 2002), few recent 
epidemiological studies have been conducted (Imai et al., 2005). 
Nevertheless, BoHV-2 was successfully isolated from systemic infections of 
cattle in the United Kingdom (Woods et al., 1996) and Egypt (Iman, 2012). It 
was also isolated from milk of cattle that suffered from teat and ductus 
papillaris ulcer (Wellenberg et al., 2002).   
1.2.6 Bovine herpesvirus 4 
BoHV-4 belongs to the gammaherpesvirus subfamily (Davison, 2010). 
The virus has worldwide distribution and has been isolated from healthy and 
infected cattle with signs of reproductive disorders (Verna et al., 2012). 
Interestingly, BoHV-4 can naturally and experimentally infect a wide range of 
hosts including ruminant and non-ruminant species. In this respect, BoHV-4 
differs from other γ-herpesviruses that require a specific natural host to infect 
(Verna et al., 2016).  
BoHV-4 has been successfully isolated from dairy herds with evidence 
of metritis (Bilge-Dağalp et al., 2010; Dubuisson et al., 1991). It is also 
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reported to be reactivated by stress conditions (Peshev & Christova, 2013) or 
isolated from cattle with neurological signs (Costa et al., 2011). The frequent 
occurrence of BoHV-4 in the genital tract indicates in some ways its role in 
causing reproductive disorders (Verna et al., 2016). Thus, BoHV-4 is tropic 
for bovine endometrial cells and induces a cytopathic effect by modulating 
the expression of host cyclooxygenase 2 and prostaglandin estradiol 
(Donofrio et al., 2007). 
BoHV-4 can be propagated in different animal cell lines such bovine, 
mice, cats, rabbits, monkey, and guinea pigs (Donofrio et al., 2002; Donofrio 
& Van Santen, 2001; Egyed et al., 1997; Vanderplasschen et al., 1995); 
interestingly also in human cell lines such as embryonic lung cell line and 
giant cell glioblastoma (Egyed, 1998).    
BoHV-4 has been detected in a high percentage (87.1 %) of cattle with 
endometritis, vaginitis, and mastitis. However, there was no evidence for its 
role as a primary causative agent within these cases and it has been 
suggested that viral cooperation with other opportunistic pathogens could be 
the main factor for these cases (Chastant-Maillard, 2015; Fabian et al., 
2008).  
The ORF73 in BoHV-4, as in other gammaherpesviruses, is necessary 
for viral latency but is non-essential for replication in vitro when was deleted. 
This finding led to the propose a development of a vaccine using BoHV-4 as 
a vector (Thirion et al., 2010). Other authors have demonstrated the 
feasibility of using BoHV-4 as a vector to deliver foreign genes because of 
the genetic properties of BoHV-4 as well as the wide range of hosts that 
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infects, and the variety of cell lines that allow viral replication (Donofrio et al., 
2002; Franceschi et al., 2015; Jacca et al., 2016). 
PCR and ELISA assays have been used to diagnose BoHV-4 infection 
(de Boer et al., 2014; Donofrio et al., 2000).   
  
1.2.7 Bovine herpesvirus 6 
BoHV-6, previously known as Bovine lymphotropic herpesvirus 
(BLHV), is a member of the Gammaherpesvirinae subfamily and Macavirus 
genus (Davison, 2010). It has novel complement of genes that are unique in 
the subfamily including: Bov2, Bov4.5, Bov5, Bov6, Bov7, Bov8 and Bov9. 
One of these (Bov2.b2) encodes an ornithine decarboxylase (ODC) that 
controls the cellular proliferation and enhances viral replication (Jia et al., 
2014).   
This virus was firstly identified in the USA from peripheral blood cells 
of cattle infected with Bovine leukaemia virus (BLV); at that time, its role as a 
co-factor in causing BLV- associated disease was proposed (Rovnak et al., 
1998). Also, it was detected in paraffin-embedded tissues of bison and cattle 
infected with MCF (Collins et al., 2000). Interestingly, BoHV-6 has been 
reported in cattle abortion in Canada (Gagnon et al., 2008) and in 
lymphoproliferative disease in buffaloes that were negative for bovine 
leukaemia virus (BLV) (de Oliveira et al., 2015). Other studies have 
confirmed the presence of BoHV-6 in the UK and other European countries in 
cows suffering from non-responsive postpartum metritis (PPM), suggesting a 
role in reproductive system disorders (Banks et al., 2008; Cobb et al., 2006; 
31 
 
Garigliany et al., 2013). PAN-herpesvirus PCR and antibody serological tests 
were used to identify this species in dairy cattle suffering from metritis in New 
Zealand (de Boer et al., 2014). However, numerous studies have reported 
that BoHV-6 is ubiquitous in healthy cattle as viral DNA was detected in 
peripheral blood of these animals, suggesting infection at a young age 
(Banks et al., 2008; Kubiś et al., 2013; Rovnak et al., 1998).  
Recently, viral meta-genomic analysis has been used to fill the 
knowledge gap in aetiological agents- associated with Bovine Respiratory 
Disease (BRD) (Ng et al., 2015) and non-suppurative encephalitis in cattle 
(Wüthrich et al., 2016); interestingly, BoHV-6 seems to be one of the viruses 
that could cause these syndromes.   
1.2.8 Ovine herpesvirus 1 
OvHV-1 was not categorised in the last review update on viral 
taxonomy that has been published by (Davison, 2010). However, analysis of 
the thymidine kinase and VP23 locus sequence by (ŽIAK et al., 2014) has 
shown that OvHV-1 lies within the Macavirus genus of the 
Gammaherpesvirinae subfamily. 
Previously, OvHV-1 was proposed as the aetiological agent of Sheep 
Pulmonary Adenomatosis (SPA) which is a tumour of sheep (Martin et al., 
1979). Subsequently, Jaagsiekte sheep retrovirus (JSRV) was identified as 
the causative agent of SPA (Martin et al., 1979). OvHV-1 has been 
experimentally inoculated into healthy lambs to study its pathogenic effects; 
although the pathological changes involved a focal cellular infiltration of lung 
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tissue at earlier stages of infection then widespread proliferative pneumonia 
at a later stage, no signs of SPA was seen (Scott et al., 1984).  
Interestingly, the results of a sero-surveillance of healthy sheep in 
Slovakia revealed a high percentage of infection (65-80 %) (Kopácek et al., 
2000). According to (Scott et al., 1984), OvHV-1 can stay quiescently in 
sheep lung tissue then be reactivated at the time when SPA appears, 
suggesting the notion of reactivation due to stressful circumstances. 
To date, no study has been conducted to quantify this virus in the UK. 
Also, there is a gap in the knowledge regarding its association with both MCF 
and SPA.  
1.3 Malignant Catarrhal Fever  
Malignant Catarrhal Fever (MCF) is a fatal disease of cattle and other 
ungulate animals including deer, bison, water buffalo, and pigs. Several 
related γ-herpesviruses cause MCF. They are harboured by their natural 
“reservoir” hosts without clinical disease and infect other “susceptible” hosts 
where they can cause fatal disease (Russell et al., 2009).  
The clinico-pathological signs of MCF are fever, ocular opacity and 
nasal discharge with arteritis, lymphoid proliferation, and mucosal necrosis of 
the digestive tract (Figure 1-6). The severity of the pathology depends on 
many factors including type of the causative agent and infected hosts 
(O’Toole & Li, 2014). A considerable amount of research has been 
conducted to understand MCF pathogenesis and to develop successful 
vaccine. To date, numerous aspects are still unknown. However, recent 
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Figure 1-6. Gross pathognomonic haemorrhagic lesions of cow infected with 
MCF shows: (A) the classical head and eye signs with corneal opacity and 
mucopurulent nasal discharge, (B) oesophagus, (C) Upper palate showing 
involvement of buccal mucosa, (C) tracheal ring with sever haemorrhage, (D) 
tongue with sever haemorrhagic and erosive lesions.   
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1.3.1 Aetiology of MCF  
Herpesviruses have co-evolved within particular hosts. Some 
herpesviruses are well adapted to their hosts; therefore, they exhibit no 
clinical signs, whereas infection of closely-related species can lead to severe 
clinical disease. All MCF-associated viruses are γ-herpesviruses within the 
macavirus genus. The aetiology of MCF is also depends on the geographical 
distribution of the reservoir hosts. For instance, MCF in cattle caused by 
alcelaphine herpesvirus 1 (AIHV-1) appears where its natural host, the 
wildebeest, is distributed in Eastern and Southern Africa. For this reason, this 
form is called wildebeest-associated MCF (WA-MCF) (Bedelian et al., 2007).  
A common cause of MCF is OvHV-2 that is distributed globally wherever its 
natural host, sheep are reared with cattle or other MCF-susceptible hosts 
(Russell et al., 2009). However, the number of aetiological agents known to 
cause MCF continues to increase. To date, there are at least ten MCF-
associated viruses, six of them can cause disease naturally whilst causal 
associations are less clear for the remaining viruses  (Table 1-2) (O’Toole & 
Li, 2014). MCF is a complex disease with a wide range of hosts (reservoir 
and susceptible) and a number of causative herpesviruses. Additionally, in 
some cases, more than one viral species might infect in one host.  
Diagnosis of the MCF agents mostly relies on using of PCR to confirm 
the infection in the clinically-affected animals and C-ELISA for the prevalence 
of infection in the natural host species (OIE, 2004). This because the fact that 
OvHV-2 load increased systemically (including blood) during clinical MCF 
which may be detected by routine PCR. However, the viral load within the 
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reservoir species and latently infected hosts is low which may not always be 
detected by PCR. Nevertheless, serology is useful in reservoir species where 
infection is associated with antibody responses but not for clinical MCF 
cases, which do not always seroconvert. The CI- ELISA is also a useful tool 
in serology of multiple MCF viruses in reservoir species, as it recognises an 
epitope conserved in the gB glycoprotein of MCF viruses.  
In the following sections, examples of the causative agents of MCF 
are discussed with focus on their relevance to MCF.  
 
Table 1-2. List of MCF related herpesviruses in ruminants. Adopted from (O 
’Toole & Li, 2014).  
The virus  Reservoir host Susceptible host  
AIHV-1 Wildebeest cattle 
AIHV-2 Hartebeest Barbary red deer  
OvHV-2 Sheep  Cattle, bison, buffalo, goat deer, 
and pigs 




Goat  Deer  







Not confirmed   
Aoudad-
MCFV 
Aoudad Not confirmed   
Muskox-
MCFV 
Muskox Not confirmed   
Gemsbok-
MCFV 




1.3.1.1 Alcelaphine herpesvirus 1 
AlHV-1 is harboured asymptomatically by blue and black wildebeest 
(Connochaetes taurinus and Connochaetes gnou, respectively). AlHV-1 can 
be transmitted horizontally and vertically so a high proportion of wildebeest 
are reported carriers from a young (Wambua et al., 2016).  
In horizontal transmission, infection occurs usually after 3 months of 
age due to maternal antibody (IgG) that provides protection during the early 
age. When calves become infected, they shed viral particles through nasal 
and ocular secretions and by six months old, infected animals shed less cell 
free virus unless they encounter stressful conditions (Russell et al., 2009; 
Wambua et al., 2016). Vertical transmission has also been demonstrated. 
This can occur via uterine transmission as about (50 %) of the parturient 
wildebeest were shown carry the viral DNA in their placental tissue 
(Lankester et al., 2015).  
AIHV-1 can be propagated in vitro by using T-lymphoblastoid cell lines 
known as large granular lymphocytes (LGLs). LGLs were originated from 
MCF-affected hosts. This has enabled researchers to understand the 
genome sequence of AIHV-1. AIHV-1 genome contains about 131,000 bp. 
This is flanked by terminal repeats of 1100 bp. The sequence contains at 
least 70 ORFs, of which ten genes are unique and are known as A1-A10. 
Eight of these unique genes are similar to those found in OvHV-2 (Figure1-
8). Most of the non-unique ORFs (60) are conserved across homologous γ-




Figure 1-7.  Schematic diagram shows the organisation of OvHV-2 and AIHV-1 genomes. The ORFs are seen as grey block arrows 
that refer to their position, and direction of translation with relevant ORF numbers. Adopted from (Hart et al., 2007).   
        
38 
 
1.3.1.2 Ovine herpesvirus 2 
OvHV-2 is the principal cause of MCF in several ruminant species 
(Hart et al., 2007; Taus et al., 2007). It is carried asymptomatically in sheep. 
Viral shedding occurs intermittently with higher shedding in adolescent sheep 
that may result in more transmission to susceptible species (Russell et al., 
2009).  
There is no permissive cell line with which to propagate OvHV-2. This 
makes studying its biology and development of a suitable vaccine difficult. 
However, propagation of large granular lymphocytes (LGLs) that carry OvHV-
2 or AIHV-1 originated from tissues of MCF-affected animals has helped to 
understand MCF pathogenesis (Russell et al., 2009).  
These T-lymphoblastoid cell lines have cytotoxic activity. The OvHV-2 
genomic form and transcripts inside these cells are variable. The genomic 
DNA appears as linear and circular conformations inside the LGLs that 
originated from MCF-susceptible hosts (cattle and rabbit), indicating latent 
and lytic viral transcripts. In contrast, the peripheral blood mononuclear cells 
that of the reservoir host (sheep) contain a circular genomic DNA 
conformation with ORF73 transcription, indicating latency phase inside these 
cells (Thonur et al., 2006). Efforts to detect the viral particles inside the 
cytoplasm of LGLs by using electron microscopy were efficient in case of 
AIHV-1 but not OvHV-2 (Cook & Splitter, 1988; Rosbottom et al., 2002).  
OvHV-2 genome contains 73 ORFs; most of these ORFs (62) are 
conserved homologues of other γ-herpesviruses (Figure 1-7) (Hart et al., 
2007).   
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Several OvHV-2 glycoproteins are encoded by ORFs that are 
homologous to AIHV-1 and other γ-HVs (Table 1-3). These glycoproteins 
play a fundamental role in OvHV-2 biology (Dry et al., 2016). Some of these 
glycoproteins are conserved among all herpesviruses. For instance, gB and 
gH/gL are highly conserved and have a pivotal role in mediating fusion of 
host membrane (Hutt-Fletcher, 2007). Other conserved orthologous 
glycoproteins are involved in receptor binding such as gp70 and gH/gL in 
MuHV-4, gp180 (homologous to gp70) in BoHV-4, and gp150 in KSHV (Gillet 
et al., 2015). All these glycoproteins bind to heparin receptor.  Others are 
involved in cell tropism such as gp350/BLLF1 and gp42/BZLF2 of EBV (Hutt-
Fletcher, 2007).  
Antibodies against gB and gH/gL were shown to protect rabbits from 
OvHV-2-MCF (Cunha et al., 2015). Recent data demonstrated that gB, gH, 
gL, and Ov8 are important glycoproteins in the fusion process of the 
cytoplasmic membrane of the infected cells (AlHajri et al., 2017). The Ov7 
gene of OvHV-2 is homologous to A7 gene in AIHV-1. The predicted product 
of this gene is likely an envelope glycoprotein and is analogous to BZLF2 
protein of EBV. Thus, it is thought to be involved in the infection of B cell 
(Hart et al., 2007).   
OvHV-2 and AIHV-1 can also form a latent infection by expression of 
LANA protein. This protein is encoded by ORF73 in both viruses (Russell et 
al., 2009; Taus et al., 2015). Recently, it has been shown that LANA in AIHV-
1 has a fundamental role in the lymphoproliferation and evading the virus 
from host immunity (Palmeira et al., 2013; Sorel et al., 2017).   
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OvHV-2 has a unique ORF, annotated as Ov2.5, that encodes a 
protein similar to ovine interleukin (IL)-10 to potentially modulate host 
immunity by stimulating mast cell proliferation and suppress the production of 
macrophage inflammatory chemokine (Jayawardane et al., 2008). 
Recently, eight microRNAs in the OvHV-2 genome have been 
suggested to be responsible for the regulation of expression the cell cycle 
inhibition (ORF20), viral reactivation (ORF50), and viral latency (ORF73) of 
OvHV-2; Although, some relationship to expression of ORF20 and ORF50, 
none of these microRNAs seems to be involved with ORF73, presumably 
other microRNAs could be involved in the latency (Riaz et al., 2014).  
 
Table 1-3. The ORFs encoding OvHV-2 glycoproteins. Adopted from (Hart et 
al., 2007).   
 
 









Glycoprotein   
ORF8 863 76 44  gB  
ORF22 750 63 27  gH 
ORF27 293 51 28 Glycoprotein for cell to cell 
spreading  
ORF39 408 80 44 gM 
ORF47 151 45 28  gL 
ORF53 102 51 35  gN 
Ov7 121 60 NA homologue of AlHV-1 A7 
Ov8 (exon 2) 473 41 NA homologue of AlHV-1 A8 
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1.3.1.3 Caprine herpesvirus 2 
CpHV-2 is a γ-herpesvirus that was first recognised in goats by means 
of consensus PCR. Molecular surveys have shown that  goats are a reservoir 
for this virus (Li et al., 2001a). Sequence alignment analysis revealed that 
CpHV-2 is closely-related to OvHV-2 and AlHV-1 (Chmielewicz et al., 2001).  
As in sheep, CpHV-2 can be transmitted to healthy goats through 
direct contact wherever they kept together, which complicates the control 
strategy of MCF in the field (Li et al., 2005a). Numerous studies have shown 
that CpHV-2 is also MCF-associated in various species of deer such captive 
sika deer (Cervus nippon) (Keel et al., 2003), moose and roe deer (Vikøren 
et al., 2006). Also, in water buffalo (Dettwiler et al., 2011).  
Although CpHV-2 and OvHV-2 are closely related to each other, they 
behave differently when they infect cattle or water buffalo as the latter appear 
to be more susceptible CpHV-2 -associated MCF (Stahel et al., 2013).   
1.3.1.4 Malignant Catarrhal Fever Virus-White-Tailed Deer  
MCFV-WTD virus was firstly identified in white tailed deer suffering 
from signs of fatal MCF. The consensus PCR assay revealed a closely 
related genetic sequence to maccaviruses: OvHV-2, AIHV-1, and BoHV-6, 
with identity of (82, 71, 60)% respectively  (Li et al., 2000). This sequence 
was then further confirmed as a γ-herpesvirus by (Kleiboeker et al., 2002). 
However, the reservoir host had not been identified in these studies until 
research by (Li et al., 2013) that confirmed goat as a potential reservoir host 
for MCFV-WD that can cause disease in deer species. 
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1.3.2 Pathogenesis of MCF  
The pathogenesis of MCF is characterised by profound consequences 
resulting in lymphoproliferation, vasculitis and epithelial inflammation (Russell 
et al., 2009, 2012a). Herein, the pathogenesis of MCF in reservoir (sheep, 
goat) and susceptible (cattle, bison) hosts as well as rabbit as a laboratory 
animal model will be addressed.  
1.3.2.1 Pathogenesis in Sheep 
Sheep are asymptomatically infected with OvHV-2. All ages are 
predisposed to infection but the adolescent lambs appear to play an 
important role in viral transmission in which viral shedding through nasal 
secretions appears to be the usual route of transmission (O ’Toole & Li, 
2014).  
Experimental infection of sheep through nasal OvHV-2-aerosol 
nebulisation revealed lytic replication in the respiratory tract of infected sheep 
(Taus et al., 2005). This was mainly in the turbinates, trachea, and lung 
tissues. This indicates the role of sheep as a reservoir host to transmit the 
virus into the environment (Cunha et al., 2008). Detailed analysis revealed 
localisation of viral replication in alveolar epithelial cells at the early infection 
stage. This infected cell type was also found in the nasal secretions of 
naturally infected sheep during OvHV-2 shedding, indicating its role in OvHV-
2 transmission (Taus et al., 2010).   
Although sheep are considered the natural host of OvHV-2, some 
studies have reported the occurrence of MCF in this species. In one report, 
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the respiratory and alimentary post-mortem pathognomonic signs included 
tracheal and pulmonary oedematous congestion, erosive lesions in the oral 
cavity and ulcerative congestion of the abomasal mucosa. Generalised 
organic and lymphatic tissue damage, involvement of widespread blood 
vascular necrosis with lymphocytes and macrophages infiltration was noticed 
as well (Yeruham et al., 2004). In another UK study, a clinically infected, six-
month old lamb suffered from clinical and pathological signs of MCF. 
Particularly, there was a generalised lymphocytoclastic arteritis. The 
molecular identification revealed OvHV-2 DNA (Gaudy et al., 2012). Similar 
pathological changes were also demonstrated experimentally through nasal 
infection with a high OvHV-2 dose, resulting in pulmonary lymphocytic 
vasculitis and broncho-interstitial pneumonia (Li et al., 2005b). Interestingly, 
the systematic distribution of vasculitis seems to depend on the mode of 
infection. For instance, in nasal viral nebulisation, vasculitis was restricted 
within lung tissue whilst in natural MCF cases, generalised vasculitis is 
usually recorded (O’Toole & Li, 2014).  
A cutaneous form of MCF in sheep has also been reported, presenting 
as granulomatous mural folliculitis with multinucleated giant cells, 
lymphocytes, and eosinophil infiltration, accompanied by an increase in the 
level of viral DNA within these lesions (Slater et al., 2016). 
1.3.2.2 Pathogenesis in Goat  
Goats are considered as a carrier and susceptible hosts for MCF-
viruses (Fernández-Aguilar et al., 2016; Jacobsen et al., 2007). It can be 
infected with OvHV-2 and CpHV-2 (Vikøren et al., 2006). Both are 
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transmitted in goats horizontally via the respiratory method. Similar to OvHV-
2 transmission in sheep, vertical transmission has not been reported in goat 
(Li et al., 2005a). Several studies have shown that goats also carry other 
MCF- viruses. For instance, three herpesvirus sequences were detected in 
wild ungulates species such as muskox (Ovibos moschatus), Nubian ibex 
(Capra nubiana), and gemsbok (Oryx gazella), these sequences have a high 
similarity to MCFV-WTD (81.5 %), CpHV-2 (89.3 %), and AlHV-1(85.1 %) 
respectively (Li et al., 2003). Recently, a new partial glycoprotein B sequence 
of a novel herpesvirus has been identified in Pyrenean chamois (Rupicapra 
p. pyrenaica) with high similarity (96.6, 81.5) % to Rupicapra rupicapra 
gammaherpesvirus 1 and OvHV-2 respectively, and tentatively named 
“Rupicapra pyrenaica gammaherpesvirus-1 (RpHV-1)”. It is suggested to be 
harboured naturally by deer (Rupicapra p. pyrenaica)  (Fernández-Aguilar et 
al., 2016).  
The pathological lesions of MCF in goats have not been widely 
reported. The signs in infected goats appeared as clinical neurological 
observations with digestive and corneal involvement. Tissue damage was 
seen in several organs including kidney, spleen, lung, brain and liver with 
vascular lesions that appeared as lympho-histiocytic with fibrinoid necrosis 
especially in medium sized arteries (Jacobsen et al., 2007). Goats are 
unusual in being reservoir and susceptible hosts.   
1.3.2.3 Pathogenesis in Cattle 
Cattle often succumb to MCF with fatal consequences (O’Toole et al., 
1997). The disease is characterised by severe clinical signs with variable 
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forms such as peracute, alimentary, neurological and cutaneous. The lesions 
may appeared in eye and head as corneal opacity and oculo-nasal discharge 
while the post mortem pathognomonic lesions appeared as systemic 
vasculitis with petechial haemorrhages in the respiratory and gastrointestinal 
tracts as well as urinary bladder (O’Toole & Li, 2014; Russell et al., 2009). 
These histopathological lesions considered as the definitive diagnostic 
approach for MCF while laboratories have recruited the serological and 
molecular approaches as diagnostic tests (OIE, 2004).   
 Tissue damage is thought to occur because of immune deregulation 
that results is accumulation of lymphocytes, predominantly CD8+, that have a 
natural killer phenotype. Interestingly, only a few of these aggregated cells 
contain viral genes while the vast majority of them do not. In some lesions, 
these cells are thought to be associated with vasculitis (Russell et al., 2009).  
Vasculitis in MCF is distributed  systemically (Liggitt et al., 1980). The 
lesions appear with numerous infiltrated mononuclear cells, including 
lymphocytes and lymphoblasts with lower proportion of macrophages, 
neutrophils and plasma cells. The mononuclear cells infiltrate mainly at the 
vascular adventitia with less in the medial and intimal layer. However, 
frequent perivascular lymphocyte infiltration was noticed at the tissue where 
the capillaries and small venules are more prevalent and sub-venular and 
pre-medial adventitial mononuclear localization tend to be found prominently 
in the mild arterial cases. However, the acute damage was noticed with 
massive accumulation of large mononuclear cells on the entire adventitia 
(Liggitt & DeMartini, 1980; Simon et al., 2003; Taus et al., 2006).  
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Recently, it has been reported that characterisation of vasculitis 
depends on the form of the disease. In the acute form, affected vessels 
appear with severe lymphocytic arteritis-periarteritis accompanied by 
necrosis of the tunica media whereas, in chronic cases where animals 
survived from the acute phase, vasculitis included persisting proliferative 
arteriopathy in the medium-calibre arteries (O’Toole & Li, 2014).  
The current hypothesis in our study includes that OvHV-2 latency 
within infiltrating cells of vasculitis lesions possibly has a role in development 
of MCF.    
1.3.2.4 Pathogenesis in Bison 
Bison are highly sensitive to OvHV-2-associated MCF with a high 
mortality rate that might reach (100 %) during stressful circumstances. The 
clinical signs are similar to that seen in cattle but the onset of the disease is 
rapid, therefore it is difficult to notice as the bison are widely spread in the 
pasture and often just found dead (Collins et al., 2000; Epp et al., 2016). In 
some studies, it has been found that the infection rate correlates with the 
distance from sheep, the lowest rate was demonstrated as (0.43 %) at 
greater than 5 kilometres (Li et al., 2008a). Experimental infection with a low 
OvHV-2 dose (5000 copies of DNA) leads to death even in seropositive bison 
(Gailbreath et al., 2010).  
The pathological lesions in natural infection showed variability; a 
remarkable change is lymphoid cell infiltration in the adventitial layer of the 
cerebral arteriole in the carotid rete, rumen papilla accompanied with 
necrosis of renal cortex. In some cases, the infection may become chronic in 
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which the vasculitis is characterised by an increase the thickness of the 
arteriole wall due to an extension of the intimal layer as a result of conversion 
its cell into a spindle shape; lymphoid cells appear in the adventitial layer to a 
lesser extent in the tunica media layer (Schultheiss et al., 1998). The 
histological lesions of arteritis-phlebitis in bison is accompanied in least 
extent with  fibrinoid necrosis in tunica medial, which in most cases appears 
as an acute endarteritis and/or endophlebitis that referred to grade 1 arteritis  
(Schultheiss et al., 2000).  
MCF in bison has been induced experimentally by intravenous 
inoculation of OvHV-2 and the histological changes were reported as an 
accumulation of lymphoid cells particularly in the adventitial layer of the rete 
mirabile artery (Liggitt et al., 1980). Since then, MCF has been produced  
experimentally by intra-nasal infection (O’Toole et al., 2007). In this case, 
pathological changes in lung tissue were seen as peribronchiolar pneumonia 
with alveolar fibrin accumulation.   
MCF in bison is a disease of immune deregulation (Nelson et al., 
2010). The predominant infiltrating lymphocytes at these sites were identified 
as CD8+/perforin+/WC1− γδ T cells, which have an innate immunological 
regulatory role, not CD8+ αβ T cells. The involvement of CD8+ cells in the 
pathogenesis of vasculitis has been demonstrated in rabbits as well. On the 
other hand, recent experimental infection in bison revealed OvHV-2 capsid 
protein within perivascular fibroblast cells. Nevertheless, the role of OvHV-2 
in the progression of vasculitis has never been shown (Nelson et al., 2013). 
OvHV-2 transcribed three viral genes (ORF25, ORF50, and ORF73) 
markers of lytic and latent cycles. These encoded proteins detected in lung at 
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a high level after 9-12 days post infection (DPI). However, expression of host 
immune response- related genes were found at a low level in both lung and 
LN. This was combined with increase the systemic viral load after (16-21) 
DPI (Cunha et al., 2012).   
1.3.2.5 Pathogenesis in rabbits  
In rabbits, there is a similar host–OvHV-2 interaction to that seen in 
bison. Thus, there is lower expression of inflammatory response genes 
accompanied by high viral replication within the lung tissue and followed by 
systemic viral dissemination. As in infection of natural hosts, the severity of 
tissue damage correlates with the level of viral DNA and mRNA transcripts 
(Cunha et al., 2013).   
Lymphoid cell accumulation in rabbits was reported previously as T-
cell infiltration not B-cell (Anderson et al., 2007). However, in another study, 
infiltration of both T and B cells were detected (Li et al., 2011a). In another 
pathological study, OvHV-2 capsid and tegument proteins that encoded by 
ORF43 and ORF63 respectively were localised in the appendix of 
experimentally infected rabbit. Histo-pathologically, epithelial and microfold 
cells (M-cells) were the exclusive target sites for viral replication, suggesting 




1.3.3 MCF-diagnosis  
The propagation of the OvHV-2 is not routinely successful unlike 
AIHV-1. MCF-like clinical signs are similar to from numerous enteric and 
vesicular syndromes such as:  vesicular stomatitis, infectious bovine 
rhinotracheitis, bovine viral diarrhoea, mucosal disease, foot and mouth 
disease, epizootic haemorrhagic disease, and bluetongue (Holliman, 2005). 
Identifying the aetiological agents of MCF depends on developing reliable 
serological tests and genomic detection (Li et al., 2011b). Currently, PCR 
technique has been used widely to detect DNA of the MCF-viruses in the 
clinically-affected animals while the C-ELISA has been recruited for diagnosis 
of the natural host species (OIE, 2004). Basically, PCR assay enables 
diagnosticians to identify clinical MCF associated with high viral load 
throughout the host organs (including blood). In contrast, reservoir species 
generally have latent infection, which is often associated with low viral load 
and therefore could not always be detected by routine PCR. A serological 
assay is useful to demonstrate infection in reservoir species where it is 
associated with antibody responses but not for clinical MCF cases, which do 
not always seroconvert. The Cl-ELISA is also a useful tool in serology of 
multiple MCF viruses in reservoir species, as it recognises an epitope 
conserved in the gB glycoprotein of MCF viruses.  
There are numerous serological tests to monitor antibodies against 
MCF viruses. These assays are mostly based on using AIHV-1 as antigen 
due to the feasibility of propagation of this species in vitro. One of these 
assays is an ELISA test that based on using a monoclonal antibody that 
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recognise a conserved epitope, MAB15-A, of the AlHV-1 glycoprotein 
complex. This assay has very high specificity (91-100%) but limited 
sensitivity (Li et al., 1994, 1995). This drawback was tackled by using a direct 
WC11-ELISA that uses AIHV1-cell lysate as an alternative antigen (Fraser et 
al., 2006).  
It has been shown that using PCR permits the detection MCF with 
high sensitivity and specificity. Since PCR and DNA processing has been 
developed, numerous epidemiological and evolutionary studies have been 
conducted that clarify different aspects of MCF. Both conventional and 
quantitative PCR makes disease diagnosis more efficient through detection 
of viral DNA (Li et al., 2011b). It has been also used for other purposes such 
as identifying novel herpesvirus (Chmielewicz et al., 2001) or differentiate 
different MCF viruses (Cunha et al., 2009).  
1.3.4 MCF-vaccine development approaches   
To date, there is no effective control measure for MCF. The sole 
strategy is to separate the reservoir host from susceptible animals, but this is 
not always possible. In addition to cattle, other susceptible hosts such as 
bison and deer are reared in farms near sheep and OvHV-2 can be 
transmitted from a distance (Li et al., 2008a; Russell et al., 2009). Therefore, 
finding a successful vaccine would be useful to protect susceptible hosts.    
Previously, two vaccine models using attenuated AIHV1, live or 
inactivated, were used in rabbit but these approaches did not prevent MCF 
(Patel & Edington, 1982; Rossiter, 1982). In another study, cattle immunised 
with AIHV-1 that had been isolated from an MCF case showed short term 
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protection when challenged with different strains of AIHV-1 (Mirangi, 1991). A 
promising approach has been achieved by (Haig et al., 2008) using a cell-
free, attenuated AIHV-1 (strain C500), with Freunds’ adjuvant. Challenge 10 
weeks after initial immunisation, reliably revealed protection against intra-
nasal challenge with virulent AIHV-1. Protection was accompanied by a high 
titre of virus-neutralising antibodies in the nasal secretions of vaccinated 
cattle. Further evaluation was conducted by (Russell et al., 2012b) to 
demonstrate the protective duration of vaccinated cattle by using the same 
vaccine but with licensed adjuvant and to examine the level of local and 
systematic antibody response. The results showed successful protection for 
three or six months, when the immunised cattle were challenged with 
intranasal virulent AIHV-1. Analysis of the initial anti-viral antibody revealed 
that vaccinated cattle had high titres of local and systematic antibodies. 
Because of this finding, it has been suggested that there is a pivotal role for 
localised mucosal defence in prevention initial viral entry. Recently, a field 
vaccination trail using a similar vaccine strategy of attenuated AIHV-1 
resulted in reducing infection by 56 % in immunised cattle that were grazed 
closely with wildebeest (Lankester et al., 2016).  
Recent data demonstrated that antibodies to gB and gH/gL protected 
rabbits from OvHV-2 MCF (Cunha et al., 2015).  
1.4 Herpesvirus vaccine development approaches 
 Several studies have been conducted to produce effective vaccine 
against human herpesviruses, particularly cytomegalovirus (CMV) and HSV-
1. However, viral latency and pathogenicity as well as vaccine 
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immunogenicity have hindered the efforts to develop efficient vaccines 
(Bialas & Permar, 2016). For instance, only a vaccine against human 
herpesvirus type 3 (HHV-3) has been adopted for clinical administration 
(McGregor et al., 2013). A live-attenuated CMV vaccine was generated but 
was unsuccessful in CMV prevention. Recombinant attenuated CMV vaccine 
was used with Interleukin-12 co-administration that showed insufficient  
immune response (Bialas & Permar, 2016; Schleiss, 2016).  
Subunit vaccination using homologous proteins from human CMV has 
proved effective in clinical trials. CMV-gB glycoprotein was reported as a safe 
and immunogenic subunit. It has been suggested that using of this subunit  
with a protein complex known as (gH/gL/UL128-UL130-UL131), most likely   
efficient in the CMV prevention (Bialas & Permar, 2016).  
1.5 Viral vectored vaccines   
Development of classical vaccines is based on using of killed or 
inactivated pathogens. These approaches have some drawbacks such as 
pathogen mutations and short-term protection. However, recent 
advancements in molecular and biological fields have improved the targeting 
of the immune response effectively (Marín-López & Ortego, 2016).  
Viral vectored vaccine technology has been developed by using a viral 
vector to deliver and express an immunogenic protein. Recently, use of this 
technology has extended to human and animal diseases (Jorge & 
Dellagostin, 2017). Also, it is useful to overcome the limitations of using the 
conventional vaccines (Baron et al., 2018). Numerous commercial viral 
vectors are available in the veterinary field (Marín-López & Ortego, 2016). 
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The attenuated poxvirus is an important vector in this new generation 
approach (Moss, 2013). It has many advantages including: efficient DNA 
recombination with strong genetic promoter as well as inducing of a high 
level of immune response (Verheust et al., 2012). Therefore, it has been 
used in many applications (Kreijtz et al., 2013).     
1.5.1 Modified Vaccinia Virus Ankara (MVA) 
Modified vaccinia Ankara (MVA) is an attenuated virus derived from 
vaccinia that was developed during the smallpox eradication programme. 
This was achieved by long-term passages (516) of vaccinia virus on primary 
chicken embryo fibroblasts (CEF) which caused genetic mutations (Verheust 
et al., 2012). This technique relies on insertion of a gene of interest into MVA 
plasmid that contains homologous flanks to MVA virus which expressed 
under potential specific vaccinia virus promotor. Transferring of this plasmid 
into MVA-infected cells consequently leads to a homologous recombination 
and generation of a recombinant virus. This recombinant virus obtained in a 
cell lysate which then subjected to several rounds of plaque purification 
(Staib et al., 2004).    
This technology is available and has been used as 
vaccines/vaccination candidates in man and other animals with a known 
safety profile (Verheust et al., 2012). MVA vaccines have been developed  
against numerous viral diseases such as: HSV-1 (Browne et al., 1993; 
Forrester et al., 1991), HIV (Wyatt et al., 2008), Smallpox (von Sonnenburg 
et al., 2014), blue tongue virus (Marín-López & Ortego, 2016), influenza virus 
(Florek et al., 2017), and Ebola virus (Domi et al., 2018). Also, it has been 
54 
 
adopted against parasitic disease (malaria), bacterial pathogens 
(tuberculosis) as well as in cancer therapy (Gilbert, 2013).   
The MVA vector has been shown to cause a high level of cellular and 
humoral immune response (García-Arriaza et al., 2010; Gilbert, 2013; Price 
et al., 2013). It can be produced in a large-scale which extends its use in 
many prophylactic and therapeutic applications (Cottingham & Carroll, 2013). 
MVA system has high safety perspectives due to highly attenuation virus and 
the virus only replicates within cell’s cytoplasm (Verheust et al., 2012).  
Recent advancement in the molecular approaches has promoted this 
technology. For instance, deleting the evasive genes leads to better immune 

















1.6 Aims of the study  
Recently, our lab has shown that OvHV2 can persist in non-diseased 
cattle suggesting that other factors, possibly other virus infections could be 
involved in the pathogenesis of MCF. In the UK, numerous pathognomonic 
cases of MCF in bison, water buffalo, and deer have been reported as OvHV-
2 negative (Amin, 2015). 
Our hypothesis involves that as well as OvHV-2, other macavirus 
members, such as BoHV-6 and OvHV-1, or other herpesviruses might have a 
role to play in the pathogenesis of MCF. Therefore, our target is to 
investigate which herpesviruses are involved in MCF. For this purpose, two 
PCR formats were employed, PAN herpesvirus nested and q-PCR, as 
qualitative and quantitative approaches to examine these cases and assess 
the potential of other herpesviruses being involved in MCF. 
The Latency Associated Nuclear Antigen (LANA) that is encoded by 
ORF73 of OvHV-2 has an essential role in maintaining the virus during 
latency but its role is not fully understood. Therefore, we aimed to express 
this protein in vitro in two approaches; firstly, by expressing a portion of 
oLANA to use it as antigen for production of polyclonal antibody to 
investigate OvHV-2 latency and its role in clinical disease. Secondly, express 
the whole length of oLANA to characterise its expression and validate the 
assay.   
Furthermore, bison, water buffalo and deer have been reared recently 
in the UK. However, farmers are facing a serious issue due to the high 
susceptibility of these hosts to MCF and without an effective vaccine against 
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OvHV-2. Therefore, we aim to express OvHV2- glycoproteins (gB, gH, gL, 
and Ov7) in recombinant modified vaccinia Ankara virus to develop a suitable 
subunit vaccine.   
Explaining the abovementioned aspects will give new insights in 
preventing MCF in reservoir host (sheep) and susceptible hosts (cattle, 





















2.1 Animal tissue samples 
Necropsy tissue specimens (n= 208) from several species were used 
in this study. Sheep (n= 14) as the natural reservoir of OvHV-2 and 
suspected Ovine Pulmonary Adenomatosis cases (n= 35) from the UK; cattle 
without clinical signs (n= 33: 15 from the UK and 18 from Switzerland) and 
with signs of characteristic MCF (n= 30), Bison without pathological signs (n= 
29) and with evidence of MCF (n= 40) from the UK, Deer (n= 13), (only 
tissues preserved in RNAlater) and goats (n= 14) (pathological cases that 
had history of pneumonia) fixed in formalin from Switzerland. All these 
samples were kindly provided by Institute of Veterinary Pathology, Vetsuisse 
Faculty, University of Zurich, Switzerland and Moredun Research Institute, 
UK.   
2.1.1 DNA extraction and processing 
All DNA extraction and processing protocols, as described in the 
following sections, were conducted according to (Vinet & Zhedanov, 2005).   
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2.1.1.1 Nasal swab 
The samples were mixed vigorously for 5 s then incubated for 1 h at 
50 °C in water bath then a (1/ 25) v/v of PG-L2P purifier™ (DNA genotek, 
Canada) was added to the nasal material in a new 1.5 ml tube and mixed for 
5 s then incubated in ice for 10 min followed by centrifugation at 15000x g for 
5 min. The clear supernatant was transferred into new 1.5 ml tube and a (1/ 
20) v/v of 5 M NaCl was added and 600 µl of 100 % ethanol was added and 
mixed gently by inversion 10 times. The DNA was then precipitated by 
standing the samples for 10 min and centrifuged at 15000x g for 2 min. The 
supernatant was removed without disturbing the pellet which then washed by 
adding 250 µl of 70 % ethanol then removed by centrifugation and pipetting. 
The DNA was dissolved by adding 100 µl of TE buffer (10 mM Tris. Cl,1 mM 
EDTA, pH= 8) with mixing gently (Bartlett & Stirling, 2003).  
2.1.1.2 Formalin-fixed paraffin-embedded (FFPE) tissue 
sections 
The paraffin-fixed samples were treated with 1 ml of xylene with 
vigorous mixing by vortex for 10 s followed by centrifugation at 15000x g for 5 
min. The supernatant was discarded by pipetting then the pellet was washed 
six-times in 1 ml (100 %) ethanol with mixing using a vortex. The tubes were 
covered with stretched parafilm and pierced with several holes into the foil 
and incubated at 37 °C until complete evaporation of ethanol. The DNA was 
extracted by using the QIAamp® DNA FFPE tissue kit according to 
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manufacturer’s recommendations as in the following protocol (section 
2.1.1.3). 
2.1.1.3 Blood and tissue specimens  
Fresh tissues collected at necropsy were homogenized in phosphate-
buffered saline (pH 7.4, (3 g of tissue/ 5 ml) then 1 ml homogenate was 
centrifuged at 12,000x g for 1 min and the pellet used for DNA extraction. 
Blood samples were collected into tubes containing 
Ethylenediaminetetraacetic acid (EDTA). DNA was extracted from 
homogenised tissues and blood using QIAamp DNA tissue and blood kit 
(Qiagen) according to the manufacturer’s manual, the samples were firstly 
lysed by using proteinase k then the lysate transferred onto the DNeasy mini 
spin column and centrifuged to bind the DNA with the membrane of spin 
column then DNA was washed to remove contaminants and eluted by the 
supplied reagents.  
2.1.2 DNA gel electrophoresis 
The electrophoresis of the DNA was performed by using gels 
containing 0.8 % agarose in electrophoresis tanks (Bio-rad, UK). The 
agarose was prepared in 1x TAE buffer (40 mM Tris-base, 20 mM acetic 
acid, 1 mM EDTA). For DNA visualisation, SYBR® Safe DNA Gel Stain (1 X) 
was added (Invitrogen, UK), then the solution was poured without creating air 
bubbles into the plastic tray after sealing its ends with laboratory tape, the 
comb was then inserted before agarose-solidify completely so both, tape and 
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comb, were withdrawn gently and the casting gel tray was placed in the 
electrophoresis tank which then filled with sufficient 1 x TAE buffer. Each 
DNA sample was mixed with 1 x DNA sample loading buffer (Bioline, USA) 
before loading into each well alongside appropriate DNA molecular weight 
markers (1 kb or 100 bp ladder) (Cleaver Scientific, UK). The DNA was 
electrophoresed at 110 mA then visualised using a UV trans-illuminator 
ChemiDoc (Bio-rad, UK).  
2.1.3 Amplicon purification  
All PCR products were either purified directly at the end of the PCR 
run in which one volume diluted with 5 volumes of PB buffer (5 M guanidine 
hydrochloride, 30 % isopropanol, QIAquick PCR Purification Kit Protocol), 
according to the manual recommendations. The mixture was then applied to 
the spin column for DNA binding and spun at 13000 rpm for 1 min followed 
by washing with 750 µl of PE buffer (10 mM Tris-HCl pH 7.5, 80 % ethanol). 
The spin column was then placed in a new Eppendorf tube to elute the DNA 
with 50 μl of EB buffer (10 mM Tris·Cl, pH 8.5) and centrifuged at 13000 rpm 
for 1 min.  
For PCR products purified from gels, the PureLink® Quick gel 
extraction Kit (Invitrogen), was used, following the manufacturer’s manual 
that involved a similar basic workflow, except that the PCR product was 
electrophoresed as in (section 2.1.2) then excised from the gel and 
solubilised with L3 buffer (undescribed components) at 50 °C for 15 min then 
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washed with buffer W1 (undescribed components) then eluted with E5 buffer 
(10 mM Tris-HCl, pH 8.5).     
2.1.4 DNA transformation and cloning 
The PCR amplicons were firstly purified (see section 2.1.3) then 
cloned by means of 3’ adenine-overhangs into the commercial vector 
(pCR2.0 TOPO), according to the manufacturer’s recommendation 
(Invitrogen, UK). The reaction was performed by mixing 4 µl of fresh purified 
amplicons with 1 µl of the provided salt buffer (1.2 M NaCl, 0.06 M MgCl2) 
and 1 µl of the supplied plasmid (10 ng/µl linearized plasmid, 100 µg/ml BSA, 
phenol red, 50 glycerol, 50 mM Tris, 0.1 % 100X triton, 1 mM DTT). The 
reaction was incubated at room temperature for 5 min then 2 µl of the mixture 
was delivered into one vial of chemically competent Escherichia coli 
(Mach1™ One Shot®, Invitrogen) and incubated for 30 min on ice. The 
bacterial mixture was then heat-shocked by at 42 °C in a water bath for 30 
sec then incubated immediately on ice for 5 min followed by adding 250 µl of 
the provided S.O.C. medium (Invitrogen) (2 % tryptone, 0.5 % yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM 
glucose) into the transformed E coli which was then incubated at 37 °C with 
shaking at 200 rpm for 1 h.   
2.1.5 Selection of transformed Escherichia coli 
Transformed bacteria (50 µl) (see section 2.1.4), was streaked on a 
pre-warmed Luria-Bretani agar plate (LB 1 % w/v tryptone, 0.5 % w/v yeast 
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extract, 1 % w/v NaCl) supplemented with 50 µg/ml ampicillin (sigma, UK) 
and pre-spread with 50 µl of x-gal (40 µg/ml) stock (Promega, USA) which 
was then incubated for 24 h at 37 °C. The white- well separated colonies 
were sub-cultured in 5 ml LB broth containing 50 µg/ ml of ampicillin at 37 °C 
for overnight for further preparation as in section (2.1.6).    
2.1.6 Preparation of recombinant plasmids DNA   
The recombinant plasmids that had been transformed and amplified 
inside bacteria were harvested for insert confirmation by mini-preparation. 
Selected clones were prepared as required by maxi-preparation according to 
the manufacturing recommendation’s (Qiagen).  
All plasmids were prepared initially by minipreparation of the saturated 
growth culture that resulted from inoculating individual-single white colony 
into 5 ml LB broth (see 1.2.5). This was pelleted by centrifugation at 6000 x g 
for 15 min at 4 °C then the pelleted cells were re-suspended in 300 µl of the 
supplied resuspension buffer P1 (50 mM Tris.Cl, 10 mM EDTA, 100 µg/ml 
RNAse A) followed by adding similar amount of lysis buffer P2 (200 mM 
NaOH, 0.1 w/v SDS). After thoroughly mixing by inverting, the mixture was 
then left at RT for 5 min and neutralised by adding 350 µl of N3 neutralisation 
buffer (4.2 M Gu-HCl, 0.9 M potassium acetate, pH 4.8). The lysed bacterial 
protein was pelleted at 2000x g for 10 min at 4 °C. Then 800 µl of 
supernatant was transferred into the supplied columns (QIAprep 2.0 spin) 
which were then spun at 3000x g for 1 min, washed once with 500 µl of 
buffer PB (5 M guanidine hydrochloride, 30% isopropanol), spun at 3000 g 
for 30 sec then washed again by adding 750 µl of PE buffer (10 mM Tris-HCl 
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pH 7.5, 80% ethanol). The flow-through solution was discarded, and the 
residual washing buffer was removed completely from column’s membrane 
by further centrifugation for 1 min. Finally, the DNA was eluted by placing the 
QIAprep column in a new Eppendorf tube and adding 50 µl of EB buffer (10 
mM Tris.Cl, pH 8.5) at the centre of the QIAprep 2.0 spin column and letting 
stand for 1 min. Plasmid was finally recovered by centrifugation at 3000x g 
for 1 min and stored at 4 °C.  
For confirmation of inserts, the EcoRI restriction enzyme (Promega, 
USA) was used to cut the 5’..GˇAATTC..3’ sequence sites within (pCR2.0 
TOPO) vector. According to the manufacturer’s recommendation, the 
reaction was performed using a mixture of 16.3 µl of deionized water, 2 µl RE 
10X buffer, 0.2 µl acetylated BSA, 1 µg/ µl DNA, and EcoRI (0.5 µl) and 
incubated at 37 °C for 2 h. The cut fragments were checked by gel 
electrophoresis, (see 2.1.2) before sending for sequence (see 2.6.8). 
  Amplification of plasmid DNA was achieved by maxi-preparation using 
column extraction (Qiagen). A purified sub-cultured single colony of E. coli 
that was carrying the plasmid of interest was used to inoculate 400 ml of LB 
broth containing the standard concentration of antibiotic, as described in 
(2.1.5). Following the manufacturer’s manual, an overnight saturated culture 
was spun at 6000x g for 15 min at 4 °C. The pelleted cells were re-
suspended by adding 10 ml of supplied P1 buffer (50 mM Tris.Cl, 10 mM 
EDTA, 100 µg/ml RNAse A), then lysed with 10 ml of P2 buffer (200 mM 
NaOH, 0.1 w/v SDS) and then incubated at RT for 5 min. The cell lysate was 
neutralised by adding 10 ml of P3 buffer (3 M potassium acetate, PH 5.5) and 
kept on ice for 5 min then centrifuged at 2000x g for 10 min at 4 °C. The 
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supernatant was transferred into (QIAgen tip 500) that had been equilibrated 
by adding 10 ml of QBT buffer (750 mM NaCl, 50 mM MOPS, 15 % 
isopropanol v/v, 0.15 % Triton X-100 v/v) and left to flow by gravity. When the 
plasmid was completely bound to the column’s membrane, it was washed 
twice with 30 ml of QC buffer (1.0 M NaCl, 50 mM MOPS, 15 % isopropanol 
v/v). Finally, the plasmid DNA was recovered with 15 ml of QF buffer (1.25 M 
NaCl, 50 mM Tris-Cl, and 15 % isopropanol v/v) and then precipitated by 
adding 10 ml of molecular grade isopropanol (Sigma, UK). After 
centrifugation at 5000x g for 1 h at 4 °C, the DNA precipitates were washed 
with 5 ml of 70 % molecular grade ethanol (Sigma, UK) and centrifuged at 
15000x g for 10 min. Pellets were then air dried and eluted in dH2O.  
To store bacterial clones, 850 µl of sub-confluent bacterial culture was 
mixed with 150 µl of sterile glycerol (100 %) and immediately snap frozen in 
dry ice and kept at -80 °C as a glycerol stock (Ferrer-Miralles et al., 2015).          
2.1.7 Deoxyribonucleic acid (DNA) measurement 
All the DNA samples were measured according to the Invitrogen 
Qubit® flourometer recommendations. Basically, each DNA and Qubit® 
standards were placed into Qubit® assay tubes and diluted (1:200) using the 
Qubit® dsDNA BR reagent to 200 µl final volume. This was then incubated at 
RT for 2 min and measured by Qubit® 2.0 Fluorometer, Invitrogen. The DNA 
was either used directly or stored at -20 °C until further use. 
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2.1.8 DNA sequences   
  Selected plasmids were sequenced at Source Bioscience (Rochdale, 
UK) after being confirmed by restriction enzyme digestion by using 
appropriate primers. Data were aligned using Basic Local Alignment Search 
Tool (BLAST) at the National Centre for Biotechnology Information website’s 
(http://www.ncbi.nlm.nih.gov/) to confirm the cloned targets. 
2.2 Polymerase Chain Reaction (PCR) 
2.2.1 PAN nested PCR 
  A nested consensus PCR of degenerate, dI-substituted primers of a 
highly conserved sequence was employed to detect the DNA polymerase 
(DPOL) gene. The reaction consists of two rounds of amplification which 
were performed in similar reaction conditions to include modified and 
unmodified primers, as has been used previously by (Ehlers et al., 2007; 
Vandevanter et al., 1996) (Table 2-1). In this protocol, the total reaction 
volume (25 µl) contained 12.5 µl of 2x Qiagen multiplex PCR master mixes 
including HotStart Taq DNA polymerase with 3 mM Mg2+. In first round, 1 µM 
of each modified (3-DFA, 4-ILK, 8-KG1) and unmodified (1-DFA, 2-ILK, 7-
KG1) primers was used and approximately 400 ng of genomic DNA was 
added. In the second round, a similar amount of primers, modified (6-TGV, 
10-IYG) and unmodified (5-TGV, 9-IYG) and master mix were used but only 
1 µl of the product from the first round was used for the second round. A 
similar temperature profile was used in both rounds as follows. Activation of 
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the Taq enzyme at 95 °C for 12 min then 45 cycles of 20 s at 95 °C, 30 s 
annealing at 46 °C, and 30 sec extension at 72 °C, followed by a final 
extension step at 72 °C for 10 min.  
All PCR products were purified, cloned and the inserts were extracted 
by miniprep, checked by EcoRI restriction enzyme then sequenced according 
to the previous sections (2.1.4); all the sequences were assembled by using 
MEGA7 software (software, version 7.0.21) (Kumar et al., 2016) and aligned 
at NCBI website to identify the detected herpesviruses.  
   
Table 2-1 
The primers used for PAN- nested PCR. 
 
Modified 
Primer  Round Sequence 5’ 3’* 
3-DFA 1 GAYTTYGCIAGYYTITAYCC 
4-ILK 1 TCCTGGACAAGCAGCARIYSGCIMTIAA 
8-KG1 1 GTCTTGCTCACCAGITCIACICCYTT 
6-TGV 2 TGTAACTCGGTGTAYGGITTYACIGGIGT 
10-IYG 2 CACAGAGTCCGTRTCICCRTAIAT 
Unmodified 
1-DFA 1 GAYTTYGCNAGYYTNTAYCC 
2-ILK 1 TCCTGGACAAGCAGCARNYSGCNMTNAA 
7-KG1 1 GTCTTGCTCACCAGNTCNACNCCYTT 
5-TGV 2 TGTAACTCGGTGTAYGGNTTYACNGGNGT 
9-IYG 2 CACAGAGTCCGTRTCNCCRTADAT 
Abbreviation: The codons include: I: inosine; Y: Pyrimidine: C or T; R: 




2.2.2 Real time PCR  
2.2.2.1 Design of primers and probes  
Conserved sequences within glycoprotein B gene were selected as a 
target for the Taqman q-PCR by means of GeneScript Bioinformatics 
software at (https://www.genscript.com/ssl-bin/app/primer). For OvHV-2, the 
genome copy number was estimated using OvHV-2-specific primers 
(ORF63-specific) (Stahel et al., 2013), For BoHV-6, we adopted the 
published assay based on the gB gene sequence (Kubiś et al., 2013) (Table 
2-2). The possibility of non- specific reactions with other sequences was 
avoided by using an alignment search tool (BLAST) at the National Centre for 
Biotechnology Information website’s (http://www.ncbi.nlm.nih.gov/). The 12s-
ribosomal DNA internal genome was used to normalise the q-PCR data 
(Gatesy et al., 1997). Specific primers and probes were delivered lyophilized 
then diluted to 100 pmol/µl by using a qPCR probe dilution buffer (10 mM 
Tris-HCl; PH 8; 1 mM EDTA) (eurofins, UK). Sets of primer stocks were 
further diluted to a working concentration of (20 pmol/µl) and for the probes 












Table 2-2. The taqman q-PCR primer sequences 
 









BoHV-6 F ACCCCGTAAAAGTGATTTACCC 56.4 
R GTAGTAGTCATGCATAGCTAGC 
Probe FAM-CAAAAGATCAGAGAGCAGCAAGAG-TAMRA 






F GGTTTGCTTCCCTGCTTAAA 60 
R CTCCAAGTCTGCGAGCTGTA 
Probe FAM-CTTTCCAGCATGGTCCGCCC-TAMRA 










Abbreviation: FAM: 5’ modification (6-Fluorescein amidite); TAMRA: 3’ 
modification quencher; VIC: 5’ modification: commercial fluorescent dye, 
MGBNFQ: 5’ modification (minor grove binder nucleotide quencher); Y: 








2.2.2.2 The q-PCR optimal conditions  
The reaction mixtures were optimized to contain 7 µl of (2x) TaqMan® 
universal PCR master mix that consists of Gold® ultra-pure AmpliTaq DNA 
polymerase, Uracil‐N glycosylase (UNG), dNTPs with dUTP, ROX™ passive 
reference dye and buffer master mix (applied biosystem, UK); the primers 
and probes were at concentration of (0.5 pmol/µl) in 20 µl total reaction 
volume. Initially, the optimal annealing temperature of primers and probes 
were determined by gradient protocols (DNA Engine Opticon 2, UK) in a 
range of (55-60) °C. The optimal cycling temperature profile in all q-PCR 
assays involved an initial 50 °C for 2 min followed by 13 min of 95 °C then 39 
cycles of 95°C for 15 sec, finally, 1 min of the optimal annealing temperature 
as mentioned in (Table 2-2). 
2.2.2.3 Production of reference plasmids for viral 
quantification 
The constructed reference genes were produced by cloning PCR 
products as described in section (2.1.4). The concentration of the obtained 
plasmids was measured by using a Qubit fluorimeter as described in (2.1.7) 
and they were sequenced (2.1.8) for final confirmation. The starting 
concentrations were calculated according to the following formula 
(Dhanasekaran et al., 2010; Godornes et al., 2007): 




Where 6.022x1023 is Avogadro's number; (length) is the number of the base 
pair (bp) in the reconstructed plasmid; 650 is the average weight of each 
base pair in Daltons. The calculation results were also checked by means of 
DNA copy number calculator software at (http://scienceprimer.com/copy-
number-calculator-for-realtime-pcr) website. Serial tenfold dilutions were 
performed using nuclease-free water supplemented with yeast tRNA (25 
mg/ml) (Invitrogen™ AM7119, UK). In order to preserve these plasmids from 
degradation, numerous aliquots (5 µl/ tube) were kept in -20 °C for further 
use.  
Genome copy numbers were estimated using 100 ng genomic DNA 
and a Taqman PCR approach with primers specific for each virus. 
Normalisation to account for variability in DNA quality and contaminants was 
performed using primers specific for the ruminant 12s-ribosomal DNA internal 
genome. Therefore, the exact genome copy number and normalization was 
determined using limiting dilutions of reference plasmids as detailed in the 
result chapter in a background of high molecular weight (Biassoni & Raso, 
2014).  
2.2.2.4 Estimation of assays validity  
The intra and inter assay variation were analysed by performing five 
runs for each reference plasmid in tenfold serial dilutions independently in 
duplicate starting from (2x 107) to (2x 100) copy/ 2 µl.  
The assay specificity was determined by cross testing clinical 
diagnostic samples known to be positive for other herpesviruses. All the 
quantification statistics were analysed by means of graph pad prizm software 
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using T-test mann-whitney and Fisher’s exact test. The assays were also 
validated according to MIQE guidelines to include: mean value, standard 
deviation, coefficients of variation (CV) of the Ct values, and the standard 
error of mean of means for each plasmid (Bustin et al., 2009; Taylor et al., 
2010). 
2.3 Cell line culture 
Cells were thawed in a 37 °C water bath for about 1-3 min then added 
into 10 ml tissue culture media containing foetal calf serum. Cells were 
passaged after 2-4 days, when they reached about 90 % confluent. All cell 
lines except the LGL cell line (see 2.3.1) were split and harvested to new 
flasks using 0.25 % Trypsin-EDTA (Life technologies, UK) to detach 
monolayer cells. Cells near 90 % confluent were washed twice by PBS, 
harvested by adding 3 ml of trypsin and incubated at 37 °C for 3 min. The 
trypsinisation process was inhibited by adding 7 ml of tissue culture media 
containing 10 % foatel calf serum. Cells were then split to new flasks after 
counting by haemocytometer. About 1 x 106 cell/ ml were seeded into T175 
cm2 tissue culture flask (Corning, UK) and maintained as in sections (2.3.1, 
2.3.2, and 2.3.3).    
2.3.1 Large granulocyte lymphocyte (LGL) 
The large granulocyte lymphocyte cell line known as (BJ2586) 
contains OvHV-2 and was propagated from infected rabbits in vitro; this line 
was kindly provided for this study by (George Russell, Moredun institute). 
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This cell line was maintained in Iscove’s Modified Dulbecco’s Medium 
(IMDM) (Sigma, USA) that contained 10 % foetal calf serum (Sigma, UK), 
penicillin (100 U/ml) / streptomycin (100 μg/ ml) (Sigma, UK), 1 % L-
glutamine (Sigma, UK), and 350 IU/ ml of IL-2 (Chiron, UK) (Schock et al., 
1998). This cell line was grown in suspension at 37 °C and 5 % CO2 as 
recommended by (Schock et al., 1998). 
2.3.2 Human embryonic kidney (HEK293) 
HEK293 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma, UK) supplemented with 10 % fetal calf serum 
(Sigma, UK), penicillin (100 U/ml) / streptomycin (100 μg/ ml) (Sigma, UK) 
and 1% L-glutamine (Sigma, UK). The cells were cultured at 37 °C with 5 % 
CO2.  
2.3.3 Baby Hamster Kidney (BHK)  
The BHK cell line was maintained in Minimum Essential Media (MEM) 
(Sigma, UK) that was supplemented with 10 % fetal calf serum (Sigma, UK), 
penicillin (100U/ ml)/ streptomycin (100 μg/ ml) (Sigma, UK) and 1 % L-
glutamine (Sigma, UK). The cells were cultured at 37 °C with 5 % CO2.  
2.4 Cell line transfection 




The transfection of HEK293 cells with [pVR1255-ORF73 alongside 
GFP vector (pEGFP-N1)] as a control for transfection efficiency was 
performed by mixing 156.16 µl of 2 M CaCl2 with 50 µg plasmid-DNA in 
Eppendorf tube. This was added gently in a drop wise fashion to 1280 µl of 
2x HBS- buffered saline (274 mM NaCl, 10 mM KCl, 1.4 mM Na2HPO, 4·7 
H2O) and then incubated for 30 min at RT. This transfection solution was 
then delivered in drop wise fashion to 150 cm2 tissue culture round dish 
containing 23 ml of complete medium seeded with 4x 106 of HEK293 (50-60 
% confluent).  After incubation for 24 h, the transfected cells were washed 
twice with PBS before being harvested, washed with a 500 µl of PBS and 
centrifuged at 4 °C for 5 min at 2500 rpm. The pellet was then treated as 
described in (2.5.2) (Wang & Mei, 2013).  
2.4.2 Lipofectamine reagent  
The transfection of BHK cells was prepared by diluting Lipofectamine-
2000 reagent (5 µl) in 250 µl of Opti-MEM media. At the same time, a similar 
amount of Opti-MEM was added into each DNA vector [rMVA-(gB, gH, gL, 
and Ov7)] (0.625 µg/ well). These components were incubated for 5 min at 
RT then the DNA vector solution was mixed with diluted lipofectamine-2000 
and then incubated for 30 min at RT. The procedures were continued as in 
(2.15.1).    
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2.5 Sodium- dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE)  
2.5.1 Reagent for SDS-PAGE and western immunoblotting  
Sample loading buffer (2 x) containing 62.5 mM Tris–HCl pH 6.8, 3 
% (w/v) SDS, 5 % β– mercapto-ethanol, 10 % glycerol and 0.01 % 
bromophenol blue. Running buffer consisting (50 mM Tris, 192 mM glycine, 
0.1 % (w/v) SDS pH 8.3. Transfer buffer 120 mM Tris, 192 mM glycine and 
20 % (v/v) methanol. Tris buffered saline-tween 20 (TBS-T) containing 20 
mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.1 % (v/v) Tween 20. Blocking 
buffer containing 5 % (w/v) fat-free skimmed-milk (Marvel) in TBS-T.  
2.5.2 Sample preparation  
2.5.2.1 Cell line 
The monolayer cell lines (section 2.3.2 and 2.3.3) were harvested from 
tissue culture flasks, 6- well or T175 (Corning, UK) by scraper then 
transferred into eppendorf tube, washed 2x by PBS and centrifuged at 2000 
rpm at 4 °C for 5 min. The suspension cell line (section 2.3.1) was harvested 
by centrifugation at 1500 rpm at 4 °C for 10 min. Equal amount of sample 
loading buffer (about 20 µl) was added into the pelleted cells for protein 
extraction. The lysates were then boiled in heating block at 90 °C for 5 min 
then kept - 80 °C    
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2.5.2.2 Animal tissue  
Whole protein lysates of sheep and cattle tissue previously tested for 
OvHV-2 by q-PCR assay was extracted by cutting frozen tissue into small 
pieces (100- 250 mg) followed by adding 500 µl of RIPA buffer (50 mM Tris, 
[pH 7.5], 150 mM NaCl, 1 % NP40 alternative (v/v), 0.5 % sodium 
deoxycholate (w/v), 0.1 % SDS) and 300 µl of a protease inhibitor cocktail 
(AEBSF 23 mM, EDTA 100 mM, Bestatin 2 mM, Pepstatin A 0.3 mM, E-64 
0.3 mM) (Sigma, USA). The lysates were then sonicated at low output and 
30% amplification for 20 sec and then spun at 14000x g at 4 °C for 10 min 
(Vibra-cell ultrasonic liquid processor, sonics vcx130). Finally, the 
supernatants were collected in aliquots and quantified by bicinchonic acid 
assay (PierceTM BCA protein assay kit, UK). The lysates were boiled and 
kept as in (section 2.4.2.1).   
2.5.3 Gel preparation and running  
The plastic plates (90 mm-wide x 83 mm-high x 1 mm-thick) (ATTO, 
AE6530 mPAGE, Japan) were thoroughly cleaned by methanol then dried 
and assembled according to the manufacturer instruction. The resolving gel 
stock (15 ml/ 2 gels) was prepared freshly with dH2O at a concentration 12 % 
[(5 ml of 1.5 M Tris pH 8.8, 3.9 ml H2O, 6 ml of 30 % acrylamide, 75 µl of 20 
% SDS, 75 µl of 10 % (w/v) ammonium persulfate (APS), 25 µl 
tetramethylenediamine (TEMED)]. After pouring the resolving gel into the 
plastic plates, it was overlaid by adding 200 µl dH2O then permitted to 
polymerize for 30 min. Then (5 ml/ 2 gels) of stacking gel [(0.62 ml of 0.5 M 
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Tris pH 6.8, 0.833 ml of 30 % acrylamide, 25 µl of 20 % SDS, 50 µl of 10 % 
(w/v) APS, 5 µl TEMD)] was added after removing the H2O, to fill the space 
above the resolving gel; the comb was then inserted immediately without 
forming air bubbles. When the gel was completely polymerized, the comb 
was removed gently. Protein samples in SDS-PAGE sample buffer were 
loaded alongside with protein marker (Spectra™ Multicolour Broad Range 
Protein Ladder, thermos scientific, Lithuania). Electrophoresis was performed 
using a vertical gel apparatus (ATTO, Japan) at 220 V for 60 min at room 
temperature (Walker, 2012).  
2.6   Comassie blue staining 
SDS-PAGE gels were stained with Coomassie Brilliant blue (0.25 % 
w/v) plus 100 ml glacial acetic acid, 400 ml methanol in a total volume of 
1000 ml H2O, filtered through Whatman filter paper before use. The gels 
were immersed in the stain for 30 min on a shaker at RT and then de-stained 
by washing 5 times with de-stain buffer comprising 400 ml methanol, 100 ml 
concentrated acetic acid in a total volume of 1L H2O. Finally, gels were 
imaged by white light transillumination using chemidoc documentation 
system (BioRad) (Walker, 2012). 
2.7 Western immunoblotting 
The wet transfer method was used to transfer the proteins from 
electrophoretic gel onto polyvinylidene fluoride (PVDF) membranes. The gel 
was washed three times for 10 min with transfer buffer and the protein then 
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transferred into PVDF membrane that had been soaked in 100 % methanol 
for 16 sec followed by 5 min in freshly prepared transfer buffer at RT.  
The transfer apparatus was assembled by placing the gel and 
membrane in a sandwich of double filter papers and sponges that were 
saturated with transfer buffer. The PVDF membrane was always placed 
between the gel and the positive electrode in a vertical electrophoresis tank 
that was filled with cold transfer buffer and frozen cool block. The tank was 
kept cold during the electrophoresis by placing in an ice tray. The electro- 
blotting was performed at 200 V for 60 min. Then the PVDF membrane was 
blocked overnight at 4 °C in blocking buffer [5 % (w/v) skimmed-milk powder 
(Marvel, UK) in TBS-T].  
Subsequently, the membrane was incubated with the required 
concentration of primary antibody diluted in blocking buffer for 2 h at RT with 
gentle shaking. Then the membrane was washed 5 times for 5 min with TBS-
T [(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % (v/v) Tween20)]. The 
membrane was then incubated with the secondary antibody labelled with 
horse raddish peroxidase, diluted appropriately (referred in the following 
relevant sections) for 1 h. The membrane was then washed a further 5 x for 5 
min in TBS-T and protein bands were then developed by adding a freshly 
prepared substrate working solution (ECL) by mixing both substrate 
components 1:1 (0.1 mL/ cm2) (Bio-Rad ECL substrate) and visualised by 
using chemidoc documentation system (Bio-Rad, UK) (Kurien & Scofield, 
2015).   
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2.8 Indirect immunofluorescent assay  
The HEK293 or BHK cells for IF staining were seeded onto coverslips 
(section 2.3.2 and 2.3.3). Initially, the cells were fixed for 15 min with 4 % 
paraformaldehyde prepared in PBS then washed 3X in buffer containing 1X 
PBS 0.1 % (v/v) Triton x-100 for 10 min at RT to induce cell membrane 
permeability. Then nonspecific binding sites were blocked by washing 3X in 
blocking buffer containing (1x PBS, 2 % donkey serum, 1 % Triton X-100). 
The slides were incubated with the primary antibody diluted 1:500 in blocking 
buffer. After 1 h, the slides were washed 3 X in washing buffer (1 X PBS-0.5 
% tween-20) for 30 min to remove unbounded antibody followed by adding 
the secondary antibody (Alexa Fluor® 488 diluted at 1:200) for 1 h. The cells 
were washed 3 X in washing buffer then one drop of Prolong Gold® anti-fade 
reagent (Invitrogen, UK) were applied on each coverslip and incubated 
overnight in dark. The slides were examined under fluorescent microscopy 
(Carl Zeiss, Axio Imager 2) (Marchisio & Trusolino, 1999).  
2.9 Immunohistological staining  
Immuno-histological staining was undertaken at the Histology 
Laboratory, Institute of Veterinary Pathology, Vetsuisse Faculty, University of 
Zurich. The horseradish peroxidase (HRP) method was used. Sections (3-5 
µm thick) were prepared from paraffin blocks and mounted on charged slides 
(Superfrost® Plus; Menzel-Gläser, Thermo Scientific). Sections were 
deparaffinised in xylene and graded alcohol (100 %, 95 %, 70 %) and 
underwent antigen retrieval by incubation in citrate buffer pH 6.0 (S2022; 
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Dako) in a pressure cooker at 98 °C for 20 min. Slides were transferred into 
TBS-Tween buffer (Dako 3006) and a Dako autostainer where they were 
incubated with the primary antibody diluted 1:500 in dilution buffer (S2022; 
Dako) for 12-15 h at 4 °C. After subsequent blocking of endogenous 
peroxidase activity with Dako REALTM peroxidase Blocking Solution (S2023; 
Dako) for 10 min at room temperature (RT), slides were incubated with the 
secondary antibody solution (EnVision + System HRP goat anti-rabbit; 
K4003; Dako) for 30 min at RT, and visualization with DAB (K3468; Dako) for 
10 min at RT. Between each incubation step, slides were washed with TBS-
Tween. After removal from the autostainer, sections were counterstained for 
2 sec with haematoxylin, rinsed with tap water, subjected to graded alcohol 
(70 %, 95 %, 100 %) and xylene and cover slipped (Buchwalow & Böcker, 
2010).  
2.10 Heterologous expression of the recombinant protein  
Recombinant GST-oLANA protein was expressed by growing a single 
colony in BL21 (DE3) bacteria in 10 ml of LB broth containing ampicillin (50 
µg/ ml) at 37 °C combined with shaking at 200 rpm. Then a (1:10) dilution 
was used in volume fresh 9 ml LB broth with a similar concentration of 
ampicillin and incubated until the growth culture a density (OD959) reached 
0.6.   
The expression of protein was induced by using β-d-1-
thiogalactopyranoside (IPTG) (Sigma, USA) at a final concentration of 0.5 
mM; the bacteria were subjected to additional incubation for 3 h then pelleted 
at 6000 rpm for 5 min. The pellet was re-suspended in 50 µl of SDS-PAGE 
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sample buffer and the cells were then disrupted by sonication on ice with low 
output and 30 % amplification for 15 sec. Proteins were analysed by SDS-
PAGE followed by Comassie blue staining (see section 2.6). BL21 strain 
containing pGEX-3X vector without insert was used as a negative control 
(Samuelson, 2011).  
2.11 GST-oLANA solubility   
The expressed protein was examined for its solubility by using GST-
Sepharose beads. GST-oLANA protein was produced by adding 1 % of 
primary culture to volume LB broth with ampicillin (50 µg/ ml). At the mid-log 
growth phase (OD595=0.6), IPTG (0.1 mM) was added for a further 3 h 
incubation at 37 °C. Then 1.5 ml was pelleted by centrifugation at 3000 rpm 
for 5 min. The pellet was re-suspended in 300 µl of protease inhibitor cocktail 
that includes AEBSF (23 mM), EDTA (100 mM), bestatin (2 mM), pepstatin A 
(0.3 mM), E-64 (0.3 mM) (Sigma, USA). The protein was released by 
sonication on ice with low output and 30 % amplification for 15 sec. The 
mixture was spun at 6000 rpm for 5 min to form a pellet which was then kept 
on ice for analysis purpose while the supernatant was transferred to a new 
tube to be purified by anti-GST-Sepharose beads.  
After equilibration of GST-Sepharose beads by washing three times 
with PBS, 50 µl of 50 % GST bead suspension was added to the supernatant 
and incubated for 5 min at RT. A 1 ml portion of PBS supplemented with 1 % 
triton X-100 was added to the solution and then spun at 6000 rpm for 30 sec 
in a microfuge. The supernatant was discarded, and the beads precipitate 
washed twice with PBS before being re-suspended in 50 µl of SDS-PAGE 
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sample buffer. The pellet from the original sample was thawed and re-
suspended in 150 µl of SDS-PAGE sample buffer. Finally, samples analysed 
by SDS-PAGE to test whether the recombinant protein was expressed in 
soluble or insoluble form (Rosenberg, 2006). 
2.12 Purification of GST-oLANA by inclusion protein 
preparation      
An overnight culture was diluted at 1:10 into 10 ml fresh LB medium 
supplemented with ampicillin (50 µg/ml) (Sigma, USA) and incubated at 37 
°C with shaking at 200 rpm until the culture reached a density (OD595) of 0.6.  
At this point, IPTG was added to the culture at a final concentration of 0.5 
mM to initiate protein expression. The incubation then continued for an 
additional 3 h at 37 °C with agitation at 200 rpm. The cells were harvested by 
centrifugation at 4000x g for 5 min and re-suspended to a final concentration 
of 10 % of 1 ml inclusion body prep buffer (100 mM NaCl, 1 mM EDTA, 50 
mM Tris PH 8.0) supplemented with 1 mg/ ml of lysozyme (Sigma, USA) and 
incubated at RT for 20 min. The solution was then pelleted by centrifugation 
at 5000x g for 10 min, the pellet was snap frozen at -80 °C overnight and 
then thawed, re-suspended in 1 ml inclusion body prep buffer supplemented 
with 0.1 % w/v sodium deoxycholate and incubated for 10 min on ice with 
occasional mixing. MgCL2 and DNaseI (sigma, USA) were added to a final 
concentration of 8 mM/ml and 10 µg/ml respectively followed by incubation at 
4 °C with occasional mixing for 1 h.  
Five aliquots were used in similar conditions to separate the insoluble 
target protein from soluble contaminants by centrifugation for 10 min at 
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(2000, 6000, 8000, 10000, 12000x g) respectively. A (1:1) dilution of 2x SDS-
PAGE sample buffer was used for the supernatant while the insoluble 
fractions were suspended once in 1 ml inclusion body prep buffer 
supplemented with 1% v/v octylphenoxypolyethoxyethanol (nonidet-NP40) 
(Sigma, USA) then pelleted and washed with 1 ml inclusion body prep buffer 
and then protein samples were prepared by suspending the pellet in 200 µl of 
2x SDS-PAGE sample buffer. Both supernatants and pellets were analysed 
by SDS-PAGE; subsequently, a large-scale inclusion body preparation was 
conducted using the same procedure with low speed centrifugation (2000 g) 
for 10 min to clarify the best inclusion body separation.  
The concentration of GST-oLANA was estimated by SDS-PAGE (12 
%) electrophoresis in comparison with serial dilutions of known 
concentrations of bovine serum albumin that were loaded in (200, 100, 50, 
25, 12.5, 6.3, 3.1, 1.6 µg/ µl) as a standard calibrator for 10 µl of GST-oLANA 
of (one pellet re-suspended in 1 ml SDS- sample buffer) then stained by 
Comassie brilliant blue (see section 2.6) and analysed by Image Lab 
software (Ferrer-Miralles et al., 2015).  
2.13 Rabbit immunisation for antibody production  
At the point when the GST-oLANA was confirmed to be immuno-
reactive, it was purified (section 2.12) and used as an antigen to immunise 
rabbit (Pacific Immunology Antibody Production Corporation (USDA 
registration 93-R-283, USDA license 93-B-179, NIH/OLAW assurance A 
4182-01) (1672 Main St. Ste., Ramona, CA 92065). The antigen was 
administered firstly with complete then incomplete Freund ’s adjuvant (CFA 
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and IFA) during the period of 19 October 2015-28 January 2016. At the end 
of the immunization programme, the antisera were collected and named 
(anti-oLANA).  
2.14 Purification of rabbit anti-oLANA antibodies  
2.14.1 Adsorption to acetone precipitated GST expressing 
bacteria  
The initial purification of anti-oLANA was performed to remove cross-
reacting and GST-specific antibodies. A suspension of BL21 bacteria 
containing merely the pGEX-3X vector induced by IPTG was lysed in 0.9 % 
NaCl (1g of bacteria/ 1 ml of saline). The mixture was incubated in ice for 5 
min, then the appropriate amount of acetone was added (8 ml acetone/ 2 ml 
of suspension). The suspension mixed vigorously and incubated at 0 °C for 
30 min with occasional mixing. The lysate was then spun at 10000 g for 10 
min in a microfuge and the pellet re-suspended and incubated at 0 °C for 10 
min. The mixture was cleared by centrifugation at 10000x g for 10 min and 
the pellet was spread in a clean filter paper until dry then collected in a 
secured container. The antisera were adsorbed using 1 % of the bacterial 
acetone powder at 4 °C with rotation for 30 min then centrifuged at 10000x g 
for 10 min (Rosenberg, 2006).  
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2.14.2 Affinity chromatography of rabbit IgG  
The adsorbed serum was purified finally by affinity chromatography 
medium that contains recombinant protein G provided in MABTrapTM Kit 
(GE healthcare Bio-science, Sweden). Firstly, the HiTrap column and the 
antisera were equilibrated by using binding buffer (2.5 ml of concentrated 
binding buffer was added to 22.5 ml high quality water). The column was 
washed with 3 ml after removing of the preserving ethanol. The antisera were 
diluted (1:1) and applied into the column. Antibody was then eluted using 
elution buffer (0.5 ml of concentrated elution buffer and 4.5 ml high quality 
water). Each 600 µl of purified IgG was re-natured immediately by using 300 




2.15 Generation of Modified Vaccinia Ankara recombinants 
expressing OvHV-2 glycoproteins 
2.15.1 Propagation and titration of Vaccinia Ankara virus 
BHK cells were seeded in 6- well plates (5x 105/ well) until they 
reached near confluence (see 2.3.3). Then ten-fold serial dilutions of 
modified vaccinia Ankara virus (10−4 to 10−8) were used to inoculate BHKs (1 
ml/ well). The cells were then incubated for 1 h at 37 °C with gentle swirling 
every 10 min.  After that, viral inocula were removed and the cells were 
overlaid with 2 ml of complete MEM containing 2.5 % FCS, 0.5 % 
methylcellulose and incubated for 48 h until cytopathic effect appeared. 
Finally, the media was removed, and the cells were washed with PBS 
carefully then fixed with acetone-methanol (60-40) for 10 min followed by 
staining with 0.1 % crystal violet for 10 min.  
2.15.2 Construction of rMVA-glycoproteins  
Plasmid insertion vectors for insertion and expression of heterologous 
proteins in modified vaccinia Ankara and containing gB, gH, gL, and Ov7 of 
OvHV-2 were designed and synthesized by Thermofisher (Wyatt et al., 
2008). These glycoproteins are encoded by ORF8, ORF22, ORF47, and Ov7 
respectively and they were named rMVA-(gB, gH, gL, and Ov7). As can be 
seen in (Figure 2-3), the MVA vectors have flanks homologous with vaccinia 
virus, facilitating insertion of the construct into the MVA genome and also 
contain GFP under the control of the P11 promotor which enable 
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identification and selection of recombinants. The glycoproteins expressed by 
the recombinant MVA vectors were also designed to contain particular 
epitope tag proteins by which they can be detected. Thus, the Flag tag was 
used in rMVA-gB and rMVA-gH vectors; the HA and V5 tags were used in 
rMVA-gL and rMVA-Ov7, respectively. These were under the control of the 
modified H5 promoter (mH5) (Wang et al., 2010).  
2.15.3 Generation of Modified Vaccinia Ankara Virus 
recombinants 
The BHK cells were firstly seeded (5x 105/ well) in 6- well plate (see 
2.3.3) then infected with vaccinia virus (0.5x 105 pfu/ ml) (see 2.15.1) and 
transfected as described in (2.4.2). Prior to the end of incubation, the virus 
inoculum was aspirated from the cell monolayer, washed twice with PBS and 
the mixtures of DNA/ lipofectamine were then added. The volume was made 
up to 1 ml with MEM media and incubated for 4 h at 37 °C in 5 % CO2. After 
that, the media was replaced with 1 ml of MEM containing 2.5 FBS and 
incubated 48 h at 37 °C. The cells were harvested in 0.5 ml media, 
transferred into sterilized tubes and lysed by conducting three cycles of 
freezing in dry ice and thawing in a 37 °C water bath. In each cycle, the 














Figure 2-3.  Schematic diagram shows the workflow of construction the 

















2.15.4 Purification of rMVA by plaque selection  
The generated recombinant viruses from (section 2.15.3) were purified 
by three rounds of plaque purification. This was performed by picking-up a 
separate GFP plaque of each recombinant MVA using a Gilson pipette tip 
and adding into 0.5 ml of MEM media. After 3 cycles of freezing and thawing, 
a portion was used to re-infect BHKs (Kremer et al., 2012). Finally, each 
purified MVA was quantified by titration as described in section (2.15.1).   
2.15.5 Large scale production of rMVAs 
Each rMVA was used to infect BHK cells in T175 flasks as described 
in section (2.15.1) at a multiplicity of infection (MOI) of 5 PFU/ cell. After 24 h 
cells were collected, and virus released by homogenization, using a tight-
fitting Dounce homogenizer. The virus stocks were then titrated as described 
in (2.15.1) and stored at -80 °C.   
2.15.6 Immuno- precipitation of flag fusion protein 
Immuno-precipitation using M2 affinity gel carrying an anti-flag mAb 
(Sigma, UK) was used to examine the expressed glycoprotein complexes.  
BHK cells (5x 105/ well) were cultured (see 2.3.3) for 24 h then infected with 
the recombinant MVAs (5 PFU/ cell) overnight, as in section (2.15.1). First, all 
the media was removed, then cells were washed carefully 3x with PBS and 
then lysed using TBS (50 mM Tris PH 8, 150 mM NaCl, 1 mM EDTA, 0.5 % 
NP40) with protease inhibitor (10 µl/ 1 ml). Anti-flag M2 affinity gel (40 µl) 
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was transferred into an Eppendorf tube and spun at 8000x g for 30 sec at 4 
°C. The supernatant was then removed, and the packed gel was washed 
twice with 500 µl of TBS before adding cell lysate to the M2 gel. It was then 
incubated with agitation at 4 °C overnight. The resin-complex was spun at 
8000 g for 30 sec at 4 °C to pellet the beads and washed 3 x with 500 µl of 
TBS. Finally, the flag- fusion complexes were eluted by adding 100 µl of 
glycine (0.1 M, HCl pH 3.5) for 5 min with low agitation then pelleted at 8000 
g for 30 sec. The supernatant was transferred into fresh tube containing 10 µl 
of buffer (Tris HCl 0.5 M, 1.5 M NaCl, pH 7.4). The protein complex was 
analyzed further as described in (2.15.6).  
2.15.7 De-glycosylation of recombinant glycoproteins   
The immuno-precipitated complexes were cleaved by using Peptide: 
N-Glycosidase F (PNGase F), following the manufacturer’s recommendation 
(BioLabs, UK). A 10 µg portion of glycoprotein complex was combined with 1 
µl of (10 x) glycoprotein denaturation buffer (0.5 % SDS, 40 mM DTT) was 
made up to 10 µl with dH2O and denatured by heating the mixture at 100 °C 
for 10 min. Then, 2 µl of 10 x Glyco-Buffer 2 (50 mM Sodium Phosphate, pH 
7.5), 2 µl of 10 % NP-40 and 1 µl of PNGase F were added. The mixture was 
made up to 20 µl with dH2O and incubated at 37 °C for 1 h. Cells were 
harvested (see 2.5.2.1) and tested by western immunoblotting as described 
in section (2.7).       
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2.15.8 Mouse immunization by the rMVAs  
To test the immunogenicity of the MVA recombinants, viruses were 
used to inoculate mice via the intraperitoneal route. All work was performed 
under UK Home Office Licence 70/8599. Mice (BALB/c strain) were 
purchased from Charles River, aged 6 weeks and were immunized with 1x 
104 PFU of virus by IP. Mice were boosted 3 weeks later and were 



















3. Chapter three: The role of gamma-
herpesviruses in the pathogenesis of 





3.1 Abstract  
There is no permissive cell line to propagate most of the aetiological 
agents of MCF, which has hindered the understanding of disease 
pathogenesis. However, PCR has improved our understanding of aspects of 
MCF disease (Russell et al., 2009). Previous studies in our laboratory have 
shown that cattle without MCF can carry OvHV-2, indicating other factors, 
possibly herpesviruses are involved in MCF (Amin, 2015). Therefore, the aim 
of this study was to identify other factors that possibly induce MCF apart from 
MCF viruses. In this study, a combination of two PCR assays (PAN 
herpesvirus endpoint and qPCR) as qualitative and quantitative approaches 
(see 2.2), were employed to examine sheep, goats, cattle without MCF and 
cattle with signs of MCF, bison, and water buffalo to identify which γ-
herpesviruses may be involved in MCF. The results showed that although the 
related bovine herpesvirus 6 and ovine herpesvirus 1 are endemic 
commensals of cattle, they could afford cross-protection from infection with 
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OvHV-2 and development MCF. Combining these two PCR assays will help 
in the diagnosis of MCF in various hosts.  
3.2 Results  
3.2.1 PAN- herpes consensus nested PCR 
Modified and unmodified primers of degenerate and deoxyinosine-
substituted primers from a highly conserved sequence of the herpesvirus 
DNA polymerase (DPOL) gene were used in this approach as described in 
(2.2.1). Specific amplified fragments, 288 bp in length, were produced from 
this technique (Figure 3-1). These were cloned into E coli to produce 
plasmids for gene sequencing. These were then aligned using NCBI BLAST 
analyses to identify the detected species. DNA samples were tested from 
animals with or without MCF from multiple ruminant species. The results 
showed detection of six γ-herpesviruses including: OvHV-2, Bison LHV, 
CpHV-2, BoHV-6, Caprine LHV, and Reindeer γ-HV (Table 3-1). Although 
OvHV-2 was identified in all cattle with MCF (100 %), it was not found in any 
bison with MCF. However, Bison LHV, CpHV-2, and Reindeer γ-HV were 
identified in 8 of 25 cases. Two of three cases of water buffalo with MCF 
were positive for OvHV-2.  
The detection of Bison LHV in water buffalo is interesting but is 
unlikely to be the cause of disease in this case.  
The data obtained from testing deer samples highlight only four cases 
were positive. Notably, one case of semi-domesticated reindeer (Rangifer 
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tarandus) was co-infected with CpHV-2 and Reindeer γ-herpesvirus. 
Interestingly, BoHV-6 was detected in goat.  
Caprine LHV was detected in one goat that had pathological signs of 
chronic granulomatous pneumonia according to the pathological report 
obtained from Institute of Veterinary Pathology, Vetsuisse Faculty, University 
of Zurich, Switzerland. Additionally, Reindeer γ-herpesvirus was identified in 
deer (Rangifer tarandus) and in one bison with MCF which is interesting. 
Therefore, to exclude contamination, this case was tested twice by PAN-
nested PCR and exactly similar sequence was found. 
The obtained DNA sequences from the currently diagnosed 
herpesviruses were further analysed to characterise the phylogenetic 
evolutionary relationship. The phylogenetic tree revealed that OvHV-2 and 
CpHV-2 were closely related to the previously identified MCF-viruses 
whereas reindeer gamma-HV, Bison LHV, BoHV-6, and Caprine LHV were 





Figure 3-1. Gel electrophoresis (1.5 % agarose) image shows PCR products 
of DPOL consensus herpesvirus nested PCR. These were amplified by 
modified and non-modified primers, electrophoresed by the end of the 
second round before being cloned into E coli, lanes (1-7) are positive 
samples; lane 8 is control negative at which ddH2O was used instead of 
template DNA. (B) The reconstructed plasmid with EcoRI enzyme for positive 















n(Lung, LN)= 8 
Bison without 
MCF signs 
n (LN)= 2 
Bison with 
MCF signs 
n (LN)= 25 
Buffalo with 
MCF signs 
n (BC)= 3 
Deer with MCF 
n (BC)= 13 
Goat 
n (lung)= 3 
Infected % Infected % Infected % Infected % Infected % Infected % 
OvHV2 8 100 0 0 0 0 2 66.6 0 0 0 0 
Bison LHV  0 0 0 0 6 24 1 33.3 0 0 0 0 
CpHV2 0 0 0 0 1 4 1 33.3 2 15.3 1 33.3 
BoHV6 0 0 0 0 0 0 0 0 0 0 1 33.3 
Caprine LHV 0 0 0 0 0 0 0 0 0 0 2 66.6 




Figure 3-2. Maximum Likelihood phylogram based on nucleotide sequences 
of the DNA polymerase genes of the identified herpesviruses. Box shaded 
are the identified species. The bootstrap consensus tree was constructed 
from 1000 replicates to provide support for individual nodes by using MEGA7 


























3.2.2 q-PCR assays  
Five quantitative assays including: OvHV-1, BoHV6, OvHV2, Bison 
LHV, and CpHV2 were developed (as described in 2.2.2) and used to 
analyse the frequency and load of different ruminant gamma-herpesviruses 
in DNA samples. These were established by designing specific primers and 
probes (see 2.2.2.1) to produce reference plasmids for viral quantification 
(see 2.2.2.3) by optimal protocol (see 2.2.2.2). The quantification results 
were normalised by quantifying 12s- ribosomal DNA.  
3.2.2.1 Assay specificity 
There was no evidence for any cross reaction when the assays used 
to test samples that are known to be positive for only particular species. For 
instance, known EHV2-positive samples were negative. Another approach 
was used by testing clinical samples of cattle with MCF that were OvHV-2 
positive. Additionally, combining the data from the PAN-consensus PCR 
provided further confirmation on q-PCR specificity, as some samples 
appeared to be infected with particular herpesviruses such as: CpHV2, 
OvHV2, Reindeer herpesvirus, and Bison LHV. All these lines of evidence 
provide confidence in the specificity of the developed assays.    
3.2.2.2 Assay sensitivity  
Repeatability (intra-assay variation) and reproducibility (inter-assay 
variation) of each developed q-PCR were estimated by five experiments in 
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which the Ct value of duplicates of each dilution of the standard plasmid was 
calculated. The validation of the sensitivity results for the OvHV-1 reference 
plasmid are listed in (Table 1 in the appendix) which revealed the lowest 
coefficient of variation for (2 × 103) copy number (0.03 %) which was in 
experiment (IV) and the highest (5.05 %) for (2 × 100) in the same 
experiment. The coefficients of determination (R2) were calculated in all 
experiments of this reference as (0.983 ± 0.466).  
The results obtained from the BoHV-6 reference plasmid are 
presented in (Table 2 of the appendix) which revealed a lowest coefficient of 
variation (0.004 %) that was calculated in (2 × 105) copy number of 
experiment (I) whilst the highest (5.31 %) for copy number (2 × 101) in the 
experiment (V). The coefficients of determination (R2) were calculated in all 
experiments of this reference as (0.983 ± 0.375).  
As can be seen from the (Table 3 of the appendix), in OvHV-2 
standard reference, the lowest coefficient of variation (0) was reported in 
copy number (2 × 104) in the experiment (II) and the highest (3.51 %) for (2 × 
102) copy number in experiment (V). The overall value of coefficient of 
determination (R2) in this reference was 0.999 ± 0.13.  
The lowest coefficient of variation in Bison LHV reference standard 
was (0.02 %) in experiment (V) of (2 × 100) copy numbers while the highest 
(2.84 %) in experiment (II) of (2 × 102) copy number (Table 4 in the 
appendix). The coefficient of determination (R2) in this reference was (0.997 
± 0.2). In CpHV-2 standard plasmids, the lowest coefficient of variation was 
found in experiment number (IV) as (0.04 %) at (2 × 106) copy number 
whereas the highest (4.72 %) was determined in experiment number (III) of 
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(2 × 107) copy number (Table 5 in the appendix). The coefficient of 
determination (R2) in this reference was (0.999± 0.1).  
It is apparent that 12s- ribosomal DNA internal genomic control was 
amplified in all DNA samples, indicating that a similar DNA template quantity 
was used in the q-PCR assays. Therefore a normalisation strategy was 
adopted successfully to account for the errors in the assay quantification and 
reaction efficiency caused by DNA quality and contamination (Figure 3-3).  
From these data, it was concluded that these assays were highly 











Figure 3-3. Logarithmic amplification of the internal 12s-ribosomal DNA\ 100 
ng template of cattle, sheep, bison, buffalo, goat, and deer DNA were plotted 
in normal distribution by using Graph Pad prism (version 7, GraphPad 
Software Inc, CA, USA). The normalisation was conducted to account the 














3.2.3 Gamma-herpesvirus frequency and loads     
In this study, different sample sources including: cattle without MCF 
(lung, LN), cattle with signs of MCF (lung, spleen, buffy coat), sheep (lung, 
LN), sheep with SPA (lung, blood), goats (lung), bison (blood, nasal swab), 
bison with MCF (lymphoid cells), buffalo with MCF (lung, LN), and deer 
(spleen, buffy coat, nasal swab) were tested for gammaherpesviruses by q-
PCR. Our results show a complex pattern of infection and co-infection with 
several ruminant γ-herpesvirus species. However, MCF was only associated 
with a high viral load of OvHV-2 or CpHV-2. 
3.2.3.1 OvHV-1 
Of interest, OvHV-1 was detected in more than half of the healthy 
cattle but not in cattle with MCF. In fact, this finding is novel as OvHV-1 has 
only been detected previously in sheep. Although, OvHV-1 was found in high 
a proportion of cattle (54 %), it was not found in cattle with MCF (P<0.01); 
apparently it does not cause MCF (Table 3-2).  
Testing sheep samples revealed that OvHV-1 was endemic in this 
species. There was higher infection rate (71 %) in comparison with sheep 
that suffered from SPA (53 %). Interestingly, goats were negative for this viral 
species. The data obtained from testing healthy bison revealed that (11 %) 
were infected with OvHV-1. Nevertheless, bison, buffalo and deer with MCF 
were negative.  
Viral DNA loads were variable among those positive samples as the 
higher median viral load (589 copies/ 100 ng DNA) was found in sheep that 
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infected with SPA whilst the lower (9 copies/ 100ng DNA) was detected in 
cattle without MCF. 
3.2.3.2 BoHV-6  
The same samples were also tested for BoHV-6. This virus was 
detected in 30 % cattle without MCF and 11 % of those with signs of MCF. 
These percentages were not significantly differ (P>0.01). Importantly, BoHV-
6 was found in goats with high frequency (50 %) with peak load of 4395 
copies/ 100 ng DNA. This level of viral load was not found in cattle. This is 
the first time that this species was detected in goats. Another interesting 
finding is that BoHV-6 appeared to be enzootic in bison as well with an 
infection rate of 22 %. However, BoHV-6 was not detected in numerous hosts 
such as sheep (with or without SPA) and deer. It was not seen in bison and 
buffalo with MCF, suggesting the possibility of cross protection against 
OvHV-2 as in OvHV-1 in these species.  
BoHV-6 quantification in cattle with MCF was detected in a median 
viral load (27 copies/ 100 ng DNA). This was lower than the median viral load 
in healthy cattle (44 copies/ 100 ng DNA). Overall, the highest median load 
(125 copies/ 100 ng DNA) was seen in healthy bison (Table 3-2).   
The results of OvHV-1 and BoHV-6 genomic loads revealed that they 
are commensals in cattle. In this aspect, both viruses were prevalent in cattle 
without MCF (lung and LN) organs as shown in (Figure 3-4). Quantification of 
OvHV-1 revealed maximum values of 36 and 136 copies/ 100 ng DNA in lung 
and LN respectively, while BoHV-6 had slightly higher viral loads (412 and 
660 copies/ 100 ng DNA in lung and LN respectively). Only a few samples of 
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cattle with MCF (3 out of 27), mainly lymphoid cells, were found positive for 
BoHV-6 but with a relatively low median viral load (26 copies/ 100 ng DNA). 
In the analysis of sheep samples, OvHV-1 was detected in lung with a 
maximum load of 1611 copies/ 100ng DNA which is higher than the load in 
the lungs of healthy cattle, while in LN tissue, it was 66 copies/ 100 ng DNA. 
3.2.3.3 OvHV-2   
OvHV-2 was detected in all cattle with MCF and in 50 % of buffalo with 
MCF whereas goats, healthy bison, bison with MCF, and deer were not 
infected.  
The obtained data revealed that cattle with MCF infected with high 
OvHV-2 viral loads as the value was reached (7.6 x 109 copies/ 100 ng DNA) 
whilst the value in buffalo was found as (3 x 105 copies/ 100 ng DNA) (Table 
3-2).  
3.2.3.4 Bison LHV 
 Bison LHV was found in healthy bison and bison with MCF. It was 
detected in a lower proportion (11 %) in the latter as compared with healthy 
bison (44 %). The median viral loads (13 copies/ 100 ng DNA in healthy 
bison and 23 copies/ 100 ng DNA in bison with MCF) were relatively low. In 
one case, a buffalo with MCF was diagnosed with this viral species (134 




Surprisingly, only one case of 14 goat samples was found positive for 
CpHV-2 (20 copies / 100 ng DNA). A high proportion of healthy bison (78 %) 
carried CpHV-2. A lower proportion of bison with MCF (48 %) were infected 
with this virus. Viral loads in both cases were relatively low (63 copies/ 100 
ng DNA in bison with MCF versus 36 copies/ 100 ng DNA in healthy bison). 
Several deer were found positive with a very low median viral load (4 
copies/ 100 ng DNA). Additionally, one case of a buffalo with MCF was found 
to be infected with CpHV-2 and with a very high viral load (1.2 x 107 copies/ 
100 ng DNA) which indicates its role in causing MCF (Table 3-2).  
3.2.3.6 Gamma-herpesviruses co-infection 
The results showed numerous multiple infections in both healthy and 
MCF cases by using pan-herpesvirus nested PCR and q-PCR. In healthy 
cattle, four cases were found positive for OvHV-1 and BoHV-6. In cattle with 
MCF, only three cases were detected positive for BoHV-6 and OvHV-2. In 
buffalo with MCF, there was one case of co-infection including OvHV-2, 
CpHV-2, and Bison LHV. In healthy bison, four positive cases were detected 
for Bison LHV and CpHV-2. One of these cases was also infected with 
OvHV-1 while another case was found positive for BoHV-6 as well. In bison 
with MCF, three cases of co-infections were found positive for Bison LHV and 
CpHV-2. In deer samples, there was one case of co-infection detected by 
pan-herpesvirus nested PCR for CpHV-2 and Reindeer gamma-herpesvirus.      
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Table 3-2. Results of q-PCR assays frequency and viral DNA load quantifications in the tested animals.  



















































































































Healthy cattle  33 54.5 3 80 9 30.3 9 536 44 - - - - - - - - - - - - 
Cattle/ MCF 27 0 0 0 0 11.1 7 31 27 100 154 7.6 x 10
9
 1.1 x 10
5
 - - - - - - - - 
Sheep  14 71.4 4 1611 18 0 0 0 0 - - - - - - - - - - - - 
Sheep/ SPA  41 53.6 4 13749 589 0 0 0 0 - - - - - - - - - - - - 








22.2 100 149 125 0 0 0 0 44 3 214 13 78 16 92 36 
Bison/ MCF 45 0 0 0 0 0 0 0 0 0 0 0 0 11.1 2 146 23 48.8 3 299 63 
Buffalo/ MCF 6 0 0 0 0 0 0 0 0 50 114 3 x10
5












Deer 13 0 0 0 0 0 0 0 0 0 0 0 0 - - - - 15.8 3 5 4 
 
Abbreviation:  minimum (min), maximum (max), median (med)/ 100 ng genomic DNA, not tested (-), only one positive sample was 






Figure 3-4. BoHV-6, OvHV-1 and OvHV-2 loads DNA (copies/ 100 ng DNA) 
in lung and LN of healthy cattle and lymphoid cells of cattle with MCF. 
Analysed by T-test mann-whitney (Graph Pad prism version 7, Inc, CA, 




3.3 Discussion  
Studies in our laboratory have revealed that OvHV-2 can be 
harboured in cattle without MCF signs. Therefore, we suggested that possibly 
other factors involved in MCF apart from MCF viruses. The hypothesis of this 
study was whether the presence of alternative gamma-herpesviruses 
involved with OvHV-2 in causing MCF or co-infections with OvHV-2 could 
induce MCF. The generated data showed a complicated scenario, arising 
from infection and co-infection by γ-herpesviruses with infection of multiple 
ruminant  hosts by some species. Importantly, the results suggested that 
quiescent infection with ruminant ɣ-herpesviruses other than OvHV-2 
provides protection for cattle against OvHV-2 infection and prevent MCF. For 
instance, although OvHV-1 was enzootic in cattle without MCF, it was not 
found in cattle with MCF. This suggests that OvHV-1 infection may in some 
way protect against the development of MCF in cattle. Assessment of the 
role of these viral species revealed that, in line with previous work, MCF is 
associated with high viral load of OvHV-2 and CpHV-2.  
The PAN-herpesvirus nested PCR was based on using consensus 
degenerate primers to amplify highly conserved coding motifs of herpes viral 
DNA polymerase. The sequence of this gene is highly conserved among the 
herpesvirus species. This assay was established by (Vandevanter et al., 
1996). For more sensitivity and wider range of herpesvirus diagnosis, the  
assay was then modified by (Ehlers et al., 1999b) through combining of the 
degenerate and deoxyinosin- substituted primers. This later assay was 
adopted in the current study (see Table 2-1). The specificity of using these 
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primers in generating species-specific products has been determined by the 
researchers who developed this approach. It has been successfully 
employed by others to demonstrate not only known herpesviruses but also 
newly recognised members with a high sensitivity and specificity 
(Chmielewicz et al., 2003; Ehlers et al., 2007; Fernández-Aguilar et al., 
2016). This technique was therefore adopted in the current study and 
resulted in detecting six herpesvirus species (OvHV-2, Bison LHV, CpHV-2, 
BoHV-6, Caprine LHV, and Reindeer γ herpesvirus). In contrast, this assay is 
perhaps not suitable for conducting epidemiological surveillance because it is 
labour-intensive and relatively expensive.  
The involvement of other ruminant gammaherpesviruses apart from 
known MCF viruses is poorly understood with no reports in their occurrence 
in bison, water buffalo, and deer. These hosts have been reported to be 
highly susceptible to MCF without producing infectious particles (Cunha et 
al., 2012; Taus et al., 2014).   
Taqman q-PCR assays were developed and used in this study to 
detect and quantify OvHV-1, BoHV-6, OvHV-2, Bison LHV, and CpHV2. This 
technique has been employed to perform numerous epidemiological and 
pathological studies due to its advantages of highly sensitivity, reliability, and 
speed (Cunha et al., 2009; Elia et al., 2008; Hughes et al., 2010; Kim et al., 
2003; Traul et al., 2005).  
OvHV-1 and BoHV-6 are highly related but both were detected to a 
greater or lesser extent in sheep (not enzootic for BoHV-6) and cattle without 
MCF. The finding of OvHV-1 in healthy cattle is novel as it has only been 
reported in sheep previously (Kopácek et al., 2000; Scott et al., 1984). 
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Importantly, OvHV-1 was not detected in cattle with MCF while BoHV-6 was 
diagnosed in some MCF cases with lower viral load than in cattle without 
MCF. This suggests particularly OvHV-1 infection may in some way prevent 
triggering of MCF in cattle and perhaps afford cross-protection among these 
viruses. They all belong to the macavirus genus, share a high degree of 
sequence homology and may therefore be antigenically cross-reactive. 
However, all these rumminant herpesviruses are split into MCF and non-MCF 
viruses depending on their genetic discrepances. The phylogenetic 
relationship between these viruses based on DNA polymerase gene 
sequence showed this attitude (Figure 3-2). This finding will help to provide 
new insight into preventing MCF.  
OvHV-1 has been associated with SPA in sheep (Martin et al., 1979). 
We used our q-PCR assay to quantify this viral species in sheep that suffered 
from SPA to demonstrate the role of OvHV-1 in this disease. The obtained 
results showed that some SPA cases are still negative for OvHV-1 while 
quantification of the positive ones revealed massive elevation of the viral 
copy number (Table 3-2). This indicates that OvHV-1 is not the causative 
agent of SPA, while the high viral copies in the identified cases might be the 
result of the OvHV-1 lytic replication due to the stressful conditions of 
adenomatosis or effects of SPA on immunity. 
The obtained BoHV-6 quantification data fits with the previous reports 
of its prevalence in healthy cattle (Kubiś et al., 2013). However, other studies 
demonstrated that BoHV-6 could be involved in unresponsive endometritis of 
dairy cattle (Banks et al., 2008; Cobb et al., 2006). Recently, BoHV-6  has 
been also detected in some buffalo cases that suffered from 
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lymphoproliferation. Interestingly, these cases were not present for bovine 
leukemia virus (BLV). However, the pathological role of BoHV-6 has not been 
confirmed yet (de Oliveira et al., 2015). In another study, viral meta-genomics 
analysis was used to address the aetiological agents associated with Bovine 
Respiratory Disease (BRD) and non-suppurative encephalitis in cattle; 
interestingly, BoHV-6 was proposed to be one of the viruses that was 
responsible in causing these syndromes (Ng et al., 2015).  
Another novel finding was identifying of BoHV-6 in goats suffering 
from chronic penumonia. This suggests a role for this host in viral 
transmission and explains how this virus may spread to cattle. This might be 
due to the direct contact between goats and cattle, which may occur in 
Switzerland where these samples came from. The most obvious conclusion 
from this analysis is that viral loads of both viruses are increased in lungs of 
diseased sheep and goats that probably resulted from a local immune defect 
in the infected animals.  
The current data demonstrates that as in sheep, goats seem to be 
another reservior host for MCF viruses (CpHV-2); this agrees with previous 
studies that suggest a potential role of goats as reservoir for MCFV-WTD that 
leads to MCF in white- tailed deer (Odocoileus virginianus) (Li et al., 2013). 
Finding BoHV-6 in goats (50 % of samples) and (30 % of cattle samples) was 
unexpected and could be explained by the fact that the nomenclature of 
BoHV-6 was established on the basis of its first identification in cattle 
therefore this name is tentatively referenced. This raises the question as to 
whether goats are the natural or merely accidental host for this viral species. 
There is strong evidence for the role of goats as a reservior host for other 
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herpesviruses. We established the q-PCR for quantification of CpHV-2. One 
case MCF in deer was also diagnosed positive for CpHV-2. It can be 
concluded that the evolutionary relationship of these ruminants make them 
suitable hosts for the closely related herpesviruses. 
BoHV-6, CpHV-2, OvHv-1, and Bison LHV were identified in healthy 
bison whereas bison with MCF were infected with only CpHV-2. Interestingly, 
CpHV-2 and OvHV-2 were quantified in high viral load in one case of water 
buffalo with MCF. In another case, a buffalo was diagnosed with Bison LHV 
raising the question of which is the natural host for this viral species. Little is 
known about this viral species. This study is the first to quantifiy bison LHV 
and further work is required to investigate its pathological role in more 
ruminants.  
Cattle are relatively resistant to MCF, probably as they have been 
farmed with sheep for long time. Sheep are the natural host for OvHV-2 and 
MCF appears as sporadic cases in cattle with occasional outbreaks. 
Previously, OvHV-2 was detected in a longitudinal study in healthy cattle 
(Powers et al., 2005). A recent study in our laboratory has shown similar 
findings (Amin, 2015).  
In this study, an OvHV-2 q-PCR assay was used to test MCF cases to 
demonstrate the prevalence and relationship with other 
gammaherpesviruses. Importantly, all the pathological MCF cases were 
diagnosed with very high viral loads of OvHV-2 (except bison with MCF), 
wherease other viral species were either not found or had low viral loads.  
It has been shown that bison are highly sensitive to OvHV-2 (O’Toole 
et al., 2002; O’Toole & Li, 2014). Our analysis of bison showed that some 
112 
 
had MCF symptoms but were not present for OvHV-2. In these cases, the 
bison may have not had MCF or the presence of low viral loads of Bison LHV 
or CpHV-2 within this highly sensitive host could still be a factor in causing 
the immune-dysregulation and MCF development. Reindeer gamma 
herpesvirus was identified in deer but due to time limitation and small number 
of deer samples to test, q-PCR assay was not developed to quantify this viral 
species.  
Our results revealed that more than half of the healthy cattle were 
positive for OvHV-1. However, cattle with MCF were not found infected. 
BoHV-6 was detected in 30 % of healthy cattle and in 11 % of cattle with 
MCF. In contrast, BoHV-6 was not detected in bison and buffalo with MCF. 
This data suggested that OvHV-1 possibly has a role in preventing MCF due 















OvHV-2    1 ATGGCGAACCCCGCTAGCACCC---TGAGCC---CTGCTGCGCTCACGACCCTCTTATGC 
OvHV-1    1 ATGGCTAGCTCCTGCAGCTTCAAAGTAAAAGTAGTTGCGATGCTGCTTTTACTTTTTTTG 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2   55 CTCGCTGCCTGCCTGGGACAGACTCCCACACC--CCCCACCACCGAGGATGACGTTATTG 
OvHV-1   61 CTCCTTGGCTGGGGCAGCCACTTTTGCAGAAGCGCTTCATTGCCACCGATAGAGTTTACA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  113 TCCCTGG-----------TAACACCGTCTCCCCCGATGTTTTGAAACAGCAGCTGGGCAG 
OvHV-1  121 CAGCTGACTCCTACACCTGAAAACCAGCCAGCTACGCCGCCTGAAGTAAT---TGTAGAG 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  162 CGGCCTCAATGAGGAGGAAGGGTCTATAAACCGGGGCCCCATGGACCCCTCTGCCTTCCC 
OvHV-1  178 CAGCCACCCAAGCCTGGAACTGTGC-CTATCCACAACAAAGAACAGAGCACCAGCTTTCC 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  222 CTTCAGAGTATGCAGCGCCTCCAACATCGGAGACATCTTCCGCTTCCAGACAACACACTC 
OvHV-1  237 ATATAGAGTGTGCAGCGCATCTGCTACAGGAGACATTTTTAGGTTTGATACTACGCACAC 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  282 CTGCCCCAACACTAAGGACAAGGAGCACAACGAGGGGATTTTGTTGATCTTTAAGGAAAA 
OvHV-1  297 GTGTCCAGATACACACGACAAGCAGCACAATGAAGGAATTTTGCTGATCTTTAAAGAAAA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  342 TATAGTGCCCTATGTGTTTAAGGTGAGAAAGTACCGGAAAATCGTGACCACCTCTACGGT 
OvHV-1  357 CCTTATTCCCTACATGTTTAAGGTTCGTAAGTACAGAAAGATTGTTACTACGTCTACAGT 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  402 CTACAATGGTATCTATTCTGATGCTATCACCAACCAGCATGAGTTTTCAAAGTCGGTGCC 
OvHV-1  417 TTATAACGGAATTTACTCAGATACTATTACTAACCAGCATGTGTTTCATAAATCTATTCC 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  462 CCACTACGAGGCCCGGCGGATGGACACCATCTACCAGTGCTACAACAGCCTGTCTTTGAC 
OvHV-1  477 TGAATACGAATACAAAAGGATGGACACTATATACCAGTGCTACAACTCTATAAAGCTTAC 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  522 CGTCGGGGGAAACCTCCTGGCCTACACAGACAACGACGGCTACAACCTGACCGTGGATTT 
OvHV-1  537 AGTTGCTGGAAACCTGTATACATACACTGATAGAGATGGATCAAATTTTACAGTAGATCT 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  582 GCAGCCCATGGACGGGTTGAGCAACAGCGTGCGCCGCTACAACAGCCAGCCCGAGATTCA 
OvHV-1  597 TAACCCAGTAGATGGGCTTACTTCTTCTGTGAGAAGGTACTGTAGTCAGCCTGATGTGTA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  642 CGCAGAGCCCGGGCGGCTCCTGGGGGGCTACCGCAGGAGGACAACAGTAAACTGTGAAGT 
OvHV-1  657 CACAGACCCTGGCTGGTTTTGGGGCAGCTACAGGCGCCGCACCACAGTTAACTGTGAAGT 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  702 TACTGACACCGAGGCCCGCTCAGTGCCCCCCTTCCGCTATTTTGTTACCAACGTCGGTGA 
OvHV-1  717 GACAGATATGCAAGCCAGATCAACGCCTCCGTTTCAGTACTTTGTAACAAGCACCGGGGA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  762 CACCATCGAGATGTCGCCCTTCTGGTCGGGCGGTGCGAACGAGACGGAGCCTAACAAGGA 
OvHV-1  777 TACTGTAGAAATGTCTCCATTTTGGCGCGGCGGCAGCAACGAAACTGAACACATGAAAGA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  822 GCCCCGGAGAACCGTGTCTGTGCTCCGAGACTACACCCTGGTGGACTACAAGGACCGAGG 
OvHV-1  837 AAAACCTTGGCTTGTAAAAGTTCACAATGACTACAGGATGGTGGACTACGAAAACAGAGG 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  882 CAGCAGGCCTCAGCCCCACACCAGAATCTTCATTGACAAGGAGGACTACACCCTTTCGTG 
OvHV-1  897 CTCTTTACCTAATCCACACGTTAGAGTTTTTGTAGATAAAGAAGACTACACGCTTTCTTG 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2  942 GGCCCAGCAGCTGAAAAACATATCCTATTGCAGATGGGCCCACTGGAAGAGCTTCCACAA 
OvHV-1  957 GGAGAGCAAGCCTAAGAACGGATCTTACTGCCCCTGGGCATTTTGGCAAGGCTTCCACAA 




OvHV-2 1002 TGCAATCAAAACTGAGCATGAGAACAGCTACCATTTTGTGGCCAATGATATCACCGCGTC 
OvHV-1 1017 CGGCATTCAAACTAAGCACAACTCCACGTATCACTTTGTAGCTAATGAAATTACAGCTTC 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1062 CTTCTTCACCCCCAACACAGAAGCTCAGGATGTCACCAAAACCCACACATGCCTGAATAG 
OvHV-1 1077 ATTTTCTACGCCACATAGTCAGTATACAGATTTTGATAAGAAGTTTCCTTGCTTAAAAGA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1122 CCTGATAGAAAGCGAGATGACCAGCAGGTTGGAGAAGGTGAATGGGACCCACGTGACGAA 
OvHV-1 1137 AAACATTGAAGCTGAAATGAACTTAAAGCTGCAAAAAGTTAATGGCACCCACCAAAAGTC 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1182 CGGCAGCCGCCAGTACTATCTAACCAACGGGGGGCTGCTGCTGGTGTGGCAGCCCCTGGT 
OvHV-1 1197 TGGACAAGTTGAATACTACAAAACTGACGGAGGCCTTATCTTAGTATGGCAGCCGTTAGT 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1242 CCAACAGAAGCTACTGAACGCCCAGGACTTGCTGGAGGCCGTGGCTTCCAAACACAACGT 
OvHV-1 1257 TCAGCAACAGCTTGTAGACGCTAAGCGAGAGCTAGATGAAGCGTCTACGCCTTCACCA-- 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1302 GACCAGGTCGGCCAGGAGCCGCCGGCAGCGCCGGGCTGTCAGCAGCATCCTCATAGATGA 
OvHV-1 1315 -------------------------GTGCGGAAGCGAGCTCGCAGACAGCTACCTGAAGA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1362 TGATGTTTACACTGCTGAGTCTGCGCTCCTCCTGACCCAGATCCAGTTTGCCTACGACAT 
OvHV-1 1350 AGAAGTGTACACGAAAGAGAACGCAGCTTTGCTAGCTCAAATTCAGTACGCTTATGACAG 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1422 GCTGCGCAGCCAAATCAATACTGTGCTCGAGGAGCTGTCCCGGGCCTGGTGTCGGGAGCA 
OvHV-1 1410 CCTGCGCACTCAAATTAACAACGTGCTAGAAGAGCTGTCTCGGGCATGGTGCAGAGAGCA 
BoHV-6    1 ------------------------------------------------------------ 
 
OvHV-2 1482 GCACAGGGCCTCCCTCATGTGGAACGAGCTGAGTAAGATCAACCCTACCAGCGTGATGAG 
OvHV-1 1470 GCAGCGAGCCACTCTAATGTGGAACGAGCTCAGTAAGATTAATCCTACCAGTGTTATGAC 
BoHV-6    1 ---------------------------------------------------------AAC 
 
OvHV-2 1542 CTCTATCTACGGGCGGCCAGTCTCTGCCAAGCGAATCGGGGACGTGATCTCCGTCTCGCA 
OvHV-1 1530 TTCTATCTATGGAAAGCCAGTTTCAGCTAAAAGGCTAGGCGACGCAATTTCAGTATCTCA 
BoHV-6    4 TTCCATTTACGGAAAACCCGTTTCAGCTAAAAGGTTAGGCGACGCTATCTCAGTGTCCCA 
 
OvHV-2 1602 CTGCGTAGTGGTGGACCAGCAGAGCGTGTCCCTGCACAGGAGCATGCGCGTCCCCGGGCG 
OvHV-1 1590 GTGCGTCGTAGTTGACCAGGGCAGTGTTTCGCTGCATAAAAGCATGAGAAAGAGT----- 
BoHV-6   64 GTGCGTCGTAGTTGACCAGAGCAGCGTTTCTTTGCACAAAAGTATGAGGCAGAGC----- 
 
OvHV-2 1662 AGACCACGCACACGAGTGCTACTCTAGGCCTCCCGTCACCTTCAAGTTTATCAATGACAG 
OvHV-1 1645 ----GACAGCGACGGCTGCTATTCAAGGCCGCTTGTGACGTTCAAGTTTATAAACGACAC 
BoHV-6  119 ----GCCGGCGACGGCTGTTACTCAAGACCGCTAGTCACATTTAAGTTTTTAAATGACAC 
 
OvHV-2 1722 CCACCTGTACAAGGGCCAGTTGGGGGTGAACAATGAAATCCTGCTCACCACAACCGCCCT 
OvHV-1 1701 AAACATATACAGGGGCCAGTTGGGAGTGAGCAACGAAATACTGCTAACTACTAGCGCGGT 
BoHV-6  175 AAACGTCTATAGGGGCCAGTTGGGAGTCAGCAATGAAATATTGCTGACCACCAGCGCGGT 
 
OvHV-2 1782 GGAGGTGTGCCACGAGAACACCGAGCATTATTTCCAGGGGGGTAACAACATGTACTTTTA 
OvHV-1 1761 AGAAACTTGCCACGATGGCGCTGAGCACTACTTTCAAGGTGGAGAGTACATGTACAAATA 
BoHV-6  235 GGAAGCCTGTCATGATGGCGCCGAGCACTACTTTCAGGGAGGAGCGCACATGTACAAGTA 
 
OvHV-2 1842 CAAAAACTACAGGCACGTAAAGACTATACCCGTGAGCGCTGTCGCTACCCTAGACACCTT 
OvHV-1 1821 CAAAAACTACGAGCATGTACAGACTATTCCTCTCAGTGCAGTAGCTACTTTAGATACCTT 
BoHV-6  295 CAAAAACTACGAACACACTGAAACTATTCCTCTCAGCGCAGTGTCCACCTTAAACACCTT 
 
OvHV-2 1902 TATCGTGCTGAACCTGACCCTGGTGGAGAACATTGACTTTCAGGTCATAGAGCTGTACTC 
OvHV-1 1881 TATAGTTTTAAACCTAACATTGCTTGAAAATATTGATTTCCACGTCATTGAGCTCTACTC 
BoHV-6  355 TATAGTCCTCAACTTGACTTTGCTCGAAAACATTGACTTCCATGTAATAGAGCTTTACTC 
 
OvHV-2 1962 CAGGGAGGAGAAGCGCATGAGCACGGTTTTTGACATCGAGACCATGTTCAGGGAGTACAA 
OvHV-1 1941 TAGAGAAGAAAAGCGACTAAGCAGCGTGTTTGACATAGAAACTATGTTTAGAGAGTACAA 
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BoHV-6  415 TAGAGAAGAGAAGCGCTTAAGCAGCGTTTTTGACATAGAGACTATGTTTCGAGAGTACAA 
 
OvHV-2 2022 CTACTACACGCAGCGGGTGACCGGCCTGAGGAGGGACCTGTCTGACATCGCCACCAACAG 
OvHV-1 2001 CTACTACACCCACAGGATGTCAGGCATTAAAAAAGATTTAAATGACTTAGCTACTAACAG 
BoHV-6  475 CTACTACACCCACAGGATGTCTGGCATTAAAAAAGACCTTAATGATTTAGCCACAAACAG 
 
OvHV-2 2082 AAACCAGTTTGTGGATGCCTTTGGGACCCTGATGGATGATCTGGGGGTGGTGGGTAAGAC 
OvHV-1 2061 AAACCAGTTCATAGACGTCTTTGGCAACCTTATGGACGACTTAGGGGGTATTGGCAAAAC 
BoHV-6  535 AAACCAGTTTATAGATGTTTTTGGCAGCCTCATGGACGACTTGGGCGGCATAGGCAAAAC 
 
OvHV-2 2142 TGTGGTGAATGCGGTGAGCAGCCTAGCCACCCTATTCAGTTCCATAGTCACAGGCCTCAT 
OvHV-1 2121 TGTAATCAACGCGGTTAGCGGCATAGCTACAATGTTTGAAACTATAGTTACAGGTGTAGT 
BoHV-6  595 TGTCATTAACGCAGTCAGCGGCGTGGCCACTATGTTTGAATCCATAGTCACGGGAATTGT 
 
OvHV-2 2202 TAACTTTATTAAAAACCCCTTTGGTGGAATGCTTATATTTGGTCTGCTGGCTGCTGTCGT 
OvHV-1 2181 TAACTTTATAAAAAACCCTTTTGGTGGAATGCTTATACTAGGGCTTGTTGTTGTTGTTAT 
BoHV-6  655 CAACTTTATCAAAAACCCATTTGGCGGCATGTTGGTCTTCGGGCTTATCATTGTTGTAAT 
 
OvHV-2 2262 GATAGCCGTCATCCTCCTGCGGAGGAGAGCCGCCAGCTTTGCTGCAAACCCGGTGCAGAT 
OvHV-1 2241 AATTATAGTGTTTATGTTGAACAGAAAAGCTAAAAATTTTGAGCAAGACCCAGTTAAAGT 
BoHV-6  715 TATCATTGTGTTTATGCTAAACAGAAAAGCTAGAAACTTTGAACAAGACCCCGTAAAAGT 
 
OvHV-2 2322 GATATATCCCGATATCCAACAAATCACCAAACAGCGGCAGGAG---------------AT 
OvHV-1 2301 AATTTACCCAGACATTCAAAAAATTAAGCAGCAGCAGGAGGAAGAAGAAAACCCTGAAAA 
BoHV-6  775 GATTTACCCGGACATTCAAAAGATCAGAGAGCAGCAAGAG------AAAGACCCAGAAAA 
 
OvHV-2 2367 GAACGTTGAGCCCATCAGTAAGCACGAACTGGATAGGATCATGCTGGCCATGCATGACTA 
OvHV-1 2361 AAGAGTGCAGCCCATCAGCAAGGAAGAGCTAGACAAAATAATGCTAGCTATGCATGACTA 
BoHV-6  829 TAAGGTGCAGCCTATTAGCAAAGAAGAGCTTGACAAAATAATGCTAGCTATGCATGACTA 
 
OvHV-2 2427 TCACCAGACTAAGCAGGACAAGCCTGACGAAAAGGAGGGCCCCGAGAGTGGTGGTTCTGC 
OvHV-1 2421 CTACCACAAGAACTCAGATCAAGAAAAAAATGAGAA------------------------ 
BoHV-6  889 CTACCAAAAAAACTCAGAGCATGAAAAAAATGAGAA------------------------ 
 
OvHV-2 2487 TAACAAGGCAAACTGGCTGAACAAGGCCAAGAATGTGCTCCGAAGGAGAGCGGGTTATCA 
OvHV-1 2457 ------AAACAGCTTGTGGGACAAGGCTAAAAATGCAGTAAGAAAAAGGTCTGGCTATCG 
BoHV-6  925 ------TAATACACTGTGGGACAAAGCTAAAAATGTAGTAAGAAGAAAATCAGGCTATCG 
 
OvHV-2 2547 GCCACTTAAGAGATCTGACTCCACAGAAAGTGCTGCTG---------CCCTTTAA 
OvHV-1 2511 CCCTTTAAACAAGTCAGAGTCTATTGAAATGTTGAATAATGCCCAAGTTCTTTAA 
BoHV-6  979 CCCTTTGAATAAATCAGAGTCTATTGAGATGCTGAATAATGTC------------ 
 
 
Figure 3-5. Sequence alignment of the nucleotides that encode for 
glycoprotein B of OvHV-2 (AF385442.1), OvHV-1 (sequence obtained from 
Moredun Research Institute), and BoHV-6 (AF327832.1) shows the genetic 
similarity. This was conducted by using “Clustal Omega” programme and is 
displayed using the “BOXSHADE” programme. The identical nucleotides are 
depicted in black, whilst similar are depicted in grey. Dashes are relevant to 








3.4 Conclusion  
The quiescent infection with ruminant γ-HV other than OvHV-2 may 
cross-protect cattle from OvHV-2 infection and perhaps MCF. This may be 
explained by the genetic similarity of the identified viruses that presumably 
share antigenic similarity. This has been reported in three herpesvirus groups 
including: bubaline herpesvirus 1 (BuHV1) and BoHV5, between the strains 
of CvHV1 with ElkHV, as well as in CpHV1 and CvHV2 that are both closely 
related to BoHV-1 (das Neves et al., 2010). Moreover, limited antigenic 















4. Chapter four: Pathological description 
of the OvHV-2-Latency Associated 
Nuclear Antigen (oLANA) in sheep, cattle 





4.1 Abstract  
The pathogenesis of MCF is characterised by complicated 
consequences resulting in lymphoproliferation and vasculitis (Russell et al., 
2009). However, there is still a gap in explaining the key events regarding 
how the host immune system is deregulated during MCF; particularly, the 
role of lymphoid cytotoxicity. The LANA protein of OvHV-2 encoded by the 
open reading frame 73 is homologous to LANA proteins of other γ-
herpesviruses and so is likely a key factor in OvHV2- latency. In KSHV, 
LANA is expressed in both latent and lytic cycles and has been found to play 
a fundamental role in establishing and maintaining latency (Verma et al., 
2007).  
The aim of the present study was to gain more insight into the 
pathogenesis of MCF through the investigation of LANA expression, using a 
novel OvHV-2 LANA (oLANA)-specific antibody (see section 2.14). An anti-
oLANA rabbit polyclonal antibody was produced and tested by western 
immunoblotting on tissue lysates of cattle and sheep positive for OvHV-2 by 
PCR, alongside lysates of a rabbit LGL cell line that carries OvHV-2. The 
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expressed oLANA protein was recognised by the generated PAb. 
Additionally, full-length oLANA was expressed in vitro for further validation of 
the results. Finally, the antibody was used to demonstrate oLANA in situ in 
cells of OvHV-2-infected sheep, cattle without MCF, and cattle with MCF, 
using immunohistochemistry (IHC). 
 The results demonstrated abundant OvHV-2- LANA in epithelial and 
endothelial cells as well as leukocytes, regardless of the infected species or 
the presence of disease. This finding could open new areas for the diagnosis 
and pathogenesis of MCF- latency. 
4.2 Results  
4.2.1 Production of anti-oLANA rabbit polyclonal antibody 
4.2.1.1 Construction of the pGEX-3X-ORF73 portion 
A portion of the ORF73 gene that encodes for the OvHV-2 LANA 
protein (C terminal) was amplified by conventional PCR (Figure 4-1). This 
domain is conserved among most gamma-herpesviruses (see section 
1.1.4.1.2) and (Figure 1-4). The primers were designed manually to include 
EcoRI restriction sites at the 5’ end as following: forward 5’ 
ATGAATTCAATGGAAGCCCCTTCTAGCG 3’ and reverse 5’ 
GCGAATTCTGTTAACCGCTCCTGCCTG 3’. The total amplification reaction 
volume was 20 μL containing 90 ng of ORF73 template [C75 cosmid clone 
(Hart et al., 2007)], 0.2 μM of each primer, 150 μM dNTPs, 2 μl of 10X buffer 
for KOD XL DNA polymerase, 0.5 U of KOD XL DNA polymerase. The 
119 
 
cycling parameters were 30 cycles of 94 °C for 30 sec, 52 °C for 5 sec and 
74 °C for 60 sec, and final extension of 74 °C for 10 min. The amplified 
product (366 bp) was electrophoresed (see 2.1.2) and purified by using gel 
extraction kit (see 2.1.3), then digested with EcoR1 restriction endonuclease 
enzyme (see 2.1.6) and purified by QIAgene purification kit (see 2.1.3). The 
fragment was cloned into pGEX-3X vector that contains glutathione s-
transferase at the C-terminus by means of EcoRI site recombination of 
restriction enzyme as described in section (2.1.6). After linearizing the vector 
(5 μg) with EcoRI restriction endonuclease enzyme, it was treated with 1 U of 
calf intestinal alkaline phosphatase (CIAP) (Invitrogen) according to the 
recommending of the supplier. The fragments were purified and then ligated 
using 45 ng PCR DNA, 304 ng vector, 1 U of T4 ligase with 4 μl of 1X T4 
ligation buffer and H2O to a final volume of 20 μl. The reaction was then 
incubated overnight at 4 °C. The ligation mix was used to transform One-
shot® Top10 competent E. coli cells as described in section (2.1.4), cultured 
as in (2.1.5), and prepared as in (2.1.6). The positive clone from a single 
ampicillin resistant colony was confirmed by BamHI restriction digest for 
orientation (Figure 4-1). DNA from pGEX-3X-ORF73 with the fragment in the 
correct orientation was transformed into BL21 E. coli for protein expression 
by electroporation. This was achieved by adding 5 μl of pGEX-3X-ORF73 in 
an ice-cold electroporation cuvette and 45 μl of thawed BL21 competent 
cells. The mixture was then shocked electrically at 2.5kv, 25mA, and 800v, 
incubated for 2 min on ice then cultured and prepared as in sections (2.1.5 
and 2.1.6) respectively. In parallel, pGEX-3X vector without insert was 






Figure 4-1. Gel electrophoresis (1 % agarose) images show (A-1) amplicon 
from ORF73 of 348 bp. (B) BamHI restriction of pGEX-3X clones; 1: the 





4.2.1.2 Heterologous expression of oLANA-antigen    
A bacterial clone that carried pGEX-3X-oLANA (or control containing 
no insert) was tested for its ability to express the GST- oLANA fusion protein 
using β-d-1-thiogalactopyranoside (IPTG) induction. The GST-oLANA fusion 
protein was expressed as expected at a molecular weight of 39 kDa after 
IPTG induction (Figure 4-2). This band was not found in the non-induced 
preparation and the negative control. To demonstrate the solubility of the 
expressed protein, affinity chromatography was undertaken by harvesting the 
protein from bacteria induced with IPTG. The protein was released by 
sonication and then pelleted by centrifugation at 6,000 rpm for 5 min. The 
pellet was kept in ice for further analysis whilst supernatant was analysed 
after binding to GST beads. The supernatant and pellet were analysed by 12 
% SDS-PAGE. No soluble fusion protein was seen, and no fusion protein 
was found in the supernatant that was processed with the GST beads. 
However, the pellet of the cell lysate revealed that GST-oLANA is highly 
insoluble, probably due to intracellular aggregation as inclusion bodies 
(Figure 4-2). Thereafter, the expressed protein was purified by cell disruption 
and inclusion body preparation. To exclude that the centrifugation speed 
would affect the purity of these inclusion bodies, optimal separation of the 
insoluble protein from the soluble contaminants was carried out by a series of 
spinning forces, from lower to higher centrifugation force: (2,000, 6,000, 
8,000, 10,000, 12,000) g for 10 min. Subsequently, both supernatant and 
pellet were analysed by 12 % SDS-PAGE. As can be seen in (Figure 4-3), 
the protein aggregates were stable at all centrifugation conditions. Thus, a 
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lower centrifugation speed (2,000 xg) for 10 min was used as a standard 
speed for this purpose. GST-oLANA protein was then produced and purified 
on a large scale by inclusion body preparation. The concentration of the 
protein produced was estimated using standard concentrations of BSA 
protein electrophoresed alongside with GST-oLANA in SDS-PAGE gels 
which were then stained with the Coomassie blue stain. These dilutions were 
used as a standard calibrator. The concentration of GST-oLANA was 






Figure 4-2. Images of Coomassie stained SDS-PAGE (12 %) gels showing 
analysis of the expressed GST-oLANA fusion protein; M: is the molecular 
weight marker (Spectra™ Multicolour Broad Range Protein Ladder, 
Thermoscientific). (A) Expression of GST-oLANA; 1: pGEX-3X vector treated 
with IPTG in which GST is expressed at a molecular weight of 24 kDa; 2: 
pGEX-3X only without IPTG treatment; 3: pGEX-3X-ORF73 treated with 
IPTG in which the fusion protein is expressed at 39 kDa; 4: pGEX-3X-ORF73 
portion without treatment. (B) Solubility analysis of the expressed GST-
oLANA fusion protein; 5: supernatant of the expressed protein processed 





Figure 4-3. Image of SDS-PAGE gel (12 %) stained with Coomassie blue 
shows analysis of the expressed GST-fusion protein after centrifugation at 
the indicated forces; S: supernatant; P: pellet lysates; M: molecular weight 








Figure 4-4.  Estimation of GSToLANA concentration. Proteins were analysed 
by SDS-PAGE (12 %) followed by Coomassie blue staining. GST-oLANA 
was run alongside known concentrations of Bovine Serum Albumin (BSA) as 
a standard; M: molecular weight marker (Spectra™ Multicolour Broad Range 
Protein Ladder, Thermoscientific); oLANA concentration was estimated using 









4.2.1.3 Production of anti-oLANA rabbit polyclonal antibody 
The expressed inclusion proteins were used as antigen for the 
generation of a polyclonal antibody (Ab) after they had been tested for their 
immune reactivity against sera from OvHV-2-infected sheep and cattle that 
had been confirmed positive by PCR (Amin, 2015). Using western 
immunoblotting analysis, the GST-oLANA inclusion bodies were 
electrophoresed using SDS-PAGE then blotted onto a PVDF membrane and 
probed with the sera, followed by HRP labelled rabbit anti-cow or anti-sheep 
antibodies (Abcam, UK). The GST-oLANA protein was recognised by both 
sera and bands of the expected size (39 kDa) observed with breakdown 
products, while the respective bands were not obtained from the 
supernatants. This finding confirms that GST-oLANA is insoluble. The GST-
oLANA fusion protein was then used as antigen to immunise two rabbits at a 
commercial provider (Pacific Immunology Antibody Production Corporation, 
Ramona, USA) and the generated polyclonal antibody (PAb) purified by  
bacterial-acetone precipitation (2.3.10.1) and affinity chromatography 
(2.3.10.2) then tested for its immune reactivity against GST-oLANA by 






Figure 4-5. Western immunoblotting analysis image shows the immune 
recognition of GST-oLANA fusion protein. (A) Is GST-oLANA reacted with the 
rabbit oLANA polyclonal antibody (1:5000) and probed with goat anti-rabbit 
IgG (1:5000) (Vector Laboratories, USA). (B) Is GST-oLANA recognised by 
OvHV-2-sheep sera (1:2000) and probed with rabbit anti-sheep (1:2000) 
(Abcam, UK). (C) is GST-oLANA recognised by OvHV-2-cattle sera (1:2000) 
and probed with rabbit anti-cow (1:2000) (Abcam, UK); M: is molecular 
weight marker (Spectra™ Multicolour Broad Range Protein Ladder, 
Thermoscientific); 1, 2, 7 are GST-oLANA fusion protein; 3, 8 are GST-
oLANA previously isolated from SDS-gel; 4, 9 are supernatants;  5, 10 are 
protein lysate extracted from bacteria carrying pGEX-3X only treated with 
IPTG; 6, 11 are protein lysate extracted from bacteria carrying pGEX-3X 
without IPTG treatment.  
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4.2.1.4 Western immunoblotting analysis of oLANA  
The anti-oLANA PAb was then used to characterise oLANA in OvHV-
2-infected cells. These showed clear bands with the OvHV-2-positive 
samples, whereas no band was found in the negative animals. To confirm the 
specificity of the assay, a mouse tissue lysate was used as a negative 
control; this showed no reaction (Figure 4-6). Similar in sheep and cattle, 
usually 36 kDa was detected but one or two with two bands including a 13 
kDa.  Subsequently, OvHV-2 infected rabbit large granulocyte lymphocytes 
(cell line-BJ2586) were also analysed by western immunoblotting. These 
revealed a similar band at 36 kDa, with a second, smaller band at 17 kDa 
(Figure 4-7). Additionally, the LGL lysates were probed with goat anti-rabbit-





Figure 4-6. Western immunoblotting analysis image shows the immune 
reactivity of oLANA in tissue lysates with anti-oLANA polyclonal antibody; M: 
is molecular marker (Spectra™ Multicolour Broad Range Protein Ladder, 
Thermoscientific); 1: is mouse tissue lysate a control negative that shows no 
reaction; 2-5: are OvHV-2-positive cattle tissue lysates; 6 is OvHV2-negative 
sheep tissue lysate; 7-9: are OvHV-2-positive sheep tissue lysate; oLANA 
polyclonal antibody was used in (1:5000) and probed with goat anti-rabbit 




Figure 4-7. Western immunoblotting analysis image shows the immune 
reactivity of oLANA in rabbit large granulocyte lymphocytes infected cell line 
(BJ2586). (A) Is the membrane incubated with anti-oLANA polyclonal 
antibody at (1:5000) and probed with goat anti-rabbit IgG (1:5000) (Vector 
Laboratories, USA). (B) Is the similar protein lysate treated with only 
secondary antibody as another control strategy; M: is molecular marker 










4.2.2 Expression of oLANA in mammalian cells  
To definitively confirm the molecular weight of oLANA, it was 
expressed in human embryonic kidney (HEK293) cells by inserting the entire 
ORF73 into the pVR-1255 mammalian expression vector. The construct was 
used to transfect HEK293 cells using the calcium chloride method (described 
in 2.4.3). oLANA was detected using the PAb in western immunoblotting and 
immune fluorescent assays.   
4.2.2.1 Construction of the pVR-ORF73 
Initially, the entire ORF73 was amplified by conventional PCR (Figure 
4-8) by means of KOD XL DNA polymerase kit (Novagen, USA). The primers 
were designed manually to include NotI restriction site at the forward primer 
5’ ATGCGGCCGCCGCCGCCACCATGGTGCTTTTACGAAGTGG 3’ and 
BclI restriction site at the reverse 5’ 
TAGCTGATCATTAATGGTGCTTTTACGAAGTGG 3’., These were designed 
so the fragment could be inserted between the NotI and BamHI sites of 
pVR1255 in the correct orientation. BclI was chosen as there is a BamHI site 
in the coding sequence of ORF73. BclI-cut DNA has a compatible overhang 
with BamHI-cut DNA but the resulting join cannot be cut with either enzyme. 
The total amplification reaction volume was 20 μL containing 90 ng of ORF73 
template [(C75 cosmid clone (Hart et al., 2007)], 0.2 μM of each primer, 150 
μM dNTPs, 2 μl of 10X buffer, and 0.5 U of KOD XL DNA polymerase. The 
thermal cycles were 30 cycles of 94 °C for 30 sec, 55 °C for 5 sec and 74 °C 
for 60 sec, and final extension of 74 °C for 10 min. The purified amplicon was 
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cut using Bcl1 and Not1 (NEB, UK) in a total volume of 20 μl containing 2 μl 
NEB 3.1 buffer, 170 ng of purified amplicon, 1 μl of Bcl1. This was incubated 
for 1 h at 50 °C then Not1 (1 μl) was added with further incubation for 1 h at 
37 °C. Similar reaction conditions were used to linearize the mammalian 
expression vector (pVR1255) with BamHI and NotI, using 1 μg plasmid. The 
vector was treated then with 1 U of calf intestinal alkaline phosphatase 
(CIAP) (Invitrogen, UK) to prevent re-ligation of blunt ends, then purified by a 
PCR purification kit before being ligated in a total reaction volume (20 μl) 
containing 300 ng of the vector and 50 ng insert, 1U of T4 ligase, 4 μl of 1x 
T4 ligation buffer and then incubated at 4 °C overnight. The ligation mixes 
were transformed into Mach1 E. coli chemically competent cells (Invitrogen, 
UK) and cultured in LB medium supplemented with Kanamycin (30 μg/ ml) as 
in section (2.1.4). Single colonies were sub-cultured overnight in LB broth 
supplemented with Kanamycin meanwhile plasmids DNA were prepared as 
in section (2.1.6). DNA sequencing was carried out for final confirmation, 
using forward 5’ AATAGCTGACAGACTAACAGACTG 3’ and reverse 5’ 
GAGTGAGCTGATACCGCTC 3’ primers of the pVR-1255 vector. Presence 
of ORF73 insert was obtained by sequencing but with some gaps possibly 
due to the multiple tandem repeats within the central domain that lead to 





Figure 4-8. Amplicon of whole ORF73 were analysed by gel electrophoresis 
(1 % agarose). The amplication of ORF73 was conducted by using primers 
including the restriction enzyme site BamHI and NotI (lane 1), lane (2) 
including H2O as template for control negative.   
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4.2.2.2 Transfection and expression of oLANA in HEK293 
cells 
The expression of oLANA protein was carried out by transfection of 
HEK293 with calcium phosphate. The expressed protein was analysed by 
western immunoblotting with anti-oLANA PAb to confirm the apparent 
molecular weight of transfected oLANA. The result showed a specific band at 
(36 kDa), corresponding to size obtained from OvHV-2-positive tissue 
samples and the infected LGL cell (Figure 4-9). This result confirms the 
native expression of oLANA. Incubation of the membrane with the pre-
immune rabbit serum (negative control) yielded no reaction. Thus, it is 
confirmed that oLANA is expressed at a molecular weight lower than the 
expected one and that the produced anti-oLANA PAb is highly specific to 
oLANA.  
An immunofluorescence and IHC assays were also carried out to 
localise oLANA within HEK293 cells. The results showed detection of the 
expressed oLANA antigen which validates the specificity of the generated 





Figure 4-9. Western immunoblotting analysis (12 %) image shows the 
immune reactivity of the expressed oLANA by using anti-oLANA poyclonal 
antibody (1:2000) which recognised by goat anti-rabbit IgG labelled with HRB 
in dilution factor (1:5000) from (Vector Laboratories, USA). (A1) is the protein 
lysate of HEK193 cells transfected with only the pVR1255 vector as a control 
negative; (A2) is the protein lysate of HEK293 cells transfected with 
pVR1255-ORF73 that encoded for LANA expression. (B) is similar to (A) but 
incubated with the pre-immune serum of the immunised rabbit as another 









Figure 4-10. Localisation of oLANA within HEK293 cells by IF. (A) Cells 
grown to 90% confluence (10X). (B-H) Fluorescence images. (B) Cells 
transfected with pEGFP-N1. The green fluorescence signal confirms GFP 
expression and thereby demonstrates the transfection efficiency. (C-E) 
HEK293 cells transfected with the pVR1255-ORF73 vector for oLANA 
expression, incubated with rabbit anti-oLANA PAb and stained with anti-
rabbit-FITC488 and DAPI as nuclear counterstain. Cells exhibit 
predominantly nuclear punctate signals and occasional cytoplasmic protein 
expression (arrows). (C) staining for oLANA. (D) DAPI staining of nuclei. (E) 
merged. (F-H) HEK293 cells transfected with pVR1255 vector, incubated with 
rabbit anti-oLANA PAb and stained with anti-rabbit-FITC488 and DAPI as 









Figure 4-11. Immunohistochemistry staining images for oLANA antigen 
expression within HEK293 cells. (A) HEK293 cells transfected with the 
pVR1255-ORF73 vector for oLANA expression (arrows), incubated with 
rabbit anti-oLANA PAb (1:500), stained with (EnVision + System HRP Rabbit; 
K4003; Dako) and visualization with DAB (K3468; Dako). (B) HEK293 cells 
transfected with the pVR1255-ORF73 vector then incubated with pre-immune 
serum and processed as in (B).    
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4.2.3 In situ demonstration of oLANA expression in tissues 
by immunohistochemistry (IHC) 
4.2.3.1 Identification of oLANA expression in tissues of 
OvHV-2 infected sheep  
Sheep are the natural hosts for OvHV-2. Therefore, the following 
tissues were examined: lung, tongue, nasopharynx, mediastinal lymph node, 
spleen, thymus, and placenta that had previously been tested for OvHV-2 by 
PCR, in situ hybridisation (ISH), and IHC in our laboratory (Amin, 2015). 
Tissue specimens originated from healthy, slaughtered sheep of variable age 
and were subjected to IHC for the detection of oLANA, using the new PAb. 
Expression of oLANA was represented by a nuclear and/or cytoplasmic 
reaction in a wide range of cell types. 
Lung and mediastinal lymph node: These were examined in a 7-
months-old, healthy, slaughtered sheep (13L-2594A) and had been tested 
OvHV-2 positive before by PCR, ISH and IHC (Amin, 2015) (Figure 4-12 to  
4-14).  
In the lung, expression of oLANA was evident as nuclear and/or 
cytoplasmic reaction in alveolar lining cells (morphology consistent with type 
II pneumocytes and/or alveolar macrophages) as well as lymphocytes and 
macrophages/ dendritic cells in the bronchus-associated lymphoid tissue 
(BALT) (Figure 4-12). Detection of oLANA in lung tissue of another healthy 
sheep (13L-4220E) revealed similar reaction with involvement of the 
bronchial epithelial cells, bronchiolar glands and BALT (Figure 4-13).  
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Expression of oLANA was also detected in the mediastinal lymph 
node of the same animal (13L-2594A) as strong nuclear and/or cytoplasmic 
reaction. Predominantly, the reaction was noticed inside and outside 
lymphatic follicles (B zone). Morphologically, macrophages and lymphocytes 
were identified as positive cells (Figure 4-14).   
 
Figure 4-12. Immunohistochemistry staining images for oLANA antigen 
expression in the lung of a 7-month-old healthy sheep previously tested 
positive for OvHV-2 by PCR, ISH and IHC (Amin, 2015) (13L-2594A). (A) 
oLANA is expressed in a wide range of cell types (arrows), scale bar= 20 µm. 
(B) Higher magnification of A, showing nuclear oLANA expression in an 
interstitial cell (arrow), scale bar= 10 µm. (C)  oLANA is seen as nuclear 
and/or cytoplasmic reaction in cells with the morphology of a type II 
pneumocyte (long arrow) and an alveolar macrophage (short arrow), scale 
bar= 10 µm. (D) oLANA expression in lymphocytes (and 
macrophages/dendritic cells) in the BALT (arrow), scale bar= 10 µm. 




Figure 4-13. Immunohistochemistry staining images for oLANA antigen 
expression in the lung of a 10-month- old healthy sheep previously tested 
positive for OvHV-2 by PCR, ISH and IHC (Amin, 2015) (13L-4220D). (A) 
Depicts a cytoplasmic oLANA expression in the bronchial respiratory 
epithelial cells (arrows), scale bar= 20 µm. (B) Higher magnification of A, 
showing cytoplasmic oLANA expression in the bronchial glands (arrows), 
scale bar= 20 µm. (C) oLANA is seen as nuclear and/or cytoplasmic reaction 
in BALT lymphocytes, scale bar= 20 µm. Visualized with DAB and 





Figure 4-14. Immunohistochemistry staining images for oLANA antigen 
expression in the mediastinal lymph node a 7-month-old, healthy sheep 
previously tested positive for OvHV-2 by PCR, ISH and IHC (Amin, 2015) 
(13L-2594A). (A) Shows oLANA expression in likely to be lymphocytes inside 
and outside follicles (arrows), scale bar = 50 µm. (B) Higher magnification of 
A, showing nuclear oLANA expression in probably lymphocytes (arrows), 
scale bar = 20 µm. (C) Higher magnification of B, showing oLANA expression 
in likely lymphocytes (arrows) and macrophages/dendritic cells (both nuclear 
and cytoplasmic reaction) in the a follicle, scale bar = 10 µm. Visualized with 




Tongue and spleen: These were tested in another healthy, 
slaughtered 10-month-old sheep (13L-4220E) previously tested OvHV-2-
positive by PCR (Amin, 2015) (Figure 4-15).  
In the tongue, oLANA was expressed in the covering epithelium, with 
weak cytoplasmic expression in the stratum basale and moderate expression 
in the stratum spinosum. The protein was also expressed in the cytoplasm of 
the lingual striated muscle cells and in scattered ductal and acinar epithelial 
cells in the salivary gland. In addition, sub-epithelial lymphocytes, venous 
endothelial cells and arterial smooth muscle cells were also found to be 
positive. Occasional stromal fibroblasts also exhibited a weak cytoplasmic 
reaction (Figure 4-15).  
In spleen of the same animal (13L-4220E), oLANA was expressed in 
the nucleus of a percentage of lymphocytes within follicles and red pulp. A 
cytoplasmic reaction of oLANA was exhibited in occasional cells within 
follicles. Morphologically, follicular dendritic cells and macrophages seem to 






Figure 4-15. Immunohistochemistry staining images for oLANA antigen 
expression in the tongue of a 10-month-old, healthy sheep previously tested 
positive for OvHV-2 by PCR, ISH and IHC (Amin, 2015)  (13L-4220E). (A) 
Strong cytoplasmic oLANA expression in the lingual epithelium, with weak 
expression in the stratum basale and moderate expression in the stratum 
spinosum (arrows), scale bar = 20 µm. (B) depicts oLANA antigen in striated 
muscle cells (arrows), scale bar= 50µm. (C) shows oLANA expression in 
salivary gland as a cytoplasmic reaction within glandular epithelial cells (long 
arrows); occasional smooth muscle cells within vascular tunica media of local 
large artery exhibited nuclear and/or cytoplasmic reaction (short arrow), scale 
bar= 20µm. (D) shows oLANA antigen with strong cytoplasmic expression in 
percentage of sub-epithelial lymphocytes (black arrows) and venous 
endothelium (arrows), scale bar = 20µm. (E) demonstrates cytoplasmic 
oLANA expression in numerous fibroblasts (long arrows); vascular 
endothelial cells and arterial smooth muscle cells within tunica are seen 
infected (short arrow), scale bar= 20 µm. Visualized with DAB and 
counterstained with hematoxylin.  
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Lung, spleen, thymus, and placenta: These were tested in a sheep 
foetus (stillborn) and from an OvHV-2-infected sheep (S13-1453), both tested 
positive for OvHV-2 by PCR and ISH (Amin, 2015) (Figure 4-16).  
In the lung, oLANA was found to be expressed by respiratory epithelial 
cells and scattered mononuclear cells with macrophage morphology in the 
parenchyma as well as in arterial smooth muscle cells (Figure 4-16). In the 
spleen, oLANA expression observed in scattered mononuclear cells in red 
pulp, and in the thymus, it was found in disseminated macrophages in cortex 
and medulla and in dendritic cells in the medulla (Figure 4-16, D-F).  
In the placenta, oLANA was expressed mainly by smooth muscle cells 
in the media of arteries. Stromal fibroblasts also exhibited weak staining for 










Figure 4.16. Immunohistochemistry staining images for oLANA antigen 
expression in the lung (A-C), spleen (D), thymus (E-F) of a stillborn sheep 
foetus suffered from atelectasis (crown rump length= 17.5 cm) previously 
tested positive for OvHV-2 by PCR, ISH and IHC (Amin, 2015) (S13-1453). 
(A) Expression of oLANA is seen in the respiratory epithelium (arrow) and in 
association with alveoli, scale bar = 20 µm. (B) Higher magnification of A, 
showing oLANA expression in scattered mononuclear cells in the interstitium 
(arrows), scale bar= 10 µm. (C) Higher magnification of B shows cytoplasmic 
reaction of oLANA in respiratory epithelial cells and vascular smooth muscle 
cells (arrows), scale bar= 10 µm. (D) In the spleen, occasional mononuclear 
cells in the red pulp are found to express oLANA (arrow), scale bar= 10 µm. 
(E) In the thymus, a moderate number of disseminated cells in cortex and 
medulla are found to express oLANA, scale bar= 20 µm. (F) Higher 
magnification of E, showing oLANA expression in likely medullary 
macrophages and dendritic cells (arrows), scale bar= 10 µm. Visualized with 




Figure 4.17. Immunohistochemistry staining images for oLANA antigen 
expression in the placenta of a stillborn sheep foetus suffered from 
atelectasis (crown rump length=17.5 cm) previously tested positive for OvHV-
2 by PCR, ISH and IHC (Amin, 2015) (S13-1453). (A) Shows arterial smooth 
muscle cells revealed oLANA expression (arrows), a proportion of stromal 
fibroblasts also exhibits a weak reaction, scale bar= 20 µm. (B) Expression of 
oLANA is restricted to vessel walls, where is mainly seen in the cytoplasm of 
smooth muscle cells of the arterial tunica media (arrow), scale bar= 20 µm. 
Visualized with DAB and counterstained with haematoxylin.   
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4.2.3.2 Identification of oLANA expression in OvHV2-infected 
cattle without MCF  
In a previous study, a number of cattle was identified as OvHV-2-
infected, but did not suffer from MCF; infection had been confirmed by PCR 
and RNA-ISH (Amin, 2015). Tissues from selected animals were also tested 
for oLANA expression. As in sheep, these cattle may be latently infected for 
OvHV-2. Similarly, oLANA expression was represented by a nuclear and/or 
cytoplasmic reaction in a wide range of cell types (Figure 4-18 to 4-25). 
Nasopharynx, tongue, lung, mediastinal lymph node, spleen, and 
thymus: These from a 7-week-old OvHV-2-positive calf (S13-1419) that had 
died with a severe ulcerative abomasitis (not related to MCF) were examined 
for oLANA expression (Figure 4-18). In the nasopharynx, oLANA was 
abundantly expressed with variable intensity in the cytoplasm of squamous 
epithelial cells. Endothelial cells also exhibited weak oLANA expression. In 
the turbinate or nasal skin, a similar reaction pattern was found; there was 
weak to moderate cytoplasmic staining of the squamous epithelium and the 
epithelium of hair follicles. Moreover, oLANA was expressed in glandular 
epithelial cells of the sebaceous glands. The sub-epithelial connective tissue 
with embedded artery and striated muscle bundles revealed weak 
cytoplasmic oLANA expression in striated muscle cells and arterial smooth 
muscle cells as well as endothelial cells with involvement of occasional 
intravascular leukocytes. Importantly, expression of oLANA was 
demonstrated in the salivary gland, both within the acinar and ductal 
epithelium (Figure 4-18).   
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Figure 4-18. Immunohistochemistry staining images for oLANA antigen 
expression in the nasopharynx of a 7 week- old, cattle without MCF suffered 
from severe ulcerative abomasitis, previously tested positive for OvHV-2 by 
PCR, ISH and IHC (Amin, 2015) (S13-1419). (A) The squamous epithelium 
exhibits variably intense cytoplasmic expression of oLANA (arrows), scale 
bar= 50 µm.  (B) Higher magnification of A, showing weak oLANA expression 
in the basal layers and moderate staining in the upper layers of the 
squamous epithelium, scale bar= 20 µm. (C) Shows again the oLANA 
expression in the squamous epithelium of the epidermis, and in the follicular 
epithelium (black arrows), scale bar= 50 µm. (D) Higher magnification of C, 
confirming oLANA expression in epithelial cells in the hair follicles (arrow) 
and in epithelial cells in the sebaceous glands, scale bar= 20 µm. (E) Sub-
epithelial connective tissue with embedded artery and striated muscle 
bundles, showing weak cytoplasmic oLANA expression in striated muscle 
cells (long arrows) and arterial smooth muscle cells as well as endothelial 
cells, and in occasional positive intravascular leukocytes (short arrows), scale 
bar= 20µm. (F)  Expression of oLANA is also seen in the salivary gland, both 
within the acinar and ductal epithelium (arrows), scale bar= 20 µm. 




In the tongue, oLANA expression was mainly seen in squamous 
epithelial cells while the reaction was weakly expressed in the presumably 
endothelium of sub-epithelial vessels or smooth muscle cells (Figure 4-19). 
 
 
Figure 4-19. Immunohistochemistry staining images for oLANA antigen 
expression in the tongue of a 7 week- old, calf without MCF suffered from 
severe ulcerative abomasitis, previously tested positive for OvHV-2 by PCR, 
ISH and IHC (Amin, 2015) (S13-1419).  (A) shows variable intensity of 
cytoplasmic oLANA reaction squamous epithelium (arrows), scale bar = 
50µm. (B) Higher magnification of A demonstrate weak to moderate 
expression of oLANA in the stratum spinosum and weakly reaction in the 
stratum basale; the endothelium of sub-epithelial vessels are also seen 
positive with weak expression (arrow), scale bar= 20 µm. Visualized with 
DAB and counterstained with haematoxylin.   
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The lung showed weak cytoplasmic oLANA expression in bronchiolar 
epithelial cells and arterial smooth muscle cells. Morphologically, scattered 
positive cells consistent with (alveolar) macrophages were found in alveoli 
and interstitium (Figure 4-20).  
 
Figure 4-20. Immunohistochemistry staining images for oLANA antigen 
expression in the lung of a 7 week- old, cattle without MCF suffered from 
severe ulcerative abomasitis, previously tested positive for OvHV-2 by PCR, 
ISH and IHC (Amin, 2015) (S13-1419). (A) There is weak cytoplasmic oLANA 
expression in bronchialar epithelial cells (long arrows) and arterial smooth 
muscle cells (short arrows), scale bar= 20 µm. (B) Scattered cells in the 
pulmonary interstitium are also positive (arrows), scale bar= 10 µm. (C) 
There are also scattered cells with the morphology of likely alveolar 
macrophages that express oLANA (arrows), scale bar = 10 µm. Visualized 
with DAB and counterstained with haematoxylin.   
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In the mediastinal lymph node, numerous cells consistent with 
macrophages and follicular dendritic cells were observed in which 
cytoplasmic oLANA was detected. However, nuclear expression of oLANA 
was noticed in proportion of lymphocytes within the lymphatic follicle (Figure 
4-21, A). In the spleen, oLANA was exhibited, with variable intensity of 
cytoplasmic reaction, in macrophages that localised in red and white pulp, 
whereas the reaction was nuclear reaction in occasional lymphocytes (Figure 
4-21, B). In the thymus, oLANA was represented in likely numerous tingible 














Figure 4-21. Immunohistochemistry staining images for oLANA antigen 
expression in the mediastinal lymph node (A), spleen (B), and thymus (C) of 
a 7 week- old, cattle without MCF suffered from severe ulcerative abomasitis, 
previously tested positive for OvHV-2 by PCR, ISH and IHC (Amin, 2015) 
(S13-1419). (A) In the mediastinal lymph node, cytoplasmic oLANA 
expression is seen in cells likely consistent with macrophages and follicular 
dendritic cells (long arrows) while a nuclear reaction is noticed in probably 
lymphocytes within the follicle (short arrows), scale bar = 20 µm. (B) In the 
spleen, macrophages (long arrows) in red and white pulp exhibit a 
cytoplasmic reaction, whereas occasional lymphocytes seem to exhibit a 
nuclear reaction (short arrows), scale bar = 10 µm. (C) In the thymus, 
cytoplasmic oLANA expression is seen in cells consistent with tingible body 
macrophages (arrows), scale bar = 20 µm. Visualized with DAB and 
counterstained with haematoxylin.   
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Lung, mediastinal lymph node, spleen, thymus, and placenta 
were examined from a 7-month-old foetus (S13-1483-8) of a cow that had 
been tested positive for OHV2 by PCR and ISH (Amin, 2015) (Figure 4-22 to 
4-25). 
The lung exhibited oLANA expression in bronchiolar respiratory 
epithelium. Expression of oLANA was detected in a proportion of positive 
cells consistent with macrophages (Figure 4-22).  
 
Figure 4-22. Immunohistochemistry staining images for oLANA antigen 
expression in lung of a 7 week- old, cattle without MCF suffered from foetal 
atelectasis, previously tested positive for OvHV-2 by PCR, ISH and IHC 
(Amin, 2015) (S13-1483-8). (A) Shows cytoplasmic oLANA expression in 
bronchiolar respiratory epithelium (arrows), scale bar = 20 µm. (B) Higher 
magnification of A depicts individual positive cells likely consistent with 
macrophages, scale bar = 10 µm. Visualized with DAB and counterstained 
with haematoxylin.   
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In the mediastinal lymph node analysis, expression of oLANA was 
demonstrated in probably numerous lymphocytes, macrophages and/or 
follicular dendritic cells within a lymphatic follicle. The adipose tissue 
surrounding the lymph node revealed cytoplasmic oLANA expression in 
arterial smooth muscle cells and endothelial cells (Figure 4-23).  
 
Figure 4-23. Immunohistochemistry staining images for oLANA antigen 
expression in mediastinal lymph node of a 7 week- old, cattle without MCF, 
suffered from foetal atelectasis, previously tested positive for OvHV-2 by 
PCR, ISH and IHC (Amin, 2015) (S13-1483-8). (A) Expression of oLANA is 
seen in numerous lymphocytes within a lymphatic follicle (arrows), scale bar= 
20 µm. (D) Higher magnification of C, demonstrating oLANA expression in 
probably numerous lymphocytes, macrophages and/or follicular dendritic 
cells (arrows) in a follicle, scale bar = 10 µm. (E) The adipose tissue 
surrounding the lymph node shows cytoplasmic oLANA expression in arterial 
smooth muscle cells and endothelial cells (arrows), scale bar= 20 µm. 
Visualized with DAB and counterstained with haematoxylin.   
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In the spleen, a proportion of positive cells in red pulp exhibited 
oLANA expression while there were occasional macrophages and/or 
dendritic cells exhibit oLANA expression within thymus tissue (Figure 4-24).  
 
Figure 4-24. Immunohistochemistry staining images for oLANA antigen 
expression in spleen (A-B) and thymus (C), of a 8 month- old cattle without 
MCF, previously tested positive for OvHV-2 by PCR, ISH and IHC (Amin, 
2015) (S13-1483-8). (A) In the spleen, a proportion of cells in red pulp shows 
oLANA expression (arrows), scale bar = 20 µm. (B) Higher magnification of 
A, showing oLANA expression in likely numerous lymphocytes (arrows), 
scale bar = 10 µm. (C) In the thymus, probably individual macrophages 
and/or dendritic cells exhibit oLANA expression (arrows), scale bar = 10 µm. 
Visualized with DAB and counterstained with haematoxylin.   
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In the placenta, oLANA was demonstrated as a strong reaction within 
vascular smooth muscle cells and epithelium. Moreover, stromal fibroblasts 
and trophoblasts were found infected (Figure 4-25).  
 
 
Figure 4-25. Immunohistochemistry staining images for oLANA antigen 
expression in placenta of an 8 month- old cattle without MCF, previously 
tested positive for OvHV-2 positive by PCR, ISH and IHC (Amin, 2015) (S13-
1483-8). (A) The placenta exhibits strong staining for oLANA in vascular 
smooth muscle cells and epithelium, scale bar = 50 µm. (B) Higher 
magnification of A, showing oLANA expression in smooth muscle cells of an 
arterial wall (short arrows), stromal fibroblasts and trophoblasts (long arrows), 
scale bar = 20 µm. (C) Higher magnification of B, depicting the same positive 
cells. In the artery, there is also weak staining in endothelial cells (short 
arrow), scale bar= 10 µm. Visualized with DAB and counterstained with 
haematoxylin.   
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4.2.3.3 Immune-histological description of oLANA in buffalo 
with MCF  
The rete mirabile, showing the pathognomonic vasculitis, and the 
retropharyngeal lymph node was examined from a 2-year-old water buffalo 
with confirmed MCF (S11-1232-8) (Figure 4-26).  
 In the rete mirabile, oLANA was expressed by infiltrating cells within 
arterial walls and in the adventitia, in the smooth muscle cells of the tunica 
media and, less intensely, in endothelial cells as well as a few intravascular 
leukocytes (Figure 4-26). 
The retropharyngeal lymph node from another buffalo with confirmed 
MCF (S12-0124) was tested as a representative of the lymphatic tissues. 
Here, oLANA expression was mainly evident in macrophages/ follicular 
dendritic cells. Moreover, there were scattered positive lymphocytes outside 
lymphatic follicles. Similar to the arteries in the rete mirabile, arteries in the 
adipose tissue surrounding the retropharyngeal lymph node also exhibited a 
strong oLANA expression in the smooth muscle layer and exhibited the 
protein also in endothelial cells (Figure 4-27). The pre-immune serum was 
used to replace the primary antibody and served in the IHC staining protocol, 









Figure 4.26. Immunohistochemistry staining images for oLANA antigen 
expression in the rete mirabile artery of a 2 year- old water buffalo with MCF 
(S11-1232-8). (A) Rete mirabile with marked mononuclear arteritis and 
periarteritis typical for MCF. (A) Expression of oLANA is widespread, within 
arterial smooth muscle cells and infiltrating leukocyte, scale bar = 20 µm. (B) 
Higher magnification of A, highlighting the expression of oLANA in adventitial 
and medial infiltrating cells and medial smooth muscle cells (arrows), scale 
bar = 20 µm. (C) Artery with oLANA expression also in endothelial cells 
(arrows), scale bar = 20 µm. (D) Arterial lumen, showing oLANA expression 
by a proportion of likely intravascular leukocytes (arrows), scale bar = 10 µm. 







Figure 4.27. Immunohistochemistry staining images for oLANA antigen 
expression in retropharyngeal lymph node of an adult buffalo with MCF (S12-
0124). (A) Expression of oLANA within a lymphatic follicle, scale bar= 20 µm. 
(B) oLANA expression is mainly evident in macrophages/ follicular dendritic 
cells (short arrows) as well as scattered lymphocytes (long arrows) outside 
follicles, scale bar= 20 µm. (C) Expression of oLANA in likely several 
macrophages (short arrows) and lymphocytes (long arrows) within medullary 
sinuses, scale bar= 10 µm. (D) In the adipose tissue surrounding the lymph 
node, there is strong oLANA expression in arterial smooth muscle cells and 
endothelial cells (arrows), scale bar = 20 µm. (E) Section incubated with the 
rabbit pre-immune serum instead of the primary antibody, as a negative 
control, showing no reaction, scale bar= 20 µm. Visualized with DAB and 
counterstained with haematoxylin.  
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4.3 Discussion  
4.3.1 Expression of oLANA in vitro  
In this study, a specific anti-oLANA PAb has been produced to assess 
the expression of oLANA in infected animals. A portion of ORF73 within the 
C terminal domain was expressed in bacteria and used to immunise rabbits 
for antisera generation. The C terminal domain of OFR73 is highly conserved 
(reviewed in section 1.1.4.1.2) and therefore chosen to produce the anti-
oLANA PAb. The GST-oLANA protein was expressed at a molecular weight 
of 39 kDa after IPTG induction. This fusion protein was found highly insoluble 
when expressed by this method (Samuelson, 2011) (Figure 4-2).    
In western immunoblotting analysis, The GST-oLANA was recognised 
by sera from OvHV-2- infected sheep and cattle. Therefore, it was used as 
an antigen for rabbit anti-oLANA PAb generation. Also, the anti-oLANA PAb 
was found to recognise the expressed GST-oLANA. When tissue lysates of 
OvHV-2-infected sheep and cattle were examined, oLANA appeared as a 
band of approximately 36 kDa and an occasional additional smaller band of 
approximately 13 kDa. This molecular weight was lower than expected from 
the 495 amino acids (Figure 4-28). Possibly, this resulted from the presence 
of numerous acidic tandem repeats that are localised within the central 
domain of oLANA (Verma et al., 2007). These repeats could lead to faster 
migration of oLANA in SDS-PAGE gels during electrophoresis as a result of 
the negative charge. Presence of this central tandem repeats was also 
demonstrated in KSHV to evade host immunity by preventing the MHC class 
I peptide presentation (Kwun et al., 2011).  
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The C terminal domain of oLANA protein (GenBank accession no.  
AAL05844) contains a putative internal ATG start codon (Figure 4-28). This 
internal domain was expressed in this study to produce the anti-oLANA. This 
possibly represents the detected 13 kDa band in the expressed oLANA within 
positive tissue lysate, LGL cells, and in vitro expressed oLANA. The 
comparison of oLANA protein from different OvHV-2 strains (personal 
communication) showed a high degree of polymorphism (Figure 4-29). 
Presumably, this genetic variability has an implication on the expression level 
of oLANA or its function that may affect the pathogenicity of OvHV-2 (Taus et 
al., 2007).  
 
 
1   MVLLRSGTSTDGDEDGRGRRPGPKKRPVTEGKGEGPGGEEEGPGGEGEGPGGEVEGPGGE 









Figure 4-28. The putative amino acid sequence of oLANA, GenBank 
accession no.  AAL05844, shows numerous tandem repeats. The glutamic 




Ov802       1 MVLLRSGTNTDGDDDGRGRRPGPKKKTVTEGKGEGPGGEGEGPGGEGEGPGGEGEGPGGE 
Ov1056      1 MVLLRSGTNTDGDDDGRGRRPGPKKKTVTEGKGEGPGGEGEGPGGEGEGPGGEGEGPGGE 
Ov809       1 MVLLRSGTNTDGDDDGRGRRPGPKKKTVTEGKGEGPGGEGEGPGGEGEGPGGEGEGPGGE 
OvBJ1035    1 MVLLRSGTSTDGDEDGRGRRPGPKKRPVTEGKGEGPGGEEEGPG-------GEGEGPGGE 
CSU         1 MVLLRSGTNTDGDEDGRGRRPGPKKKPVTEGKGEGPGGEEEGPG-------GEE------ 
 
Ov802      61 VEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEEEGPGGEGEGPGGEGPGGEGEGPGG 
Ov1056     61 VEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEEEGPGGEGEGPGGEGPGGEGEGPGG 
Ov809      61 VEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEEEGPGGEGEGPGGEGPGGEGEGPGG 
OvBJ1035   54 VEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEVEGPGGEGEGP-----GEEVEGPGG 
CSU        48 -EGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGEGPEGEGEGP-----GGEGEGPGG 
 
Ov802     121 EVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGKGPGGEVEG 
Ov1056    121 EVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGKGPGGEVEG 
Ov809     121 EVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGKGPGGEVEG 
OvBJ1035  109 EGEGPEGEGEGPGGEGEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGEGPEG---- 
CSU       102 EVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGEGPGGEVEGPGGEGEGPEG---- 
 
Ov802     181 PGGEEEGPGGEGEGPGGEGEGPGGEGEGPGGEVEGPGGEGEGPGGEGEGPGGEGEGPGGE 
Ov1056    181 PGGEEEGPGGEGEGPGGEGEGPGGEGEGPGGEVEGPGGEGEGPGGEG-------EGPGGE 
Ov809     181 PGGEEEGPGGEGEGPGGEGEGPGGEGEGPGGEVEGPGGEGEGPGGEG-------EGPGGE 
OvBJ1035  165 -----EG-----EGPGGEGEGPGGEEEGPGGEEEGPGGEEEGPGGEG-------EGPGGE 
CSU       158 -----EGPGGEVEGPGGEGEGPGGEVEGPGGEVEGPGGEGEGPGGEG-------EGPGGE 
 
Ov802     241 GEGPVGEGEGPGGEGEGPVGEGEGPVGEGEGPGGEGEGPGGEGE-PGGEGEGPGGEEGPG 
Ov1056    234 GE----------------------------GPGGEGEGPGGEGEGPGGEGEGPGGEEGPG 
Ov809     234 GEGPVGEGEGPGGEGEGPVGEGEGPVGEGEGPGGEGEGPGGEGEGPGGEGEGPGGEEGPG 
OvBJ1035  208 GEGPVGEGEGPGGEGEGPGGEEEGPGGEEEGPGGEGEGPE-------------------- 
CSU       206 GEGPGGEGEGPGGEGEGPGGEGEGPVGEGEGPGGEGEGPG-------------------- 
 
Ov802     300 GEGEGPGGEGEGPGGGGPGGEEEEGEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE---- 
Ov1056    266 GEGEGPGGEGEGPGGGGPGGEEEEGEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE--- 
Ov809     294 GEGEGPGGEGEGPGGGGPGGEEEEGEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE 
OvBJ1035  248 GEGEGPGGEGEGPGGGGPGGEEEEEEEEGEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE- 
CSU       246 GEGEGPGGEGEGPGGGGPGGEEEEGEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE 
 
Ov802     356 ---EEEEEEEEEEEEEEEEEEEEEEGEEGEGEEGGEGPGGEGEGPGGEGE-PGGEGEEGE 
Ov1056    323 ----EEEEEEEEEEEEEEEEEEEEEGEEGEGEEGGEGPGGEGEGPGGEGEGPGGEGEEGE 
Ov809     354 E----EEEEEEEEEE---EEEEEEEGEEGEGEEGGEGPGGEGEGPGGEGEGPGGEGEEGE 
OvBJ1035  307 -----E--EEEEEEEEEEEEEEEEEGEGEGPGGEGEGPGGEGEGPGGEGEGPGGEGEE-- 
CSU       306 EEEEEEEEEEEEEEEEEGEEGEREEGEGEG--PGGEGPGGEGEGPGGEGEGPGGEGEEGE 
 
Ov802     412 GEEPEDPMEGPSSGPPVRGRRKRPPKHQPETDRAKRKKLAPIWDP-LKEATYSLHLNCTS 
Ov1056    379 GEEPEDPMEGPSSGPPVRGRRKRPPKHQPETDRAKRKKLAPIWDPTLKEATYSLHLNCTS 
Ov809     407 GEEPEDPMEGPSSGPPVRGRRKRPPKHQPETDRAKRKKLAPIWDPTLKEATYSLHLNCTS 
OvBJ1035  358 GEEPEDPMEGPSSGPPVRGRRKRPPKHQPETDRAKRKKLAPIWNPTLKEATYSLHLNCTS 
CSU       364 GEEPEDPMEGPSSGPPVRGSRKRPLKHKPETDRGKRKKLASIWDPTKMEATYALHLNCPK 
 
Ov802     471 KDPVVRVSRSVRALNPNAPHSNIFFTGGMYTFVIYGNDKEAVESLFQFLLQDAMNNPQAG 
Ov1056    439 KDPVVRVSRSVRALNPNAPHSNIFFTGGMYTFVIYGNDKEAVESLFQFLLQDAMNNPQAG 
Ov809     467 KDPVVRVSRSVRALNPNAPHSNIFFTGGMYTFVIYGNDKEAVESLFQFLLQDAMNNPQAG 
OvBJ1035  418 KDPVVRVSRSVRALNPNAPHSNIFFTGGMYTFVIYGNDKEAVESLFQFLLQDAMNNPQAG 
CSU       424 KDPLVRVFRSVRELNPGAPHSNIFYTCGRYTAVIYGNDQTAVQSMFQFLLQDSMNNPQAE 
 
Ov802     531 AVNISTGPLTPSLPFNQQ 
Ov1056    499 AVNISTGPLTPSLPFNQQ 
Ov809     527 AVNISTGPLTPSLPFNQQ 
OvBJ1035  478 AVNISTGPLTPSLPFNQQ 
CSU       484 PVNISTGPLTPALPFGQP 
 
Figure 4-29. Sequence alignment of oLANA amino acids in different OvHV-2 
strains shows the genetic polymorphism. This was conducted by using 
“Clustal Omega” programme and is displayed using the “BOXSHADE” 
programme. The identical residues are depicted in black, whilst similar 
residues are depicted in grey. Dashes are relevant to gaps in the sequence.    
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4.3.2 Expression of oLANA in vivo  
OvHV-2 is a cell-associated virus and has not yet been propagated in 
vitro. Therefore, the latent phase of OvHV-2 infection  is poorly understood 
(Russell et al., 2009). Identifying oLANA as a possible marker of latently 
infected cells is important to understand MCF. The aim of this study was to 
define the key events in MCF latency and pathology. Expression of oLANA 
was demonstrated in OvHV-2-infected sheep, OvHV-2-infected cattle without 
MCF and ruminants with confirmed MCF using the novel anti-oLANA PAb 
that was produced in this study. 
The results showed abundant oLANA expression in epithelial cells in 
the oral cavity and respiratory tract, in arterial smooth muscle cells, vascular 
endothelial cells and leukocytes (i.e. lymphocytes as well as macrophages 
and dendritic cells), regardless of infected species and disease. Also, 
although oLANA is mainly known as a nuclear protein (Verma et al., 2007), 
here we showed that a cytoplasmic isoform exists in most positive cell types.  
This finding was also observed in the transfected cells used to demonstrate 
where oLANA is expressed in an infected cell. The detection of latently 
infected cells by demonstration of OvHV-2-LANA is informative, as they likely 
have a role in viral persistence in the host. Latent infection of epithelial cells 
could also enable OvHV-2 to spread into the environment, whereas latently 
infected endothelial cells could be a source for viral systemic spread. 
In infected cattle without MCF, oLANA was detected in B cells and 
macrophages/dendritic cells in lymphatic tissues. In cattle with MCF, oLANA 
was found in infiltrating leukocytes in the arteritis and periarteritis in the rete 
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mirabile. A recent study confirmed that the infiltrating cells are mainly T cells 
and macrophages (Saura et al., 2018). Both were found to express oLANA, 
and so did the endothelial cells. Arteritis in the rete mirabile is considered as 
pathognomonic for MCF (O ’Toole & Li, 2014).   
Nuclear expression of LANA is a characteristic feature and well-known 
in other γ-herpesviruses such as KSHV where it tethers viral DNA to the host 
cell chromosome (Rahayu et al., 2016). However, oLANA was also observed 
in the cytoplasm (Figure 4-12). To date, a high level of cytoplasmic LANA 
expression was noticed during the lytic phase of KSHV reactivation (Zhang et 
al., 2016). This cytoplasmic form blocks cGAS-STING–dependent induction 
of interferon in host cells and causes suppression of the innate immune 
response while inducing viral reactivation.  
Recently, an additional pathway of cytoplasmic-LANA in KSHV has 
been found that inhibits innate immunity via suppression of IF-β and NF-kB 
as well as inducing KSHV-reactivation. This occurs by interfering with cGAS-
STING and production of IF-β and Rad50-Mre11-CARD9 (MRN complex) 
(Mariggiò et al., 2017). The cytoplasmic-LANA in KSHV is encoded by the C 
terminal domain of ORF73 which is highly conserved as in OvHV-2 (reviewed 
in section 1.1.4.1.2). This mechanism could be similar in the pathogenesis of 
OvHV-2; it implies that OvHV-2 potentially modulates host cells to survive via 
oLANA expression.   
4.3.3 Detection of oLANA in the natural host (sheep) 
Sheep are well-adapted to OvHV-2 and do not develop any clinical 
signs after infection (O ’Toole & Li, 2014). Tissues from infected sheep that 
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had previously been found positive by PCR and ISH (Amin, 2015) were 
examined for oLANA expression. The results showed abundant expression in 
epithelial and endothelial cells, likely macrophages/ dendritic cells, and 
lymphocytes. Importantly, viral gene expression in vascular endothelial cells 
might play a pivotal role in viral systemic spread in sheep. Also, in this 
species, oLANA expression was found to be both nuclear and cytoplasmic 
(Figure 4-12).  
In the respiratory tissue, oLANA was demonstrated as nuclear and/or 
cytoplasmic reaction in alveolar lining cells (morphological consistent with 
type II pneumocytes and/or alveolar macrophages). Moreover, likely 
lymphocytes and macrophages/ dendritic cells in the BALT (Figure 4-12) as 
well as bronchial epithelial cells and bronchiolar glands were found positive 
for oLANA expression (Figure 4-13). These immune cells could be modulated 
by OvHV-2 because the virus encodes for a similar to ovine IL-10 to 
deactivate the function of macrophages (Jayawardane et al., 2008).    
Detection of infected alveolar epithelial cells (predominantly with 
cytoplasmic reaction of oLANA) could support the notion that cytoplasmic 
oLANA could be evidence of OvHV-2 reactivation as in KSHV by modulating 
this cell type via the cGAS-STING and MRN complex pathway (Mariggiò et 
al., 2017). OvHV-2 reactivation within respiratory epithelial cells may reflect 
the way by which OvHV-2 spreads. This corroborates the previous finding by 
(Li et al., 2004) of OvHV-2 replication in the sheep nasal cavity as well as in 
lung tissue of experimentally infected sheep (Taus et al., 2005). The airway 
epithelium supports lytic OvHV-2 infection (Taus et al., 2010). However, the 
results of the present study also indicate oLANA as a possible marker for 
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latency within the respiratory epithelium; viral reactivation does also occur in 
infected sheep. Thereby, the airways could mediate viral spread at any time 
post infection. Indeed, nasal secretions were found as the principle mode of 
transmission between the reservoir hosts and susceptible host (Li et al., 
2001b).       
Detection of oLANA in the lower airway (lung) presented as a 
predominant cytoplasmic expression within the bronchiolar epithelial layer 
while the reaction was nuclear in numerous cells within the alveolar wall and 
interstitium. This suggests a dynamic role possibly led by shifting the oLANA 
expression within these tissues in comparison with the upper airway enabling 
OvHV-2 maintenance and/or its release because of the efficient viral-host 
interaction. The modulation of host cells by OvHV-2- was suggested by (Riaz 
et al., 2014) as transcriptional modulation controlled by encoding of viral 
microRNAs. These microRNAs contain predicted interaction codons with 
ORF73 (latency associated), ORF50 (reactivation), and ORF20 (cell cycle 
inhibition) to control OvHV-2 biology (lytic and latent cycles). This also agrees 
with our observations, but further work is needed to understand the relation 
between cytoplasmic or nuclear expression of oLANA and encoding of these 
microRNAs.      
Finding oLANA expression within respiratory tissue is logical because 
OvHV-2 initially replicates in the lung (Li et al., 2008b). Here, transcription of 
a lytic gene (ORF25) was initially detected in the sheep respiratory tract, 
particularly within turbinate tissue, whilst there was no expression in other 
tissues (Cunha et al., 2008). OvHV-2 gene expression including: replication 
(ORF25), reactivation (ORF50), and latency (ORF73), correlated with the 
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severity of MCF-lesions in experimentally infected rabbits (Cunha et al., 
2013). Therefore, finding evidence of oLANA expression in these tissues may 
support the notion of the efficient adaptation of OvHV-2 to sheep.  
In the tongue, oLANA was also expressed by the covering epithelium, 
with cytoplasmic expression in the stratum basale and stratum spinosum. 
Moreover, similar reaction was demonstrated in scattered ductal and acinar 
epithelial cells in the salivary gland. Importantly, the sub-epithelial 
lymphocytes, venous endothelial cells and arterial smooth muscle cells were 
also found to be positive (Figure 4-15). This could also contribute to OvHV-2 
spread via salivary secretions. Another route possibly occurs via direct 
contact in newly-born lambs when they come into nose-to-nose contact with 
their mothers and are infected by released virus from salivary glands. 
The obtained data from testing the lymphatic tissues such as lymph 
node, spleen, and thymus described oLANA as strong nuclear and/or 
cytoplasmic reaction. Morphologically, macrophages, follicular dendritic cells, 
and lymphocytes appeared positive (Figures 4-14). Establishment of OvHV-2 
infection in these cell types had previously been confirmed by (Amin, 2015). 
Eventually, macrophages have phagocytic activity and thus OvHV-2 is likely 
to be engulfed by this cell type and consequently dysregulated. Generally, 
targeting of these cell types by OvHV-2 was confirmed by (Meier-Trummer et 
al., 2010). Macrophages and splenic dendritic cells are also latently-infected 
by MHV-68 in mice (Flano et al., 2000). Detection of oLANA in numerous 
antigen presenting cells (macrophages and/ or dendritic cells) is important 
because these cells are responsible for potential sentinel immunity (Hussell 
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et al., 2014). However, harbouring latent infection could cause dysregulation 
of these cell types as in KSHV (Thakker et al., 2015). 
We observed oLANA expression in the placenta, predominantly by 
smooth muscle cells in the media of arteries as well as stromal fibroblasts 
(Figure 4-17). A previous study in our laboratory by (Amin, 2015) showed 
OvHV-2 transcription in the placenta, mainly in placental epithelium and 
stromal fibroblasts. This was detected by PCR (with low copy number) but 
not RNA-ISH or IHC.  
Together with these data, the expression of oLANA suggests that 
OvHV-2 may be vertically transmitted and may even lead to persistent 
infection and immune tolerance in the offspring in sheep. Vertical 
transmission of OvHV-2 has been reported in cattle (Headley et al., 2015); 
similarly, it has been demonstrated for AlHV1 in wildebeest (Li et al., 2011b), 
and CvHV2 in reindeer (das Neves et al., 2009a, c). However, no 
confirmation has yet been achieved for OvHV-2 in sheep (O’Toole & Li, 
2014) and CpHV-2 in goat (Li et al., 2005a). 
4.3.4 Detection of oLANA in cattle without MCF  
Cattle are sensitive to MCF. However, it has been shown that a high 
proportion of cattle without MCF carry OvHV-2 (Amin, 2015). These 
confirmed positive animals were examined here to detect oLANA expression 
in cattle without MCF.  
Interestingly, OvHV-2 positive cattle without MCF exhibited oLANA 
expression, again both cytoplasmic and nuclear, in various cell types, i.e.  
epithelial cells, endothelial cells, and vascular smooth muscle cells.  
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In the nasopharynx, oLANA was predominantly expressed with 
cytoplasmic reaction in squamous epithelial cells as well as glandular 
epithelial cells of the sebaceous glands. A similar reaction was also revealed 
within the sub-epithelial connective tissue as the striated muscle cells and 
arterial smooth muscle cells as well as endothelial cells with involvement of 
occasional intravascular leukocytes were found positive. Importantly, 
expression of oLANA was also demonstrated in the salivary gland, both 
within the acinar and ductal epithelium (Figure 4-18). These sites are 
considered as portals for entrance of OvHV-2 (O ’Toole & Li, 2014). MCF 
was induced by nasal aerosol infection with OvHV-2  in numerous 
susceptible hosts such as cattle (Taus et al., 2006) and pigs (Li et al., 2012), 
and it was shown to occur in bison even when sheep were some distance 
away (Li et al., 2008a). 
The lung exhibited oLANA expression in bronchiolar and alveolar 
respiratory epithelium. Morphologically, scattered positive cells consistent 
with (alveolar) macrophages were found in alveoli and interstitium (Figure 4-
20). The lung tropism of OvHV-2 infection in bison has been determined by 
(Cunha et al., 2012) as OvHV-2 transcribed three viral genes (ORF25, 
ORF50, and ORF73) that encodes for lytic and latent cycles. These encoded 
proteins were detected in lung at a high level after 9-12 days post infection 
(DPI). However, expression of the host immune response- related genes was 
found at a low level in both lung and LN. This was combined with increase 
the systemic viral load after (16-21) DPI.   
It can be suggested that oLANA expression is highly regulated to 
enable OvHV-2 to disseminate systematically inside host organs via 
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migration of the infected macrophages that carry OvHV-2 into local lymph 
nodes. 
In the tongue, abundant cytoplasmic oLANA was detected in the 
epithelium and salivary gland. Additionally, the endothelial cells and smooth 
muscle cells of sub-epithelial vessels were also found positive (Figure 4-15). 
As stated above, this cytoplasmic form of oLANA could occur during viral 
reactivation for the systemic spread.  
Examination of the mediastinal lymph nodes from infected cattle 
revealed oLANA staining in numerous macrophages and presumably 
follicular dendritic cells with a cytoplasmic reaction that localised in the 
lymphatic follicles. Occasional lymphocytes also exhibited nuclear oLANA 
staining. In other lymphatic tissues, i.e. spleen and thymus, oLANA staining 
was seen in the same cell types including macrophages, follicular dendritic 
cells, and tingible body macrophages (in the thymus). This fits with previous 
reports by (O ’Toole & Li, 2014; Russell et al., 2009) including infection of 
lymphoid cells by OvHV-2. Our finding suggests a possible modulation of 
these cell types by OvHV-2 to evade host immunity.    
The role of oLANA in lymphoid tissues seems to be fundamental. For 
instance, in cattle with MCF, transcriptional analysis was conducted for host 
tissue (lymphoid tissues) and OvHV-2 during the early and late infection 
periods. This showed a low level of IL-2 transcripts that correlated with 
elevated ORF73 (oLANA transcript) (Meier-Trummer et al., 2009b). Thus, 
oLANA may negatively regulate lymphocyte activation by IL-2. This could 
further support the previous concept of circumventing host defence in these 
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cell types during the latent cycle (Kwun et al., 2011; Sorel et al., 2017; 
Thakker et al., 2015; Zaldumbide et al., 2007).  
It was interesting to see oLANA expression in the vasculature 
(endothelial cells and smooth muscle cells) and the epithelium in the placenta 
(Figure 4-25). This provides further evidence of vertical transmission of 
OvHV-2 as possible in naturally infected cattle and supports previous 
findings, where viral lytic gene expression was seen in the placenta  of cattle 
(Headley et al., 2015). Finding oLANA expression within the placental 
epithelium implies the possibility of OvHV-2 dissemination.      
In this study, finding oLANA expression within vascular endothelial 
cells is important to find possible explanations for the way in which OvHV-2 
circulated and trigger MCF. Possibly, infected endothelial cells induce 
vascular inflammatory responses. This consequently causes infiltration and 
recruitment of leukocytes from the blood within tunica adventitia via vasa 
vasorum as well as the remodelling processes (cytokines and chemokines 
stimulation) at the later stages (Davis et al., 2003). Other herpesviruses such 
as KSHV, HSV,HCMV, and EBV have a tropism to the endothelial cell and 
likely remodel this cell type (Brunson et al., 2016; Hong et al., 2004; Sinzger, 
2008). This mechanism likely induces the fatal vasculitis of MCF.       
4.3.5 Detection of oLANA in cattle with MCF 
The expression of oLANA in MCF lesions was examined, choosing the 
rete mirabile showing the typical arteritis and periarteritis.  
A severe vasculitis with fibrinoid necrosis and thickening of the 
vascular intima was seen with substantial mononuclear infiltration within the 
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tunica adventitia and tunica intima. The pathological changes have been 
reported in numerous susceptible hosts such as rabbit, bison, cattle, and 
water buffalo (O ’Toole & Li, 2014).  
In the present study, oLANA was detected as a strong nuclear and/or 
cytoplasmic reaction within infiltrating cells. It was also found in endothelial 
cells and medial smooth muscle cells. Positive intravascular leukocytes were 
also observed, which confirm systemic viral infection during disease. 
Critically, there are oLANA positive endothelial cells in the rete mirabile 
associated with vasculitis. The rete mirabile is critical for the supply of blood 
to the brains of ungulates so this novel observation may explain sudden 
death in MCF.  
In previous experimental studies inducing MCF in bison, cells 
infiltrating the vascular walls were found to be predominantly CD8+/perforin+ 
γδ T cells (Nelson et al., 2010). It may be these cells express oLANA. 
Whether this is the case is currently being investigated in a separate study 
undertaken at the Institute of Veterinary Pathology, Vetsuisse Faculty, 
University of Zurich. Preliminary results have shown oLANA expression 
within infiltrating cells in acute and chronic vascular lesions. Besides an 
infiltration by macrophages and fewer T cells within the tunica adventitia, 
activation of the endothelial cells was seen in affected arteries. Cells 
expressing oLANA were endothelial cells, smooth muscle cells as well as 
infiltrating macrophages and lymphocytes as confirmed by specific immuno-
histology. Both types of leukocytes were observed to be proliferating. These 
findings suggest that MCF-vasculitis is macrophage-driven rather than 
lymphoproliferative and that the vasculitis is virus driven (Saura et al., 2018). 
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Macrophages play a fundamental role in host innate immunity. However, 
detection of oLANA as a marker for latency within morphologically detected 
macrophages could explain the dysregulation of this cell type as a sentinel 
cells within vasculatures. This possibly led to evade the innate immunity and 
enables OvHV-2 to survive. Also, macrophages considered a long-living cell 
in the tissue. Therefore, dysregulation of this cell type could be fundamental 
in MCF pathogenesis. Dysregulation of the macrophages by KSHV has been 
observed by (Bhaskaran et al., 2017) and deactivation of the dendritic cells 
as evasive mechanism was demonstrated in AIHV-1 (Myster et al., 2015).  
In experimentally induced MCF in bison, it was shown that an OvHV-2 
protein (ORF25) was expressed in infiltrating fibroblasts. However, this was 
not found in the vascular endothelium, smooth muscle cells or leukocytes 
(Nelson et al., 2013).  
The localisation of OvHV-2 within the vasculature may have an impact 
on triggering MCF. It appears to drive infiltration of lymphocytes and 
vasculitis. 
4.3.6 Comparison of oLANA expression in sheep, cattle 
without MCF, and cattle with MCF 
The expression of oLANA was demonstrated in non-lymphatic and 
lymphatic tissues. Generally, infected cell types were similar regardless of 




In both infected sheep and cattle, oLANA expression was seen in the 
respiratory tract and oral mucosal epithelium. This could indicate OvHV-2 
reactivation/ replication resulting in virus spread. However, the protein was 
also expressed in the vasculature (endothelium) and in lymphatic tissues. 
Predominantly, macrophages and lymphocytes (B subtype) were found 
positive for oLANA. This suggests a successful strategy by which OvHV-2 
can be spread systemically. The vascular endothelium has a permeability 
function, and this could help for the systemic spread of OvHV-2 via infected 
cells. This could also cause initial inflammation to evoke the immune 
response via the expressed cytokines and chemokines by endothelial cells of 
the adventitial vasa vasorum and ultimately leading to fatal vasculitis. These 
key events were similarly found in KSHV (Ballon et al., 2015).     
In cattle with MCF, oLANA was expressed more intensely, and 
particularly in infiltrating leukocytes in the typical vascular lesions and in cells 
in the vessel walls and the endothelium. Critically, there are infected 
endothelial cells in the rete mirabile associated with vasculitis. In this 
instance, presence of oLANA in the vasculature likely plays a pivotal role in 
developing MCF as both types of leukocytes (macrophages and 
lymphocytes) can carry OvHV-2. However, both cell types play different 
fundamental roles in MCF pathogenesis. The inflammatory infiltrates within 
the vascular lesions have been demonstrated as abundant T-lymphocytes 
(CD8+ that have a natural killer phenotype), B- cells (CD79a+), and 
macrophages (O’Toole & Li, 2014). Interestingly, only small numbers of these 
lymphocytes have been shown carry OvHV-2 (Russell et al., 2009; Schock & 
Reid, 1996).   
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4.3.7 Conclusion   
The survival of OvHV-2 in the adapted and susceptible hosts most 
likely occurs by numerous strategies. It may remain entirely latent following 
primary infection as an episome inside cells. Demonstration of oLANA 
antigen within the epithelial cells might be supportive for the environmental 
spread. Detection of positive vascular endothelial cells and smooth muscle 
cells possibly help OvHV-2 to disseminate systemically and ultimately MCF- 
triggering. Presenting of oLANA expression within likely macrophages and 
follicular dendritic cells could imply the dysregulation of antigen presentation 
and recognition of OvHV-2. This could allow OvHV-2 to survive efficiently 
inside the hosts. Finding oLANA expression within the placenta may be an 
evidence for the vertical transmission during the sub-clinical infection. These 














5. Chapter five: Generation of 
Recombinant Modified Vaccinia Ankara 






5.1 Abstract  
Recently, highly MCF-susceptible hosts including bison, water buffalo 
and deer have been farmed in the UK. However, they are facing serious 
issues of developing clinical MCF. Therefore, an effective vaccine is urgently 
needed to prevent the disease. Nevertheless, since OvHV-2 has not yet been 
propagated in vitro, neither live-attenuated nor killed vaccines have been 
effectively produced (Russell et al., 2009). Therefore, attempts towards 
developing a preventive vaccine mostly depend on producing virus 
glycoprotein subunits. For instance, effective candidates including gB and 
gH/gL heterodimer complex were found to prevent MCF in rabbits (Cunha et 
al., 2015). The aim of this study was to express the OvHV-2- glycoproteins 
including gB, gH, gL, and Ov7 in modified vaccinia Ankara virus (MVA) to 
develop a suitable subunit vaccine. The gB and gH/gL glycoproteins have an 
important role OvHV-2 biology by inducing membrane-fusion while Ov7 is 
homologous to A7 gene in AIHV-1 and analogous to BZLF2 protein of EBV 
that interact with gp42 and involved in membrane fusion and B cell infection 
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(Hart et al., 2007; Hutt-Fletcher, 2007). We hypothesised that Ov7 possibly 
interact with gH/gL complex as a heterotrimer. The results demonstrate 
modification and production of rMVA virus that carried OvHV-2-glycoproteins. 
As expected, gH and gL interacted as a heterodimer and were glycosylated 
in Baby Hamster Kidney fibroblast (BHK) cells via post translational 
modification. However, the Ov7 glycoprotein did not interact as a heterotrimer 
with this complex. Production of these rMVA-glycoproteins could help in 
prevention of MCF. 
5.2 Results  
5.2.1 Recombination of rMVA-glycoproteins  
The MVAs plasmids were designed to carry ORF8, ORF22, ORF47, 
and Ov7 that encode gB, gH, gL, and Ov7 glycoproteins respectively. All the 
targeted genes were expressed under the MVA H5 promoter and fused with 
tags: FLAG (for gB and gH), HA (for gL), V5 (for Ov7) genes to enable a 
suitable selection, purification, characterisation and large-scale production of 
each rMVA-glycoprotein (see 2.15.1 to 2.15.7).  
The recombination was performed using BHK cells via MVA 
inoculation and transfection with MVA-plasmid insertion vectors. The 
resulting recombinants appeared as green fluorophore signals under 
fluorescent microscopy (Figures 5-1, 5-2, 5-3, and 5-4). These recombinants 
were harvested and purified by three cycles of plaque isolation and 
inoculation of the single separated fluorescent plaque. Cytopathic effect 
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Figure 5-1. MVA-gB recombination. (A and B) are BHK cells infected with 0.5 
x 105  PFU of vaccinia virus  followed by transfection with MVA-gB plasmid 
(0.62 µg/ well) then incubated for 24h post inoculation. (C and D) are the 
same cells after 48 h post inoculation. All imaged under fluorescent 




Figure 5-2. MVA-gH recombination. (A and B) are BHK cells infected with 
0.5 x 105 PFU of vaccinia virus followed by transfection with MVA-gH plasmid 
(0.62 µg/ well) then incubated for 24h post inoculation. (C and D) are the 
same cells after 48 h post inoculation. All imaged under fluorescent 




Figure 5-3. MVA-gL recombination. (A and B) are BHK cells infected with 0.5 
x 10
5
 PFU of vaccinia virus followed by transfection with MVA-gL plasmid 
(0.62 µg/ well) then incubated for 24h post inoculation. (C and D) are the 
same cells after 48 h post inoculation. All imaged under fluorescent 




Figure 5-4. MVA-Ov7 recombination. (A and B) are BHK cells infected with 
0.5 x 10
5
 PFU of vaccinia virus followed by transfection with MVA-Ov7 
plasmid (0.62 µg/ well) then incubated for 24h post inoculation. (C and D) are 
the same cells after 48 h post inoculation. All imaged under fluorescent 




Figure 5-5. Final plaque purification of the rMVA-glycoproteins in BHK cells 
after 3-rounds of inoculation and purification. (A) Is rMVA-gB. (B) Is rMVA-gH. 
(C) Is rMVA-gL. (D) Is rMVA-Ov7. All are imaged under fluorescent 
microscopy at 60X magnification.   
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5.2.2 Expression of rMVA-glycoproteins  
BHK cells were inoculated with each rMVA-glycoproteins at (0.5 x 105 
pfu/ ml)/ well as described in section (2.15.3). Thereafter, the expressed 
proteins were identified and characterised via detection of the expressed 
TAG-fusion proteins by western immunoblotting and live immunofluorescent 
assays.   
5.2.2.1 Detection of rMVA-glycoproteins by western 
immunoblotting  
 The whole cell-lysate of BHK cells infected with each rMVA-
glycoprotein were analysed by immune blotting using MAbs for the 
corresponding glycoproteins as described in section (2.6.5.1).  
The whole cell-extract that had been infected with rMVA-gB was 
analysed with anti-FLAG-HRP. The gB protein was detected as three bands 
with molecular weight approximately 130, 92, and 55 kDa. In the rMVA-gH 
infected cells, the expressed protein was detected as two bands of 95 and 57 
kDa. However, the rMVA-gL expressed protein was detected by anti-HA-HRP 
with a molecular weight of 33 kDa. Detection of the expressed recombinant 
protein in rMVA-Ov7 infected BHK cells was demonstrated by using anti-V5-
HRP and showed a molecular weight of approximately 30 kDa (Figure 5-6).  
In other viruses, gH and gL form a heterodimer. It was also possible 
that, like EBV, Ov7 could associate with gH/gL in a heterotrimeric complex. 
The combined expression of gH/gL and gH/gL/Ov7 (mixed inoculation of 
these rMVA-glycoproteins) was initially characterised by western 
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immunoblotting. The predicted product of Ov7 gene is likely a glycoprotein 
and this is analogous to BZLF2 protein of EBV that interacts with gb42 to 
induce fusion membrane and B cell infection (Hart et al., 2007).  
After mixing rMVA-gH/gL, gH expression was detected as a single 
band at 94 kDa. A gH protein band of a similar molecular weight was seen in 
rMVA-(gH/gL/Ov7) mixed infection by using anti-FLAG to detect gH while 
detection of the gL in rMVA-(gH/gL) and rMVA-(gH/gL/Ov7) revealed a 
similar size of 28 kDa. This was slightly lower than the previously detected 
band. The expressed Ov7 protein from this mixture revealed detection of 
band at 32 kDa. However, two bands at higher molecular weight (134, 89) 
kDa were additionally demonstrated from this mixture by using anti-V5 






Figure 5-6. Western immunoblotting analysis (12 %) images show the 
immune reactivity of the expressed rMVA-glycoproteins. (A) Is detection of 
the expressed gB, subjected to anti-FLAG primary antibody and probed with 
anti-mouse secondary antibody labelled with HRP. (B) Is detection of the 
expressed gH, subjected to anti-FLAG primary antibody and probed with anti-
mouse secondary antibody labelled with HRP. (C) Is detection of the 
expressed Ov7, subjected to anti-V5 primary antibody and probed with anti-
mouse secondary antibody labelled with HRP. (D) Is detection of gL, 
subjected to anti-HA primary antibody and probed with anti-rat secondary 




Figure 5-7. Western immunoblotting analysis (12 %) image shows the 
immune reactivity of the expressed rMVA-glycoproteins (mixed infection) in 
BHK cells. (A) Is detection of the expressed gH after co-infection with either 
rMVA-(gH/gL) or rMVA-(gH/gL/Ov7) and subjected to primary anti-flag and 
secondary anti-mouse labelled with HRP. (B) Is detection of the expressed 
Ov7 after co-infection with rMVA-(gH/gL/Ov7) and subjected to primary anti-
V5 and secondary anti-mouse. (C) Is detection of the expressed gL after co-
infection with either rMVA-(gH/gL) or rMVA-(gH/gL/Ov7) and subjected to 
anti-HA primary antibody and anti-rat secondary antibody labelled with HRP.  
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5.2.2.2 Detection of rMVA-glycoproteins by live 
immunofluorescent assay   
Live IF assay was performed for cellular localisation of the expressed 
rMVA-glycoproteins. This was achieved by detecting the corresponding 
rMVA-glycoprotein fusion-TAGs using FITC-conjugated specific monoclonal 
antibodies (see 2.15.2). The BHK cells for IF staining were seeded onto 
coverslips and infected with rMVA-gB, rMVA-gH/gL, and rMVA-gH/gL/Ov7 (5 
PFU/ cell) (see 2.15.1). Initially, the cells were washed twice with PBS 
containing 0.2 % BSA, 0.2 % Sodium Azide (Sigma, UK). Then, the 
appropriate amount of the relevant primary antibodies supplied from (Sigma, 
UK); anti-Flag (1:1000) and anti-V5 (1:2000) were both of mouse-origin while 
the anti-HA (1:2000) of rat origin were diluted in PBSAA (PBS, 0.2 % BSA, 
0.2 % sodium azide) and then added. The slides were incubated for 10 min 
at RT. Cells were then washed very carefully 3 x with PBSAA before adding 
the relevant secondary (anti-rat, 1:500, anti-mouse, 1:200) labelled with FITC 
(Sigma, UK). Finally, cells were washed gently 3 x with PBSAA, fixed with 4 
% paraformaldehyde in PBS and treated with anti-fade DAPI stain and 
examined as in section (2.8). 
The staining with anti-FLAG-FITC conjugate showed that rMVA-gB in 
BHK infected cells was detected predominantly at the cell surface. This cell-
surface localisation was also found in the mixed inoculation with rMVA-
(gH/gL) when gL protein detected by anti-HA-FITC conjugate (Figure 5-8). 
The gH protein in rMVA-(gH/gL) and rMVA-(gH/gL/Ov7) detected 
using anti-FLAG-FITC conjugate appeared also on the cell surface (Figure 5-
188 
 
9). In the latter mixed inoculation, gL and Ov7 were also detected by anti-HA-
FITC and anti-V5-FITC conjugates respectively (Figure 5-10).  







Figure 5-8. Live Indirect immunofluorescent analysis of the produced rMVA-
glycoproteins (MVA-gB, MVA-gH/gL) in BHK cells inoculated with 5 PFU/ cell 
and incubated for 24 h. (A) Is rMVA-gB subjected to anti-FLAG primary 
antibody then anti-mouse secondary antibody labelled with FITC stain. (B) Is 
similar cells stained with DAPI. (C) Is merged image of A and B. (D) Is the 
negative control in which non-infected cells were stained. (E) Is detection of 
gL in the mix of rMVA-(gH/gL) stained with anti-HA primary antibody then 
anti-rat secondary antibody labelled with FITC. (F) Is similar cells stained with 
DAPI. (G) Is merged of E and F. (H) Is the negative control in which non-




Figure 5-9. Live Indirect immunofluorescent analysis of the produced rMVA-
glycoproteins (MVA-gH/gL, MVA-gH/gL/Ov7) in BHK cells inoculated with 5 
PFU/ cell and incubated for 24 h. (A) Is detection of gH in the mix of rMVA-
(gH/gL) stained with anti-FLAG primary antibody then anti-mouse secondary 
antibody labelled with FITC stain. (B) Is similar cells stained with DAPI. (C) Is 
merged image of A and B. (D) Is the negative control in which non-infected 
cells were stained. (E) Is detection of gH in the mix of rMVA-(gH/gL/Ov7) 
stained with anti-FLAG primary antibody then anti-mouse secondary antibody 
labelled with FITC. (F) Is similar cells stained with DAPI. (G) Is merged image 





Figure 5-10. Live Indirect immunofluorescent analysis of the produced rMVA-
glycoproteins (MVA-gH/gL/Ov7) in BHK cells inoculated with 5 PFU/ cell and 
incubated for 24 h. (A) Is detection of gL in the mix of rMVA-(gH/gL/Ov7) 
stained with anti-HA primary antibody then anti-rat secondary antibody 
labelled with FITC stain. (B) Is similar cells stained with DAPI. (C) Is merged 
image of A and B. (D) Is the negative control in which non-infected cells were 
stained. (E) Is detection of Ov7 in the mix of rMVA-(gH/gL/Ov7) stained with 
anti-V5 primary antibody then anti-mouse secondary antibody labelled with 
FITC. (F) Is similar cells stained with DAPI. (G) Is merged image of E and F. 







5.2.3 Characterisation of the expressed rMVA-glycoproteins  
The combined expression of gH/gL and gH/gL/Ov7 were characterised 
for interaction in complexes by immunoprecipitation and de-glycosylation. 
Whole cell lysates were extracted following combined viral inoculation and 
then subjected to immunoprecipitation by Mab M2 affinity gel that pulls down 
FLAG tagged proteins. The immuno-precipitated gH-FLAG protein from these 
complexes was probed with anti-FLAG-HRP conjugate (PA1-984B) to detect 
gH protein. In rMVA-(gH/gL), a 94 kDa band corresponding to this protein 
was detected, indicating that gH/gL was expressed as heterodimer. The 
detected gL protein (originated from gH/gL/Ov7) revealed exactly the same 
size at 28 kDa (Figure 5-11C). However, the expressed Ov7-V5 was not 
detected following the pulldown lysate using anti-V5-HRP conjugate. This 
indicates that Ov7 was not part of a heterotrimer in gH/gL complex. 
The gH protein from the gH/gL and gH/gL/Ov7 complexes was 
cleaved by using N-glycosidase F enzyme (PNGase F). The cleaved gH 
protein was detected at 74 kDa, indicating that this protein is processed post-






Figure 5-11. Western immunoblotting analysis (12 %) image shows 
immunoprecipitation of the expressed rMVA-glycoproteins with M2 beads 
carrying an anti-flag mAb followed by PNGase treatment for the de-
glycosylation. (A-B) are detection of the de-glycosylated gH using anti-FLAG-
HRP conjugate after co-infection of BHK cell line with rMVA-(gH/gL) and 
rMVA-(gH/gL/Ov7) respectively. (C) Is detection of gL using anti-HA-HRP 
conjugate after co-infection of BHK cell line with rMVA-(gH/gL/Ov7). 
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5.3 Discussion  
5.3.1 Construction of MVA recombinants 
In this study, MVA virus was modified to encode OvHV-2 glycoproteins 
(gB, gH, gL, and Ov7) as the question was how MCF genes can be exploited 
for vaccine purpose. The obtained results also showed that among these 
glycoproteins, gH and gL were produced inside BHK cells as a heterodimer 
whereas Ov7 did not interact with this complex as heterotrimer. This was 
revealed by immunoprecipitation and de-glycosylation (described in section 
5.2.3 and Figure 5-11).  
The plasmid MVA-cassettes were designed to contain GFP-TAG-
glycoproteins. Homologous sequences to vaccinia virus were also included in 
both sides for efficient recombination. One direct repeat was located in one 
side followed by vaccinia P11 promoter to drive GFP expression and prevent 
its sequence deletion during rMVA passages. This also provides a visible 
marker of the rMVA during the purification or expression of these 
glycoproteins. These constructs were designed similar to  (Wyatt et al., 2008) 
(see 2.15.2).  
 All the inserted targeted genes (ORF8, ORF22, ORF47, and Ov7) 
were expressed under the control of the modified H5 promoter (mH5). This 
native sequence promoter is potentially important for the genetic stability of 
rMVAs even after multiple passages (Wang et al., 2010). These genes were 
also fused and tagged with FLAG protein in gB and gH, HA in gL, and V5 in 
Ov7. This was necessary for selection, purification, and characterisation of 
the produced glycoproteins.  
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Recently, numerous applications have been developed using MVA for 
many vaccine candidates such as HIV (Wyatt et al., 2008), ebola virus (Domi 
et al., 2018), and influenza virus (Barbieri et al., 2018). This because of high 
clinical safety as well as inducing a potential immune response arising from 
stimulation of dendritic cells and activation of T cell responses (Verheust et 
al., 2012).  
5.3.2 MVA-glycoproteins production  
The expression of the rMVA-glycoproteins was evaluated by infecting 
BHK cells with the generated rMVAs (either individually or by mixing gH/gL or 
gH/gL/Ov7). The cell lysates were then probed by western immunoblotting 
and IF assays. As expected, all the recombinant MVAs demonstrated stable 
modification. This was observed from expression of the GFP protein after 
three cycles of cells inoculation and during the passages (Figure 5-5). These 
glycoproteins are fundamental in OvHV-2 biology (AlHajri et al., 2017; Cunha 
et al., 2015; Russell et al., 2009). Therefore, gB, gH, gL, and Ov7 
glycoproteins were expressed in the MVA system as logical candidates that 
could provide potential immune responses to prevent MCF in susceptible 
hosts.     
In most herpesviruses, there are orthologous glycoproteins that have 
an important role in host- cell entry (Eisenberg et al., 2012). Although the 
biological role of OvHV-2-glycoproteins is poorly characterised, numerous 
studies have shown that gB, gH, and gL are important vaccine candidates to 
prevent MCF in rabbit model (Cunha et al., 2015). Additionally, as in most 
herpesviruses, these glycoproteins are likely responsible for variable cell-
196 
 
tropism (Sathiyamoorthy et al., 2017). This could explain our observation of 
OvHV-2 targeting numerous cell types (as showed in 4.2.3), including 
epithelial and endothelial cells as well as leukocytes. 
 Recently, it has been shown that gB, gH, gL, and Ov8 of OvHV-2 are 
essential to induce fusion of the membrane of the infected cells (AlHajri et al., 
2017). This pathway was also shown in KSHV by glycoproteins gB, gH, and 
gL (Pertel, 2002). As well as in herpes simplex virus infection via recruitment 
of gB, gH,gL, and gD (Spear et al., 2006). 
The predicted molecular weight of these glycoproteins using 
bioinformatics software analysis 
(https://www.bioinformatics.org/sms/prot_mw.html), revealed that gB protein 
(GenBank accession no. ABB22229) of 863 amino acids should have a 
molecular mass of 97.5 kDa. A similar molecular weight was predicted for gH 
(GenBank accession no. ABB22240) (750 amino acids; 85.68 kDa) while the 
predicted size of gL (GenBank accession no. YP_438170) (151 amino acids) 
was predicted to be 50.1 kDa molecular weight. Finally, Ov7 (GenBank 
accession no. YP_438174) (121 amino acids), was predicted to be 14.25 
kDa.   
Western immunoblotting analysis showed that rMVA-gB with the 
FLAG tag was detected as three bands at molecular weights of 130, 92, and 
55 kDa (Figure 5-6). These bands most likely corresponded to whole gB 
length but could reflect cleavage of the recombinant protein and indicating a 
post translational processing inside BHK cells. Additionally, there was a 
smaller size band at 52 kDa detected in the supernatant of the same infected 
cells. This was possibly breakdown product.  
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These results are comparable to those previously generated by 
(Cunha et al., 2015) as two bands at (102 and 90) kDa were detected from 
transfected Chinese Hamster Ovary (CHO) cells.  
The OvHV-2-gB (encoded by ORF8), is homologous to that in AlHV-1 
(Hart et al., 2007). A1HV-1gB was previously shown to have a similar 
molecular weight, approximately ~100 kDa with additional two bands (50 and 
20) kDa that resulted from cleavage process (Dry et al., 2016). 
The glycoprotein B in both viruses share antigenic and serological 
cross-reactivity (Dry et al., 2016). Therefore, here, production of OvHV-2-gB 
could be valuable candidate to neutralise both viral species.  
In rMVA-gH, two bands were detected at 95 and 57 kDa. This was 
slightly higher than expected, but these bands possibly represent the 
cleavage of the whole protein. However, rMVA-gL expression, a lower 
molecular weight at 33 kDa than expected was observed representing gL 
protein that fused with HA tag (Figure 5-6). The expressed rMVA-Ov7 protein 
was detected at 30 kDa which was higher than expected. These results 
agreed with those obtained by (Cunha et al., 2015) as a single band 
corresponding to OvHV-2-gH protein was observed at 90 kDa whereas the 
gL protein was not detected from the individual transfection until was co-
expressed with gH protein which revealed the size of gL protein as 35 kDa. 
The gB was expressed at 102 kDa with a smaller band representing the 
cleavage protein. Combining of gB and gH/gL vaccines were found protective 
to all the challenged animal while using of either gB or gH/gL revealed 
prevention of MCF at 83 % (Cunha et al., 2015). In numerous herpesviruses, 
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gL is required for processing (folding and transport) of gH, and both are 
expressed as a heterodimer  (Eisenberg et al., 2012; Peng et al., 2010).   
5.3.3 Glycoproteins interaction  
The obtained data demonstrated expression of the rMVA-
glycoproteins as a monomer. The aim was to examine whether OvHV-2-
glycoproteins as in other herpesviruses could possibly co-exist as multimers 
when combined. These glycoproteins were initially co-infected and analysed 
by western immunoblotting and IF assays then further studied by IP analysis. 
The results revealed that gH/gL were expressed as heterodimer but not 
heterotrimer with Ov7 (see 5.2.3). The interaction of gB with gH/gL complex 
as a trimer for the entry stoichiometry has not been studied here due to lack 
of required techniques.  
 Finding of gH/gL complex has been shown in many herpesviruses 
such as EBV (Hutt-Fletcher, 2007). However, this complex could co-exist as 
trimer or even pentamer when combined with other glycoproteins. These 
glycoprotein combinations are known as entry complexes, which allow the 
virus to infect wide range of cell types. For instance, EBV is able to target 
epithelial cells via gH/gL complex but it can also invade B cells through 
gHgL/gp42 complex (Sathiyamoorthy et al., 2017).  
The combined expression was analysed by western immunoblotting 
and IF assays. The results exhibited detection of the expressed protein at the 
expected molecular weights and predominantly localised within the cell 
membrane (see 5.2.2.1, 5.2.2.2, and 5.2.3).  
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For further confirmation, these complexes were additionally analysed 
by immunoprecipitation using M2 affinity gel pulldown and then western 
immunoblotting. Anti-FLAG antibody was found to be eluted from M2 gel. 
Therefore, alternative Mabs (PA1-984B, Sigma) was used to detect the 
epitope-FLAG-tag sequence (DYKDDDDK) (see 5.2.3) and (Figure 5-11).   
The expected molecular weight of gH at 94 kDa was detected from the 
eluted gH/gL combinations confirming the heterodimer expression of gH/gL. 
This finding reflects that of (Cunha et al., 2015) who also found that both 
glycoproteins are expressed as a complex and the presence of gL is 
important for efficient processing and transporting of gH inside cells. 
However, in this study, Ov7 was not detected from the gH/gL/Ov7 mixture, 
indicating that Ov7 was not part of a heterotrimer with gH/gL (Figure 5-11). 
This could explain our previous finding of how OvHV-2 infects the epithelial, 
endothelial cells and leukocytes. The gH/gL complex was shown to be 
important for entry into these cells in other herpesviruses (human 
herpesviruses) (Sathiyamoorthy et al., 2017). However, further analysis 
should be conducted to define which glycoprotein components enable OvHV-
2 to infect B cells or other cell types.     
5.3.4 De-glycosylation of gH/gL complex  
The eluted gH/gL complex was de-glycosylated using N-glycosidase F 
enzyme (PNGase F). The deglycosylated gH protein was detected at 74 kDa, 
indicating the post-transitional modification of gH protein inside BHK cells. 
This occurs by addition of 21 kDa of glycan group (Figure 5-11). Addition of 
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this glycan group could better define the activity of the gH/gL complex and 
virus biology.  
Prediction of the N-glycosylation sites within the gH protein (GenBank 
accession no. ABB22240) using bioinformatics analysis software 
(https://www.hiv.lanl.gov/cgi-bin/GLYCOSITE/glycosite_main.cgi) revealed 9 




Figure 5-12. Predicted amino acids sequence of gH protein. Red letters 
indicate the N-glycosylation sites. 
 
5.4 Conclusions  
The technology for producing recombinant MVA expressing foreign 
proteins is available with a well-known safety profile. The produced rMVA-
glycoproteins (gB, gH/gL) are likely to be valuable in OvHV-2 biology. These 
candidates were found as an effective candidates to prevent MCF in rabbits  
(Cunha et al., 2015). These glycoproteins have a fundamental role in the cell 
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entry. Using of multiple glycoproteins perhaps provide potential antigenic 
response. The expressed oLANA protein could also be used as another 
vaccine candidate against the latent infection. These vaccine candidates 

















6. Chapter six: General discussion and 





6.1 Triggering of MCF   
MCF pathogenesis is poorly defined. The lack of a permissive cell line 
to propagate OvHV-2 has hindered the understanding of MCF. Nevertheless, 
numerous studies have been conducted by employing PCR and since this 
technique has improved, much has been discovered about MCF (Russell et 
al., 2009). Recently, our laboratory has shown that OvHV-2 can be 
harboured in cattle without obvious signs of MCF. Therefore, it has been 
suggested that other factors or herpesviruses could be involved in triggering 
MCF (Amin, 2015).  
The main hypothesis of this study was whether the presence of 
alternative γ-herpesviruses could interact with OvHV-2 in causing MCF or co-
infections with OvHV-2 could induce MCF. Possibly, other factor involved to 
induce MCF apart from MCF-viruses.   
Therefore, the first aim was to investigate the γ-herpesviruses in both 
asymptomatic and diseased hosts by using two PCR formats as qualitative 
and quantitative approaches: PAN-herpesvirus consensus and Real time 
PCR. The second aim was to describe which cell type supports latent OvHV-
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2 infection in sheep, cattle without MCF, and cattle with MCF using an anti-
oLANA PAb. The third aim was to produce OvHV-2-glycoproteins in MVA as 
logical vaccine candidates. 
The results showed for the first time that (see Table 3-2), although the 
related ovine herpesvirus 1 is an endemic commensal of cattle, it may afford 
cross-protection from infection with OvHV-2 and development of MCF. It has 
been suggested that most animal herpesviruses have co-evolved with their 
corresponding hosts and these have some phylogenetic evolutionary 
relationship (Li et al., 2005c). This phylogenetic relationship could provide 
some antigenic similarity. This was shown in three cervid herpesviruses 
including: Elk herpesvirus (ElkHV), cervid herpesvirus-1 (CerHV-1), and 
rangiferine herpesvirus (RanHV) as the encoding genes for gB, gC, and gD 
exhibited a closely relationship (Deregt et al., 2005). More evidence was also 
found in a neutralisation study conducted by (Taus et al., 2015) that revealed 
two potential antigenic members (AIHV-I/ AIHV-2) and (OvHV-2/CpHV-2) in 
which the neutralising antibody cross reactivity is only found within MCF virus 
subgroup but not between subgroups. This is likely based on the 
phylogenetic relationship between macaviruses that clustered into two 
groups, MCF and non-MCF virus group as stated in section (3.2.1). However, 
no clear sequence distinction within the MCF virus clade has so far been 
made, mainly due to a lack of extensive sequence data for the antigens of 
most MCF viruses.  
Glycoprotein B is a highly conserved immunogenic protein. Alignment 
analysis of the genes that encode for this protein in OvHV-2, OvHV-1, and 
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BoHV-6 showed significant similarity as depicted in (Figure 3-5).  This might 
explain the antigenic relationship between these viruses. However, these 
viruses discriminated genetically into MCF and non-MCF members as 
showed in (Figure 3-2).    
It was assumed that MCF was possibly triggered by infiltrating 
cytotoxic T lymphocytes (Russell et al., 2009). It has been hypothesised that 
detection of oLANA in asymptomatic and diseased animals will further define 
this hypothesis. The obtained data showed for the first time that, in cattle 
without MCF, oLANA is present likely in macrophages and B cells in lymph 
nodes. In cattle with MCF, virus can be seen predominantly in activated T 
cells, but more importantly endothelial cells as possibly induced by local 
inflammation that resulted from cytokines and chemokines. There are 
infected endothelial cells in the rete mirabile associated with vasculitis. The 
rete mirabile is critical for the supply of blood to the brains of ungulates, 
possibly explaining the sudden death in MCF.  
The obtained data also showed that oLANA was detected in a wide 
range of cell types. This may explain the way by which OvHV-2 can survive. 
As in most herpesviruses, the virus genome can persists as an episome 
(Kelley-Clarke et al., 2009). If the viral load increases for some reason, it may 
target T lymphocytes and inducing MCF. Finally, vascular endothelial cells 
also seem to be supportive for OVHV-2 infection. This might allow a 
continuous OvHV-2-influx into the blood circulation which consequently could 
lead to triggering MCF.  
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Use of this toolkit will be useful in the diagnosis of latent OvHV-2 
infection in different hosts.   
6.2 OvHV-2 vaccine candidates   
OvHV-2 has not yet been propagated in vitro efficiently. Therefore, no 
effective vaccine has been produced (Russell et al., 2009). In this study, 
OvHV-2 glycoproteins (gB, gH, gL, and Ov7) were produced in vaccinia virus 
as a vaccine candidate. These glycoproteins have been shown as efficient 
antigens (Cunha et al., 2015). As in most herpesviruses, these glycoproteins 
are important in virus biology especially in binding to the host cell and fusion 
(Adler et al., 2017). Conducting challenge immunisation trial will be useful to 
evaluate these vaccine candidates. Vaccine trials in small animals (rabbits or 
hamster) could be helpful because both are susceptible to MCF. We propose 
to vaccinate these animals with the recombinant MVAs then challenge with 
OvHV-2. However, the intravenous challenge with infected cells that carry 
OvHV-2 does not mimic a natural challenge and this route of infection may 
not be protected against by any vaccine, but OvHV-2 cannot be propagated 
therefore challenge virus is not available except when collected from sheep 








Appendix: Detailed results of repeatability (intra-assay variation) and reproducibility (inter-assay 
variation) precisions of the developed q-PCR assays.    





Inter-assay variation Experiment 





































 20.46 0.07 0.3 19.91 0.94 4.72 20.2 0.07 0.3 20.81 0.19 0.91 20.46 0.07 0.34 20.36 0.33 1.62 0.15 
2 × 10
6
 22.26 0.72 3.23 21.62 0.29 1.34 22.64 0.15 0.66 19.16 0.41 2.13 22.26 0.72 3.23 21.5 1.4 6.51 0.62 
2 × 10
5
 23.87 0.41 1.71 24.89 0.38 1.52 24.27 0.33 1.35 23.29 0.22 0.94 23.87 0.41 1.71 24.03 0.59 2.45 0.26 
2 × 10
4
 25.66 0.18 0.7 27.17 0.12 0.4 26.4 0.11 0.41 25.42 0.06 0.23 25.66 0.18 0.7 26.06 0.72 2.76 0.32 
2 × 10
3
 28.74 0.16 0.5 31.84 0.13 0.4 29.93 0.01 0.03 28.89 0.36 1.24 28.74 0.16 0.55 29.62 1.33 4.49 0.59 
2 × 10
2
 32.93 0.14 0.4 35.47 0.27 0.76 33.76 0.39 1.15 32.68 0.31 0.94 32.93 0.14 0.42 33.55 1.14 3.39 0.51 
2 × 10
1
 35.71 0.21 0.58 38.4 1.66 4.32 38.69 1.15 2.9 35.41 1.12 3.16 35.71 0.21 0.58 36.78 1.61 4.37 0.72 
2 × 10
0
 39.71 0.33 0.83 39.01 0.98 2.51 37.2 1.88 5.05 37.24 1.67 4.48 39.71 0.33 0.83 38.5 1.26 3.27 0.56 









Inter-assay variation Experiment 





































 18.55 0.37 1.99 18.85 0.45 2.38 18.32 0.62 3.38 18.13 0.42 2.31 17.84 0.22 1.23 18.33 0.38 2.07 0.17 
2 × 10
6
 20.76 0.04 0.19 19.95 0.57 2.85 19.37 0.61 3.14 19.37 0.6 3.09 19.68 0.16 0.8 19.82 0.57 2.87 0.25 
2 × 10
5
 22.09 0.1 0.004 21.91 0.24 1.09 21.34 0.37 1.73 20.9 0.36 1.72 20.68 0.55 2.65 21.38 0.61 1.26 0.27 
2 × 10
4
 25.98 0.04 0.15 25.8 0.23 0.89 25.35 0.24 0.94 24.6 0.12 0.48 24.84 0.03 0.12 25.31 0.59 2.33 0.26 
2 × 10
3
 29.44 0.28 0.95 29.35 0.31 1.05 28.88 0.27 0.93 27.69 0.14 0.5 28.03 0.09 0.32 28.67 0.78 2.72 0.35 
2 × 10
2
 31.86 0.33 1.03 33.41 0.48 1.43 32.9 0.49 1.48 30.71 0.89 2.89 31.2 0.44 1.41 32.01 1.13 3.53 0.5 
2 × 10
1
 36.67 0.33 0.89 36.92 0.52 1.4 36.32 0.55 1.51 32.19 1.71 5.31 35.27 0.41 1.16 35.47 1.94 5.46 0.86 
2 × 10
0
 39.16 0.09 0.22 38.49 1.34 3.48 37.33 0.89 2.38 38.22 1.19 3.11 39.17 0.36 0.9 38.47 0.76 1.97 0.34 












Inter-assay variation Experiment 





































 13.41 0.07 0.52 13.45 0.35 2.6 13.05 0.18 1.37 13.26 0.03 0.22 13.79 0.14 1.01 13.39 0.27 2.01 0.12 
2 × 10
6
 16.24 0.36 2.21 16.12 0.22 1.36 16.53 0.15 0.9 16.44 0.16 0.97 16.68 0.08 0.47 16.4 0.22 1.34 0.1 
2 × 10
5
 19.14 0.38 1.98 19.05 0.16 0.83 19.46 0.32 1.64 19.21 0.36 1.87 19.77 0.4 2.02 19.32 0.29 1.5 0.13 
2 × 10
4
 21.67 0.09 0.41 22.06 0 0 22.22 0.04 0.18 22.29 0.45 2.01 22.5 0.09 0.4 22.14 0.31 1.4 0.13 
2 × 10
3
 24.73 0.3 1.21 25.18 0.26 1.03 25.52 0.03 0.11 25.33 0.12 0.47 25.68 0.14 0.54 25.28 0.36 1.42 0.16 
2 × 10
2
 28.03 0.19 0.67 27.87 0.18 0.64 28.58 0.21 0.73 28.34 0.007 0.02 28.41 0.16 3.51 28.24 0.28 0.99 0.12 
2 × 10
1
 30.39 0.36 1.18 30.58 0.08 0.26 30.87 0.3 0.97 30.53 0.3 0.98 30.86 0.18 0.58 30.64 0.21 0.68 0.09 
2 × 10
0
 33.33 0.33 0.99 33.87 0.05 0.14 34.46 0.23 0.66 34.34 0.53 1.54 34.08 0.1 0.29 34.01 0.44 1.29 0.19 












Inter-assay variation Experiment 





































 13.82 0.04 0.28 13.37 0.27 2.01 13.63 0.12 0.88 13.37 0.01 0.07 13.76 0.31 2.25 13.59 0.21 1.54 0.9 
2 × 10
6
 16.65 0.02 0.12 16.68 0.09 0.53 16.22 0.007 0.04 17.06 0.09 0.52 16.87 0.09 0.53 16.69 0.31 1.85 0.13 
2 × 10
5
 19.51 0.35 1.79 19.87 0.02 0.1 19.66 0.04 0.2 19.78 0.18 0.91 19.89 0.08 0.4 19.74 0.15 0.75 0.07 
2 × 10
4
 22.64 0.16 0.7 22.28 0.05 0.22 22.84 0.33 1.44 23.2 0.38 1.63 23.19 0.18 0.77 22.83 0.38 1.66 0.17 
2 × 10
3
 25.93 0.16 0.61 25.58 0.29 1.13 25.72 0.17 0.66 25.86 0.35 1.35 25.73 0.13 0.5 25.76 0.13 0.5 0.06 
2 × 10
2
 28.81 0.3 1.04 28.14 0.8 2.84 28.37 0.33 1.16 28.4 0.17 0.59 28.75 0.2 0.69 28.49 0.28 0.98 0.12 
2 × 10
1
 32.05 0.11 0.34 31.23 0.54 1.72 31.69 0.36 1.13 30.73 0.55 1.78 31.59 0.06 0.18 31.45 0.5 1.58 0.22 
2 × 10
0
 34.27 0.57 1.66 35.6 0.26 0.73 35.52 0.41 1.15 36.6 0.14 0.38 36.98 0.01 0.02 35.79 1.05 2.93 0.47 













Inter-assay variation Experiment 





































 10.52 0.21 1.99 10.61 0.03 0.28 10.59 0.5 4.72 10.18 0.15 1.47 10.54 0.43 4.07 10.48 0.17 1.32 0.07 
2 × 10
6
 14.02 0.02 0.14 14.37 0.33 2.29 14.26 0.08 0.56 14.76 0.007 0.04 14.26 0.08 0.56 14.33 0.27 1.88 0.12 
2 × 10
5
 17.59 0.12 0.68 17.25 0.32 1.85 17.53 0.36 2.05 17.58 0.29 1.64 17.53 0.36 2.05 17.49 0.14 0.8 0.06 
2 × 10
4
 20.57 0.35 1.7 21.22 0.27 1.27 20.58 0.04 0.19 20.64 0.29 1.4 20.58 0.04 0.19 20.71 0.28 1.35 0.12 
2 × 10
3
 23.91 0.17 0.71 24.69 0.12 0.48 24.29 0.32 1.31 24.47 0.61 2.49 23.29 0.32 1.37 24.13 0.54 2.23 0.24 
2 × 10
2
 27.57 0.47 1.7 27.91 0.09 0.32 27.81 0.09 0.32 27.44 0.16 0.58 27.81 0.09 0.32 27.7 0.19 0.68 0.08 
2 × 10
1
 30.22 0.41 1.35 30.28 0.12 0.39 30.03 0.16 0.53 30.77 0.64 2.07 30.03 0.16 0.53 30.26 0.3 0.99 0.13 
2 × 10
0
 10.52 0.21 1.99 10.61 0.03 0.28 10.59 0.5 4.72 10.18 0.15 1.47 10.54 0.43 4.07 10.48 0.17 1.32 0.07 
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